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Abstract: Summary Human immunodeficiency virus (HIV) infections can currently not be cured with
antiretroviral drugs. The strategy of the therapy is to inhibit the viral replication with a daily intake of an-
tiretroviral drugs. Thus, viral load can be suppressed to undetectable levels. Long-term viral suppression
can be achieved with the simultaneous administration of different drug classes, the so-called combination
antiretroviral therapy (cART). If intracellular drug levels decrease, e.g. because of missed drugs or drug-
drug interactions, resistance-associated mutations may occur and may lead to a therapy failure. In this
study, we aimed to analyze different aspects of HIV drug resistance by using data from the Swiss HIV
Cohort Study (SHCS) and the SHCS drug resistance database. The SHCS is an ongoing, observational
database that is recruiting HIV infected patients since 1988. The SHCS drug resistance database is linked
to the SHCS and exists since 2001. It includes all HIV sequences from the four authorized laboratories
in Switzerland that were generated for the purpose of genotypic resistance testing in the framework of
the SHCS. Etravirine is a new generation nonnucleoside reverse transcriptase inhibitor (NNRTI). It has a
different resistance profile than common NNRTIs. Therefore, it is still effective among highly treatment-
experienced patients with multi-drug resistant HIV strains. In chapter 1, we analyzed the therapeutic
potential of etravirine in the SHCS. We showed that about 10% of treatment-naïve patients had etravirine
resistance- associated mutations. These mutations were mainly polymorphisms. Further, we saw that the
estimated activity of etravirine is lowest in patients harbouring extensive multi-drug resistant viruses,
thus limiting etravirine use in those who are most in need. However, the estimated activity of etravirine
varied widely between different interpretation algorithms for genotypic resistance tests. Raltegravir is
also a new antiretroviral drug. It is the first integrase inhibitor (INI) and was registered in 2008 for
highly treatment-experienced patients with detectable viral loads. In chapter 2, we demonstrated that
raltegravir initially was mainly administered in salvage treatment, whrere no other potent drugs were
available or to circumvent a treatment with toxic drugs, such as enfuvirtide. The week 24 efficacy of
raltegravir in our study was comparable to randomized-controlled trials performed by the manufacturer.
To date, the optimal treatment strategy for patients harbouring extensive multi-drug resistant viruses is
unknown. Usually, new antiretroviral drugs or antiretroviral drug classes are administered in combination
with nucleoside reverse transcriptase inhibitors (NRTI), even if NRTI resistance-associated mutations are
present. However, it is unknown whether the administration of these NRTIs results in an additional vi-
rological benefit. In chapter 3, we studied highly treatment-experienced patients who initiated a therapy
including raltegravir. We found evidence that the administration of partially active or inactive NRTIs
improved the viral suppression rate at week 24. Two genotypic changes exist that reduce the activity of
all NRTIs, the 69 insertion and Q151M mutation. In chapter 4, we identified predictors for the emergence
of these mutations. We saw that the 69 insertion and Q151M only occurred if patients were previously
treated with a mono-/dual-NRTI therapy. Exposure to didanosine was associated with the emergence of
69 insertion. For Q151M, no risk factor was identified. However, patients with Q151M tended to have an
increased mortality risk compared to a control group of highly NRTI experienced patients. In chapter 5,
we additionally identified polymorphic mutations associated with the emergence of 69 insertion or Q151M.
We found evidence that the 69 insertion is the end point of the thymidine-analogue mutation (TAM) 1
pathway. Further, we identified eight polymorphic mutations associated with the emergence of 69 inser-
tion or Q151M. HIV-1 is subdivided into different subtypes and circulating recombinant forms (CRF).
Subtypes and CRFs are determined on the basis of the viral genome and generally originate from distinct
geographic areas reflecting different HIV subepidemics. All antiretroviral drugs against HIV were mainly
designed and tested in Western countries where subtype B is predominant. A long time, it remained un-
clear whether antiretroviral drugs have a comparable activity to non-B subtypes. In chapter 6, we showed
that the long-term virological outcome was even better among Caucasians infected with non-B subtypes
compared to subtype B. In particular, patients infected with CRF02AGandsubtypeAhadabetterlong −
termvirologicaloutcome.ZusammenfassungHeutekanneineInfektionmitdemHumanenImmundefizienz−
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Summary 
Human immunodeficiency virus (HIV) infections can currently not be cured with 
antiretroviral drugs. The strategy of the therapy is to inhibit the viral replication with a 
daily intake of antiretroviral drugs. Thus, viral load can be suppressed to 
undetectable levels. Long-term viral suppression can be achieved with the 
simultaneous administration of different drug classes, the so-called combination 
antiretroviral therapy (cART). If intracellular drug levels decrease, e.g. because of 
missed drugs or drug-drug interactions, resistance-associated mutations may occur 
and may lead to a therapy failure. 
In this study, we aimed to analyze different aspects of HIV drug resistance by using 
data from the Swiss HIV Cohort Study (SHCS) and the SHCS drug resistance 
database. The SHCS is an ongoing, observational database that is recruiting HIV 
infected patients since 1988. The SHCS drug resistance database is linked to the 
SHCS and exists since 2001. It includes all HIV sequences from the four authorized 
laboratories in Switzerland that were generated for the purpose of genotypic 
resistance testing in the framework of the SHCS. 
Etravirine is a new generation nonnucleoside reverse transcriptase inhibitor (NNRTI). 
It has a different resistance profile than common NNRTIs. Therefore, it is still 
effective among highly treatment-experienced patients with multi-drug resistant HIV 
strains. In chapter 1, we analyzed the therapeutic potential of etravirine in the SHCS. 
We showed that about 10% of treatment-naïve patients had etravirine resistance-
associated mutations. These mutations were mainly polymorphisms. Further, we saw 
that the estimated activity of etravirine is lowest in patients harbouring extensive 
multi-drug resistant viruses, thus limiting etravirine use in those who are most in 
need. However, the estimated activity of etravirine varied widely between different 
interpretation algorithms for genotypic resistance tests. 
Raltegravir is also a new antiretroviral drug. It is the first integrase inhibitor (INI) and 
was registered in 2008 for highly treatment-experienced patients with detectable viral 
loads. In chapter 2, we demonstrated that raltegravir initially was mainly administered 
in salvage treatment, whrere no other potent drugs were available or to circumvent a 
treatment with toxic drugs, such as enfuvirtide. The week 24 efficacy of raltegravir in 
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our study was comparable to randomized-controlled trials performed by the 
manufacturer.  
To date, the optimal treatment strategy for patients harbouring extensive multi-drug 
resistant viruses is unknown. Usually, new antiretroviral drugs or antiretroviral drug 
classes are administered in combination with nucleoside reverse transcriptase 
inhibitors (NRTI), even if NRTI resistance-associated mutations are present. 
However, it is unknown whether the administration of these NRTIs results in an 
additional virological benefit. In chapter 3, we studied highly treatment-experienced 
patients who initiated a therapy including raltegravir. We found evidence that the 
administration of partially active or inactive NRTIs improved the viral suppression rate 
at week 24. 
Two genotypic changes exist that reduce the activity of all NRTIs, the 69 insertion 
and Q151M mutation. In chapter 4, we identified predictors for the emergence of 
these mutations. We saw that the 69 insertion and Q151M only occurred if patients 
were previously treated with a mono-/dual-NRTI therapy. Exposure to didanosine 
was associated with the emergence of 69 insertion. For Q151M, no risk factor was 
identified. However, patients with Q151M tended to have an increased mortality risk 
compared to a control group of highly NRTI experienced patients. In chapter 5, we 
additionally identified polymorphic mutations associated with the emergence of 69 
insertion or Q151M. We found evidence that the 69 insertion is the end point of the 
thymidine-analogue mutation (TAM) 1 pathway. Further, we identified eight 
polymorphic mutations associated with the emergence of 69 insertion or Q151M. 
HIV-1 is subdivided into different subtypes and circulating recombinant forms (CRF). 
Subtypes and CRFs are determined on the basis of the viral genome and generally 
originate from distinct geographic areas reflecting different HIV subepidemics. All 
antiretroviral drugs against HIV were mainly designed and tested in Western 
countries where subtype B is predominant. A long time, it remained unclear whether 
antiretroviral drugs have a comparable activity to non-B subtypes. In chapter 6, we 
showed that the long-term virological outcome was even better among Caucasians 
infected with non-B subtypes compared to subtype B. In particular, patients infected 
with CRF02_AG and subtype A had a better long-term virological outcome.
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Zusammenfassung 
Heute kann eine Infektion mit dem Humanen Immundefizienz-Virus (HIV) mit 
antiretroviralen Medikamenten nicht geheilt werden. Die Therapie hat zum Ziel, durch 
tägliche Einnahme von Medikamenten die virale Replikation zu hemmen. Dadurch 
kann eine undetektierbare Viruslast erreicht werden. Mit den heutigen 
Kombinationstherapien, die verschiedene Medikamentenklassen enthalten, können 
langjährige Therapieerfolge erzielt werden. Bei unregelmässiger Einnahme der 
Medikamente oder wenn die intrazelluläre Medikamentenkonzentrationen aus 
anderen Gründen zu tief sind, können Resistenzmutationen auftreten, die zu einem 
Therapieversagen führen. 
In dieser Arbeit haben wir verschiedene Aspekte der HIV Resistenz anhand von 
Daten der Swiss HIV Cohort Study (SHCS) und der SHCS drug resistance database 
studiert. Die SHCS ist eine fortlaufende Studie, die seit 1988 HIV Patienten rekrutiert. 
Die SHCS drug resistance database ist eine angekoppelte Datenbank, die seit 2001 
besteht. Sie enthält alle HIV Sequenzen, die zwecks genotypischer Resistenztestung 
in den vier autorisierten Labors in der Schweiz im Rahmen der SHCS gemacht 
werden. 
Etravirine ist ein neuer, nicht-nukleosidanaloger Hemmer der reversen Transkriptase 
(NNRTI). Etravirine ist wirksam in stark vorbehandelten Patienten, da sich das 
Resistenzprofil von herkömmlichen NNRTI unterscheidet. In Kapitel 1 haben wir das 
therapeutische Potential von Etravirine in der SHCS studiert. Wir haben aufgezeigt, 
dass, zirka 10% der unbehandelten Patienten Viren mit Etravirine-Mutationen 
vorweisen. Weiter sahen wir, dass die geschätzte Aktivität von Etravirine in Patienten 
mit den geringsten Therapieoptionen am kleinsten ist, also in den am stärksten 
vorbehandelten Patienten, welche am meisten auf die Aktivität angewiesen wären. 
Die geschätzte Aktivität von Etravirine variierte aber stark zwischen verschiedenen 
Interpretationsalgorithmen von genotypischen Resistenztests. 
Raltegravir ist ebenfalls ein neueres Medikament. Es ist der erste Hemmer der 
Integrase und wurde 2008 für stark vorbehandelte Patienten mit nachweisbarer 
Viruslast zugelassen. In Kapitel 2 zeigten wir, dass Raltegravir anfänglich vor allem 
eingesetzt wurde in Patienten, die keine anderen aktiven Medikamente zur 
Verfügung hatten und um Behandlungen mit toxischen Medikamenten, wie 
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Enfuvirtide zu umgehen. Die Wirksamkeit von Raltegravir nach 24 Wochen war 
vergleichbar mit den randomisierten, kontrollierten Studien des Herstellers.  
Es gibt immer noch Unklarheiten, wie man stark vorbehandelte Patienten mit vielen 
Resistenzmutationen am besten therapiert. Oft werden neuere Medikamente 
verschrieben, aber trotz vorliegender Resistenz zusätzlich noch nukleosidanaloge 
Hemmer der reversen Transkriptase (NRTI) dazugegeben. Der Nutzen dieser NRTI 
ist aber unklar. In Kapitel 3 konnten wir nachweisen, dass in stark vorbehandelten 
Patienten, die Raltegravir erhalten, die Verabreichung solcher NRTI eine positive 
Auswirkung auf den Therapieerfolg nach 24 Wochen hatte. 
Es gibt zwei sehr seltene genotypische Veränderungen, die 69 Insertion und die 
Q151M Mutation, die die Wirksamkeit von allen NRTIs reduzieren. In Kapitel 4 haben 
wir Risikofaktoren für das Auftreten dieser Mutationen studiert. Wir zeigten, dass die 
69 Insertion und die Q151M Mutation in der SHCS nur vorkamen, wenn die Patienten 
zuvor alleine mit NRTIs behandelt wurden (nicht in einer Kombinationstherapie). Das 
Verabreichen von Didanosine war assoziiert mit dem Auftreten von der 69 Insertion. 
Für Q151M wurde kein Risikofaktor gefunden, aber Patienten mit Q151M hatten 
tendenziell ein höheres Mortalitätsrisiko als Patienten einer Kontrollgruppe. In Kapitel 
5 haben wir zusätzlich analysiert, ob es Polymorphismen gibt, die mit dem Auftreten 
der 69 Insertion oder Q151M zusammmenhängen. Wir stellten fest, dass die 69 
Insertion erst auftrat, nachdem Thymidinanaloge-Mutationen (TAM) 1 entstanden 
sind. Zudem fanden wir acht Polymorphismen, die möglicherweise das Auftreten der 
69 Insertion und Q151M beeinflusst haben. 
HIV-1 wird in verschiedene Subtypen und zirkulierende rekombinante Formen 
(CRFs) unterteilt, die anhand des Genoms unterschieden werden und jeweils gehäuft 
in bestimmten geographischen Regionen vorkommen und unterschiedliche HIV 
Subepidemien representieren. Alle antiretroviralen Medikamente gegen HIV wurden 
hauptsächlich in westlichen Ländern entwickelt und getestet, wo Subtype B-
Infektionen am häufigsten vorkommen. Lange wusste man nicht, ob diese 
Medikamente für Infektionen mit anderen Subtypen dieselbe Wirkung haben. In 
Kapitel 6 wiesen wir in einer Population von Kaukasiern nach, dass im Vergleich zu 
Subtyp B die Zeit bis zum Therapieversagen in nicht-Subtyp B infizierten Patienten 
länger ist. Vor allem CRF02_AG und Subtyp A hatten ein besseres langfristiges 
Therapieansprechen. 
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Introduction 
1.1 Epidemiology and diversity of HIV  
In 1981, physicians in San Francisco firstly described the acquired immunodeficiency 
syndrome (AIDS) among previously healthy homosexual men.1-3 It was initially also 
called gay-related immunodeficiency syndrome (GRID).4, 5 The cause of AIDS 
remained unknown until 1983, when the human immunodeficiency virus (HIV), a 
retrovirus of the lentivirus family, was discovered.6-9 HIV is transmitted by body fluids, 
such as blood, semen, breast milk, or vaginal secretions. The main transmission 
routes of HIV are sexual intercourse, sharing injection paraphernalia and vertical 
transmission from mother to child, as well as transmission via blood products.10 In the 
last 30 years, the HIV epidemic has spread all over the world. In 2009, approximately 
33 million people were estimated to be infected with HIV worldwide, approximately 
2.6 new HIV infection occurred and 1.8 million people died of AIDS.11 The prevalence 
of HIV differs markedly between regions. The highest prevalence is described in Sub-
Saharan countries where up to 28% of adults (15-49 years) are infected.11 
 
HIV
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HIV-2
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(major)
O
(outlier)
N
(non-M/
non-O)
A
B
D
C
G
F
H
K
J
A-G
AB
AE
AGHK
AG
AGJK
DF
CD
…
Type Group Subtype CRF
P
 
Figure 1. Nomenclature of HIV. 
 
The HIV epidemic is characterized by a large viral diversity that is partially explained 
by its evolution. HIV entered the human population as a result of zoonotic 
transmission from primates. There is evidence that such events occurred several 
times.12-18 As shown in figure 1, at least two major types of HIV exist, HIV-1 and HIV-
2.19, 20 HIV-1 is more infectious, has a more rapid disease progression and has 
spread globally,21 whereas the epidemic of HIV-2 is mainly endemic in Western 
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Africa. HIV-1 was classified into three groups, the major group M, the outlier group O, 
and another group N (non-O/non-M). Recently, a new group was described and 
named P. Viruses from group P are closely related to the gorilla simian 
immunodeficiency virus.22, 23 Group M is most common. It is further subdivided into 
different subtypes, circulating recombinant forms (CRFs) and unique recombinant 
forms (URFs).20 CRFs are intersubtype recombinant forms that are spreading in the 
populations. A new form is defined when at least three people without direct 
epidemiologic linkage are found to be infected. URFs are intersubtype recombinant 
forms that were described less often, only once or twice.20 
In Western countries, subtype B is predominant, but in the last decade the 
prevalence of non-B subtypes rose also in these regions, in particular in Europe.24-26 
Globally, subtype B causes only about 11% of infections.27 Worldwide, subtype C is 
most common, it accounts for nearly half of all infections. Subtype C mainly occurs in 
Sub-Saharan Africa. Other highly predominant subtypes and CRFs are A (12%), 
CRF02_AG (8%) and CRR01_AE (5%). Specific subtypes and CRFs are strongly 
correlated with geographical regions (figure 2).27 
 
B
BF
CRF02_AG
B
B
B
C
D
C
A
B
CRF01_AE
B, C, BC
A, B, AB
F, G, H, J,
K, CFR01, 
other CRFs
Figure 2. Global distribution of HIV-1 subtypes and circulating recombinant forms. Adapted from 28. 
1.2 Viral structure and genome 
HIV-1 is a retrovirus with a diameter of about 120 nm. It consists of two single 
stranded RNAs (figure 3) that are enclosed by the nucleocapsid. The RNA is bound 
to proteins and important enzymes such as the reverse transcriptase and integrase. 
A matrix with the viral protein p17 surrounds the capsid and the envelope consists of 
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a lipid membrane including the glycoproteins gp120 and gp41.29, 30 The HIV-1 
genome is encoded by 9749 nucleotides.31 It is primarily a coding RNA and contains 
9 open reading frames (gag, pol, env, tat, rev, nef, vif, vpr and vpu) that encode 15 
proteins.30 Four gag proteins exist that are essential for the viral structure: matrix, 
capsid, nucleocapsid and p6. The pol region encodes for the following three essential 
enzymes: the polymerase, reverse transcriptase and integrase. The env region 
encodes for the two surface gp120 and gp41. The six other genes code for regulatory 
or accessory proteins.29, 30 Recently, the secondary structure of the entire HIV-1 RNA 
genome was characterized.32 
 
SU TM
Abbreviations:
LTR, long terminal repeats
MA, matrix
CA, capsid
NC, nucleocapsid
PR, protease
RT, reverse transcriptase
IN, integrase
SU, glycoprotein (gp) 120, surface envelope protein
TM, gp41, transmembrane envelope protein  
Figure 3. Structure and genome of HIV-1. Adapted from 30. 
1.3 Viral life cycle 
HIV’s most common route of entry in the human body is via the mucosa: vaginal, 
rectal, and to lesser extent also oral. In these cases, HIV needs to overcome the 
mucosal barrier to reach its target cells, a step that is not necessary when HIV is 
transmitted by a direct route (e.g. sharing injection paraphernalia, injuries or blood 
products).10 Once HIV entered the body, the initial step of the life cycle is the 
attachment and binding of the virus to the host cell (figure 4). Mainly CD4+ cells and 
macrophages are infected by HIV and allow viral replication, but all cells expressing 
CD4 receptors and certain coreceptors, are potential targets (e.g. dendritic cells, 
microglial cells, or glomerular epithelial cell)33, 34. The viral membrane protein gp120 
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binds to the coreceptors (also termed chemokine receptors), CCR5 or CXCR4, on 
the host cell and triggers conformational changes. 
Next, the fusion takes place and the viral core is released into the cytoplasm. In the 
cytoplasm, the viral reverse transcriptase converts the HIV RNA into double-stranded 
HIV DNA. During this step, if a cell has been co-infected by two or more different viral 
HIV-1 strains, recombination can occur. In a next step, the HIV DNA is integrated into 
the host’s chromosomal DNA. From now on, the host cell machinery for making 
cellular proteins is also used for making viral proteins. The integrated DNA provirus is 
transcribed into messenger RNA and exported from the nucleus into the cytoplasm 
where translation takes place. Afterwards budding from the cell membrane happens 
and the viral protease cleaves the large polyproteins to functional units. A mature 
virus is produced that is able to infect new host cells (reviewed in35-37). 
 
Fusion
Budding
Integration
Binding
Proteolytic cleavage
Reverse
transcription
CD4
Cytoplasm Nucleus
Latent provirus
CCR5 or CXCR4
Immature
virion
Mature
virion
 
Figure 4. HIV-1 life cycle. Adapted from 37. 
1.4 The natural history of HIV infections 
The natural history of the HIV infection is characterized by three clinical stages: the 
acute, chronic and AIDS-defining phase (figure 5).38 Within the first weeks after 
transmission, the level of HIV RNA often increases to very high levels and CD4+ cell 
count usually drop considerably.39 In about 40-90% of newly infected patients, an 
acute retroviral syndrome (ARS) occurs. The ARS consists of variable symptoms 
such as fever, fatigue, pharyngitis, rash, headache, lymphadenopathy, diarrhea, 
myalgia or arthralgia. It is often clinically not distinguishable from other acute viral 
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syndromes (e.g. acute EBV infection and acute cytomegalovirus infection) and 
traveller’s diseases (e.g. malaria, dengue virus infection, and travel-associated 
diarrhea). Thus, ARS remains often undiagnosed. 40-42 
 
Plasma viral load
CD 4+ T lymphocytes
Weeks Years
Acute Chronic AIDS
 
Figure 5. Natural course of an HIV-1 infection. 
 
During the chronic phase of HIV infection, plasma viral load stabilizes at an individual 
level, the so-called viral set-point, and CD4+ cells often normalize to a certain extent. 
However, interpatient differences are extensive. A high viral set-point is associated 
with a more rapid loss of CD4+ cells and a faster progression to AIDS.43, 44 However, 
the chronic phase can last several years and it is in most infected people 
asymptomatic. Untreated HIV-1 infected individuals will develop AIDS symptoms at a 
median of 8 to 10 years.45 During the further course of infection a steady decrease of 
CD4+ cells occurs and the risk to enter the third stage, the AIDS-defining phase, 
increases with the decrease of the CD4+ cell count (reviewed in35). The AIDS-
defining phase is symptomatic and defined by the occurrence of specific opportunistic 
infections (viral, bacterial, fungal, or parasitc diseases) and malign diseases. The 
Centers of Disease Control and Prevention (CDC) classified the phase of infection in 
so-called CDC stages depending on the disease progression.38 In untreated patients, 
the average time between the first manifestations of AIDS and death is usually 2-4 
years.45 
1.5 Antiretroviral treatment 
With the current antiretroviral therapy (ART) a cure from HIV is not possible. 
Therefore, the major aim of ART is to reduce the morbidity and mortality by fully 
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inhibiting active viral replication thereby suppressing the viral load. But HIV can 
survive in resting, latently infected cells, mostly of the CD4RO+ memory type, and it 
starts to replicate rapidly after ART is discontinued.46-49 This rapid rebound suggests 
that viral replication persists at a very low level despite therapy and/or rapid 
reactivation of latently infected cells occurs when treatment is interrupted.50-52 
However, sustained viral suppression subsequently leads to a recovery of the CD4+ 
cell count in the large majority of patients. Antiretroviral compounds are usually 
classified by the viral life cycle step they inhibit (information about the mode of 
actions is given in sections 1.6.5-1.6.10). Currently, five major drug classes are 
approved in Switzerland including more than 20 different compounds. As shown in 
table 1, the first registered antiretroviral drug was zidovudine, a nucleoside reverse 
transcriptase inhibitor (NRTI).53-55 However, mono- or dual-therapy with NRTIs was 
only transiently effective, because rapid selection of resistance occurred.56, 57 The 
introduction of protease inhibitors (PIs) in 1995 was initially the major breakthrough in 
HIV treatment. The combination of a PI and NRTIs were proof of concept that triple 
therapy really made the difference and showed highly promising results in clinical 
trials. It was the first time that long-lasting viral suppression was achieved.58 The term 
combination ART (cART) or highly active antiretroviral treatment (HAART) was 
introduced for the simultaneous administration of different drug classes. Today all 
PIs, except nelfinavir, if still used, and rarely atazanavir, are administered as 
ritonavir-boosted PIs.59 Ritonavir is a very potent inhibitor of the hepatic enzyme 
cytochrome P450 (CYP) 3A4 that normally metabolizes PIs. The inhibition of this 
enzyme leads to a slower decrease of the PI drug levels. Therefore, a lower dosage, 
respectively longer dosing intervals are possible which reduces toxicity and pill 
burden immensely.60 NNRTIs are an additional drug class approved in 1996.61 
Several years later, a fusion inhibitor (enfuvirtide) was registered.62, 63 It is 
administered as a subcutaneous injection and adverse events are common, but it 
was until the registration of the CCR5 antagonists maraviroc and the integrase 
inhibitor (INI) raltegravir the only options for patient with multi-drug resistant 
viruses.64-67 
To summarize, nowadays antiretroviral therapy is very potent and typically quite well 
tolerated. With a daily regimen of different drug classes long-term viral suppression 
can be achieved. The first-line ART usually consists of two NRTIs and a PI or a 
NNRTI, whereas drug combinations after multiple therapy failures are more complex 
Introduction 
11 
and usually include newer drug classes. Overall, the highly potent treatment, the 
reduction of pill burden and improved toxicity profiles changed HIV into a chronic 
illness with an estimated life expectancy comparable to other chronic diseases such 
as diabetes. 68-70 At least if treatment is available and affordable.  
 
Table 1. Antiretroviral drugs against HIV-1 in Switzerland. 
 Date of registration Drug Abbreviation Brand name 
NRTIs 1987 Zidovudine AZT Retrovir 
 1992 Didanosine DDI Videx 
 1992 Zalcitabine DDC Hivid 
 1996* Stavudine D4T Zerit 
 1996 Lamivudine 3TC Zeffix 
 1999 Abacavir ABC Ziagen 
 2002 Tenofovir TDF Viread 
 2004 Emtricitabine FTC Emtriva 
NNRTIs 1997 Nevirapine NVP Viramune 
 1998 Efavirenz EFV Stocrin 
 2008 Etravirine ETV Intelence 
PIs 1996 Indinavir IDV Crixivan 
 1996 Ritonavir RTV Norvir 
 1997 Nelfinavir NFV Viracept 
 1998 Saquinavir SQV Fortovase/Invirase 
 1999* Amprenavir APV Agenerase 
 2000 Lopinavir LPV Kaletra 
 2004 Atazanvir ATV Reyataz 
 2005 Fosamprenavir FPV Telzir/Lexiva 
 2005 Tipranavir TPV Aptivus 
 2006 Darunavir DRV Prezista 
Entry inhibitors 2003 Enfuvirtide T20 Fuzeon 
 2008 Maraviroc MVC Celsentri 
Integrase inhibitor 2008 Raltegravir RAL Isentress 
*Registration is expired. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, 
nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor 
 
1.6 HIV drug resistance 
HIV drug resistance is an important cause for treatment failure, although the 
introduction of cART reduced the emergence of drug resistance markedly in 
developed countries.71-73 The simultaneous administration of different drug classes 
makes the development of resistant strains more difficult because it suppresses the 
viral replication more effectively and several mutations have to emerge on the same 
viral genome until viruses are able to replicate.74 However, if intracellular drug levels 
decrease, e.g. because of drug-drug interactions or missed doses, latently infected 
cells may be reactivated and the replication cycle restarts. A Darwinian selection 
process takes place and the viral strain with the highest replication capacity, or viral 
fitness, takes over the viral population. The selection of mutations is a possible 
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adaption of the viral strain to increase its replication capacity under drug pressure. 
We are talking about drug resistant strains, if viruses are able to replicate besides 
appropriate drug levels (reviewed in 74, 75). 
There are two main reasons why HIV drug resistance can occur quite rapidly. First, 
HIV has a very high mutation rate. The reverse transcriptase of HIV lacks a 
proofreading activity. It is not able to confirm that the DNA transcript is an accurate 
copy of the RNA. It introduces on average one mutation for each viral genome 
transcribed.76, 77 The second reason is the high replication rate of HIV.78 In untreated 
individuals, it is estimated that 107 to 108 cells are infected.79 They have an average 
life time of 1-2 days.80, 81 It is obvious that the replication rate has to be very high to 
maintain a steady state. Thus, the combination of the error prone reverse 
transcriptase and the high replication rate leads to the generation of each possible 
mutation in an HIV-1 individual every day.82 Further, recombination of different viral 
strains can occur during replication which increases the viral diversity even more (see 
section 1.3). 
1.6.1 Nomenclature of mutations associated with drug resistance 
Proteins are built of a chain of amino acids. Twenty different amino acids exist and 
their sequence in a protein is defined on the genome. An amino acid is encoded by a 
three-letter code of nucleotides (codon). Mutations emerge when this three-letter 
code is modified by replacement, deletion or insertion of nucleotides. Mutations can 
be synonymous or non-synonymous. A synonymous mutation occurs when a change 
of a nucleotide does not result in the expression of another amino acid. This is 
possible because there are 43=64 codons, but only 20 amino acids. The change at 
the third position is quite often synonymous or silent, e.g. lysine is encoded by AAA 
and AAG. Relevant drug resistance-associated mutations are non-synonymous, 
meaning that the change leads to an expression of another amino acid, e.g. when the 
code of lysine (AAA) is modified at the second position to AGA, arginine is 
expressed.  
The nomenclature of drug resistant-associated mutations has two letters and a 
number. The first letter is the abbreviation for the amino acid of the wild type 
(consensus strain), the number is the position of the mutation on the genome, and 
the second number is the abbreviation of the amino acid of the mutant strain. The 
mutation K103N for example is a substitution of the amino acid lysine (K) with 
asparagine (N) at position 103.83 
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1.6.2 Impact of mutations associated with drug resistance on viral 
fitness 
Viral strains often have a decreased viral fitness in the presence of drug resistance 
mutations, M184V for example has a large impact on the replication capacity.84 But 
other mutations, so-called secondary or accessory mutations, can be selected that 
partially compensate for this effect. However, if ART is cessed, the wild type strain 
most often has a better replication capacity and therefore, drug resistant strains may 
partially or fully diminish to undetectable levels during treatment interruptions. This is 
a reason why genotypic resistance tests must be interpreted with care when 
performed before ART initiation or during treatment interruptions.83, 85 
1.6.3 HIV drug resistance testing 
The major indicator for the presence, respectively for the emergence of drug 
resistance is a relapse of a detectable viral load in a previously suppressed patient 
on ART or lack of initial treatment response. Generally, HIV drug resistance is 
measured with two assays, a genotypic and phenotypic test. These assays have 
different assets and drawbacks.83 Both tests suffer from the limitation that a minimum 
amount of virus (>500 copies/mL) is necessary to perform the test and minority 
subpopulations can not be detected. Viral strains that represent <20% of the total 
population may remain undetected with these assays.86, 87 
Genotypic resistance test 
The genotypic resistance test predicts the susceptibility of antiretroviral drugs based 
on the viral sequence. To estimate the activity of PIs, NRTIs, NNRTIs and INIs parts 
of the pol region are sequenced. To predict the susceptibility to the fusion inhibitor 
enfuvirtide, a part of the env region is sequenced. 
The major limitation of the genotypic resistance tests is the interpretation of the 
results, because the impact of different mutations on drug susceptibility varies widely. 
Therefore, several interpretation algorithms were developed to estimate the activity of 
ART based on the viral sequence. Some of the widely used algorithms are the 
Stanford [http://hivdb.stanford.edu/pages/algs/HIValg.html], the REGA88 or ANRS 
algorithms [www.hivfrenchresistance.org/index.html]. Additionally, the international 
aids society (IAS-USA) regularly publishes recommendations on how to interpret 
resistance mutations.89 However, the concordance of the algorithms is not always 
given which can make the interpretation of resistance tests difficult.90, 91 
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Phenotypic resistance test 
Phenotypic resistance tests are direct in vitro measurements to determine the 
sensitivity of viruses to particular drugs. Originally, replication competent viral isolates 
from patients were grown in presence and absence of drugs in cell culture. However, 
for better standardization recombinant assays have been developed. For this 
purpose, a recombinant virus is constructed inserting protease and reverse 
transcriptase genes of patient’s viruses into a HIV reference strain. These 
recombinant viruses are than tested in vitro for the amount of drugs needed to inhibit 
the viral replication by 50%. This level is called the half maximum inhibitory 
concentration (IC50). For interpretation, a clinical cut-off indicates at which levels of 
IC50 a successful treatment can still be expected. However, the determination of 
these cut-offs is difficult.92 
In contrast to genotypic resistance test, the phenotypic resistance is rarely used in 
clinical practice. It is more time consuming and more expensive than the genotypic 
test. Currently, the most commonly used commercial phenotypic tests are 
PhenoSense [http://www.monogrambio.com/417.aspx] and Virco's Antivirogram 
[http://www.vircolab.com/hiv-resistance-products/antivirogram].93 
Virtual phenotype 
The virtual phenotype is a mathematical approach to predict the phenotype based on 
the genotypic information without performing a phenotypic resistance test in 
laboratory. These estimates are derived from large databases that combine 
information from phenotypic and genotypic tests. There are two widely used 
interpretation system, geno2pheno [http://www.geno2pheno.org/] and vircoType 
[http://www.vircolab.com/hiv-resistance-products/vircotype-hiv-1]. Geno2Pheno uses 
machine learning techniques94, 95 to determine the phenotype, whereas vircoType 
interpretation is based on multiple, linear regression models.96 
Minority variants harbouring drug resistance 
Ultrasensitive methods, such as allele-specific real-time PCR and deep sequencing, 
were developed to achieve higher sensitivities for genotypic resistance tests. These 
assays are able to detect viral strains occurring at very low frequency (up to 0.1%), 
but are only used for research purpose and not in routine clinical care yet.87, 97-99 
They are labour intensive and are not approved for diagnostic testing. 
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However, the clinical relevance of low-frequency mutations is still under 
investigation.100-102 But a recently published systematic review found evidence that 
the presence of low-frequency mutations, in particular NNRTI mutations, is 
associated with an increased risk for virological failure.103 
1.6.4 Transmission of HIV drug resistance  
In Western countries, the prevalence of transmitted drug resistance is about 8-
15%.26, 104-109 Less data are available from resource-limited settings, but recent 
studies reported comparable rates.110-114 However, a correlation was found between 
the prevalence of transmitted drug resistance and the time since ART scale-up in 
these countries. Therefore, it is possible that rates are increasing in the next few 
years.115 Transmission of minority variants harbouring drug resistance mutations also 
occurs, but the clinical relevance is currently unknown.116  
In Switzerland, the transmission rate of HIV drug resistance remained stable between 
1996 and 2005 and was approximately 8%.26 The transmission rate may be 
associated with the prevalence of drug resistance in the population which reached a 
plateau in the last few years, or is even decreasing in Switzerland.71  
The presence of transmitted drug resistance is associated with a worse treatment 
outcome.117-121 It is recommended to perform a genotypic resistance test prior to first-
line ART and to adapt the treatment to the drug resistance profile.122 
1.6.5 NRTI resistance-associated mutations 
NRTIs are nucleoside/tide analogues. They compete with natural nucleotides to be 
incorporated in the viral genome during the reverse transcription. In contrast to 
natural nucleotides, NRTIs lack a 3’ hydroxyl group and after its incorporation the 
reverse transcription is interrupted, because no further nucleotides can be attached. 
However, mutations exist that affect the efficacy of NRTIs. In general, NRTI 
mutations act in two different ways, they reduce the ability to incorporate NRTIs in the 
genome during reverse transcription (e.g. K65R, L74V, M184V or the Q151M 
complex) or lead to an ATP dependent removal of NRTIs after its incorporation (e.g. 
thymidine analogue mutations [TAMs]) (reviewed in74, 75). Depending on the type of 
selected mutation, different levels of resistance against drugs emerge (figure 6). 
Cross-resistance within drug classes is often problematic, also among NRTIs. Cross-
resistance occurs if a mutation is selected by a specific drug and the presence of this 
mutation additionally leads to resistance against other drugs. K65R for example is 
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most often selected by tenofovir, but if K65R is present, the viral strain is resistant 
against several other NRTIs. 
The reverse phenomenon also occurs. A mutation selected by a particular drug can 
lead to hyper-susceptibility to another drug. An example is M184V. It is a very 
common NRTI mutation. The presence of M184V results in high level resistance to 
lamivudine and emtricitabine, but increases the susceptibility to zidovudine, stavudine 
and tenofovir, most likely by reducing ATP-dependent nucleotide excision.123, 124 
M184V has a low genetic barrier meaning that selection of drug resistance occurs 
rapidely. The genetic barrier is defined as the number of viral changes needed to 
overcome the drug-selective pressure.125  
 
Mutation 3TC FTC ABC AZT D4T DDI TDF 
M41L        
A62V        
K65R        
D67N        
69 ins        
K70R        
L74V        
V75I        
F77L        
Y115F        
F116Y        
M184I        
M184V        
L210W        
T215F        
T215Y        
K219E        
K219Q        
 
Figure 6. Estimated susceptibility of nucleoside reverse transcriptase 
inhibitors in the presence of particular mutations. Susceptibility is estimated 
based on Stanford algorithm (version 6.0.11). Colour code: ■ 
hypersuceptible, ■ susceptible, ■ potential low-level resistance ■ low-level 
resistance, ■ intermediate resistance, ■ high-level resistance. 3TC, 
lamivudine; FTC, emtricitabine; ABC, abacavir; AZT, zidovudine; D4T, 
stavudine; DDI, didanosine; TDF, tenofovir. 
 
The type of mutation that emerges is highly dependent on the drugs used, but also 
interaction between mutations play a role. Mutations can occur as clusters, e.g. 
TAMs emerge as two different patterns. The TAM 1 pattern includes M41L, L210W, 
and T215Y and the TAM 2 pattern consists of D67N, K70R, T215F, and K219Q/E, 
but the two patterns are not fully exclusive.126-130 The interaction between mutations 
can also be an important criterion to choose a drug combination. For example, 
M184V acts antagonistically with TAMs. The use of thymidine analogue (zidovudine 
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or stavudine) with lamivudine or emtricitabine results in lower resistance rates.131 In 
addition, combination of thymidine analogue and tenofovir, basically precludes the 
emergence of tenofovir resistance, even if the virus is harbouring resistance mutation 
against thymidine analogue.132 
1.6.6 NNRTI resistance-associated mutations 
In contrast to NRTIs, NNRTIs are not incorporated in the viral genome during reverse 
transcription. NNRTIs are small molecules that bind to a hydrophobic pocket close to 
the catalytic site of the reverse transcriptase. Their binding causes a conformational 
change in the reverse transcriptase resulting in an inhibition of the polymerization. 
NNRTI mutations are almost all located in the hydrophobic pocket or nearby. They 
decrease the binding affinity of the drug.133-135 
 
Mutation EFV NVP ETV 
L100I    
K101E    
K101P    
K101H    
K103N    
V106A    
V106M    
V108I    
Y181C    
Y181I    
Y188C    
Y188H    
Y188L    
G190A    
G190S    
P225H    
 
Figure 7. Estimated susceptibility of nonnucleoside reverse transcriptase 
inhibitors in the presence of particular mutations. Susceptibility is estimated 
based on Stanford algorithm (version 6.0.11). Colour code: ■ 
hypersuceptible, ■ susceptible, ■ potential low-level resistance ■ low-level 
resistance, ■ intermediate resistance, ■ high-level resistance). EFV, 
efavirenz; NVP, nevirapine; ETV, etravirine 
 
NNRTIs generally have a low genetic barrier, only one or two mutations are needed 
for high-level resistance (e.g. K103N).136 The selection of particular mutations is 
usually dependent on the drugs used. Efavirenz selects mostly for K103N, but also 
for Y188L and Y181C. Nevirapine selects more often for Y181C, but also other 
mutations such as K103N, V106, Y188C and A190A occur. As shown in figure 7, 
cross-resistance is an important problem among NNRTI. If a viral strain is resistant 
against efavirenz, it is usually also resistant against nevirapine and vice versa. In 
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2008, a new generation NNRTI, etravirine, entered the market. It has a different 
resistance pattern and cross-resistance is clearly reduced. Especially the common 
mutation, K103N, has no or only little impact on etravirine susceptibility.137, 138 
TAMs are associated with a hyper-susceptibility to NNRTIs, although the clinical 
significance of hyper-susceptibility is currently not known.139, 140 
1.6.7 PI resistance-associated mutations 
The HIV protease cleaves large precursor polyproteins and generates functional 
subunits. If this action is inhibited viral particles are still produced, but they are 
noninfectious. Most PIs have been designed to mimic the natural substrates of the 
viral protease and they bind with a high affinity to the active site of the protease 
(reviewed in74, 75). This process hampers the cleavage of polyproteins. PI mutations 
are usually located inside the substrate-binding domain of the protease or at 
neighboring sites. PI mutations are classified in major and minor mutations. Major PI 
mutations have the largest clinical impact on susceptibility and occur at 13 positions 
on the protease. Minor PI mutations, also called accessory or secondary mutations, 
either improve the viral fitness or increase drug resistance.141 Minor mutations do not 
 
 FPV/r IDV/r NFV SQV/r LPV/r ATV/r TPV/r DRV/r  
D30N          
V32I          
M46I          
M46L          
I47V          
I47A          
G48V          
I50V          
I50L          
I54L          
I54M          
Q58E          
T74P          
L76V          
V82A          
V82F          
V82S          
V82T          
V82L          
N83D          
I84V          
Figure 8. Estimated susceptibility of protease inhibitors in the presence of particular mutations. 
Susceptibility is estimated based on Stanford algorithm (version 6.0.11). Colour code: ■ 
hypersuceptible, ■ susceptible, ■ potential low-level resistance ■ low-level resistance, ■ 
intermediate resistance, ■ high-level resistance. FPV, fosamprenavir; IDV, indinavir; NFV, 
nelfinavir; SQV, saquinavir; LPV, lopinavir; ATV, atazanavir; TPV, tipranovir; DRV, darunavir; /r, 
ritonavir boosted 
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lead to high-level resistance when occurring alone, but evidence was found that the 
time to virological failure is shortened when specific minor mutations are present.142, 
143 Minor PI mutations occur quite frequently as polymorphisms and its prevalence 
differs largely between subtypes.144 
Cross-resistance is also an important issue among PIs (figure 8). But the genetic 
barrier to develop resistance is higher for PIs compared to NNRTIs or some NRTIs.  
1.6.8 Fusion inhibitor resistance-associated mutations 
When HIV enters target cells gp41 interacts with chemokine receptors on the cell 
surface and during the entry process the two hydrophobic regions HR1 and HR2 bind 
to enable HIV’s entry. Enfuvirtide, a small peptide, the only registered fusion inhibitor, 
destabilizes this process. It mimics a part of the HR2 and binds to a conserved part of 
HR1.145 Enfuvirtide is only used in salvage therapy and in absence of other active or 
partially active drugs resistance mutations occur rapidly.146 Drug resistant mutations 
emerge at position 36 to 45 in the gp41. This region is part of the HR1 where T20 is 
binding.147-149 A single mutation usually leads to a 10-fold decrease in susceptibility 
and the occurrence of a second mutations leads up to a 100-fold reduction in 
susceptibility.150 There are several accessory mutations in the HR2 region which can 
compensate for the loss of viral fitness. 
1.6.9 CCR5 inhibitor resistance-associated mutations 
CCR5 inhibitors affect gp120 binding to the CCR5 co-receptor by an allosteric 
binding mechanism. Maraviroc is currently the only registered CCR5 inhibitor.64, 65 It 
is only effective when viruses exclusively use CCR5 for entry and not CXCR4. In the 
early stage of an HIV infection about 80-99% of the patients have viruses that 
exclusively use CCR5, but in later stages, the percentage of patients using CXCR4 
increases.151, 152 Different assays exist to determine the coreceptor usage (e.g. 
Trofile, a single-cycle recombinant virus assay in which a pseudovirus is produced 
from the full length env genes from patient’s virus population), but also genotypic 
prediction algorithms exist where the phenotypic activity is estimated based on 
genotypic information mostly of the V3 region, such as geno2pheno 
[http://coreceptor.bioinf.mpi-inf.mpg.de/index.php], Web PSSM [http://indra.mullins. 
microbiol.washington.edu/webpssm/], or Wetcat [http://genomiac2.ucsd.edu:8080/ 
wetcat/v3.html]. However, rarely drug resistance can also emerge independent of the 
tropism. It was shown that some mutations located in the V3 loop of gp120 are 
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associated with maraviroc resistance but there is no consensus about the clinical 
relevance of these mutations.89, 153, 154 
1.6.10 INI resistance-associated mutations 
The HIV integrase incorporates the double-stranded cDNA in the host’s genome. 
This process includes generally three steps: 1) formation of the preintegration viral 
DNA complex, 2) 3’ processing, and 3) strand transfer. INIs hamper the last step.155 
As in other drug classes, primary and secondary mutations occur during treatment 
with INIs. The selection of secondary mutations leads to further loss of activity or 
improved viral fitness. The single occurrence of mutation Y143R, Q148H/K/R or 
N155H is sufficient to lead to considerable reduction of INI activity. The genetic 
barrier to INI resistance is rather low.66, 67 
1.7 The Swiss epidemic and the Swiss HIV Cohort Study 
In contrast to Sub-Saharan Africa where HIV transmission mostly occurs during 
heterosexual contacts, HIV transmission in Switzerland currently occurs most often 
by homosexual intercourse between men (about 50%) [http://www.bag.admin.ch/ 
hiv_aids/]. The number of infections caused by intravenous drug use decreased in 
the last decade markedly, most likely due to the free delivery of needles, methadone 
and heroine programs. Furthermore, the role of intravenous drug users in 
transmission to the heterosexual population diminished over time.156 It is estimated 
that about 19,000-26,000 HIV infected patients live in Switzerland. Between 2000 
and 2010, the number of newly diagnosed persons was usually between 600 and 
800 per year. This results in a rate of 8.0-10.9 cases per 100,000 people 
[http://www.bag.admin.ch/hiv_aids/]. The number of AIDS-related death decreased 
markedly since the introduction of cART in 1995.157 
The Swiss HIV Cohort Study (SHCS) was established in 1988. It is an observational, 
multi-centre study of HIV infected individuals in Switzerland. The study is a 
collaboration of seven centres: Basel, Bern, Geneva, Lausanne, Lugano, St. Gallen, 
and Zürich. The SHCS has been approved by ethical committees of all participating 
institutions and written informed consent has been obtained from all participants. 
Overall the SHCS is estimated to include about 69% of patients living with AIDS and 
approximately 45% of patients infected with HIV in Switzerland.158 Until December 
31, 2010, 16,778 individuals were registered (figure 9). At registration, basic 
information is collected (e.g. year of birth, sex, transmission category and ethnicity) 
Introduction 
21 
Year
Nu
m
be
r o
f e
nr
ol
le
d 
pa
tie
nt
s
 85 87 89 91 93 95 97 99 01 03 05 07 09
0
200
400
600
800
1000
1200
1400
MSM
HET
IDU
OTH
Figure 9. Patients enrolled in the SHCS stratified by the transmission category. Adapted from 
www.shcs.ch. IDU, intravenous drug user; MSM, men who have sex with men; HET, heterosexual; 
OTH, other.  
 
and further on, laboratory and clinical data are collected at each semi-annual study 
visit. Also additional performed laboratory measurements, such as CD4+ cell count or 
viral load, are stored. Further, the antiretroviral treatment is recorded in detail, but 
also adherence data and adverse events are available. 
1.8 The SHCS drug resistance database 
Since 2000, genotypic resistance tests are performed in routine clinical care. In 
Switzerland, four laboratories are authorised from the Swiss Federal Office for Public 
Health to perform these tests. All laboratories use population-sequencing methods. 
The full protease gene and in minimum codon 28 to 225 of the reverse transcriptase 
gene are sequenced using commercial assays (Viroseq Vs. 1 PE Biosystems, 
Rotkreuz, Switzerland; Virsoseq Vs. 2, Abbott AG, Baar, Switzerland; vircoTYPE 
HIV-1 Assay, Virco Lab, Mechelen, Belgium) and in-house methods.159 In 2001, it 
was decided to store the sequences in a central database (SmartGene’s Integrated 
Database Network System, Zug, Switzerland) and to link the sequences to the SHCS 
with the SHCS identification number. In the first years, problems occurred with the 
data transfer of SHCS identification numbers to the laboratories and the linkage 
remained incomplete. In 2005, a large effort was undertaken to link data to the SHCS 
and in the following years, several thousand resistance test were performed 
retrospectively from stored plasma samples to complete the data set (von Wyl, 
Günthard, Scherrer, unpublished data). 
At the end of 2010, 16,399 sequences were stored in the database (figure 10). Out of 
these, 13,980 sequences from 9,660 different patients were linked to the SHCS. 
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Figure 10. Number of sequences stored in the SHCS drug resistance database stratified by samples 
from treatment-naïve and treatment-experienced patients. 
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Abstract 
Objectives 
Etravirine (ETV) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) 
with reduced cross-resistance to first generation NNRTIs, which has been primarily 
studied in randomized clinical trials and not in routine clinical settings. 
Methods 
ETV resistance-associated mutations (RAMs) were investigated by analysing 6072 
genotypic tests. The antiviral activity of ETV was predicted using different 
interpretation systems: International AIDS Society-USA (IAS-USA), Stanford, Rega 
and Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS). 
Results 
Prevalence of ETV RAMs was higher in NNRTI-exposed [44.9%, 95% confidence 
interval (CI) 41.0-48.9%] than in treatment-naïve patients (9.6%, 95% CI 8.5-10.7%). 
ETV RAMs in treatment-naïve patients with documented recent (<1 year) infection, 
who had acquired HIV before the introduction of NNRTIs, were almost identical 
(9.8%, 95% CI 3.3-21.4). Discontinuation of NNRTI treatment led to a marked drop in 
the detection of ETV RAMs, from 51.7% (95% CI 40.8-62.6%) to 34.5% (95% CI 
24.6-45.4%, P=0.032). Differences in prevalence among subtypes were found for 
V90I and V179T (P<0.001). Estimates of restricted virological response to ETV 
varied among algorithms in patients with exposure to efavirenz (EFV)/nevirapine 
(NVP), ranging from 3.8% (95% CI 2.5-5.6%) for ANRS to 56.2% (95% CI 52.2-
60.1%) for Stanford. The predicted activity of ETV decreased as the sensitivity of 
potential optimized background regimens decreased. The presence of major IAS-
USA mutations (L100I, K101E/H/P, Y181C/I/V) reduced the treatment response at 
week 24. 
Conclusions 
Most ETV RAMs in drug-naïve patients are polymorphisms rather than transmitted 
RAMs. Uncertainty regarding predictions of antiviral activity for ETV in NNRTI-treated 
patients remains high. The lowest activity was predicted for patients harbouring 
extensive multidrug-resistant viruses, thus limiting ETV use in those who are most in 
need. 
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Introduction 
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are important components 
in the drug combination schemes that are currently used in the treatment of HIV-1 
infections.1, 2 Because of overlapping resistance profiles of currently approved NNRTI 
drugs, cross-resistance can emerge rapidly, which excludes future use of this drug 
class.3-5 Recently, the situation has changed with the introduction of the 
diarylpyrimidine derivative etravirine (ETV), a novel, next generation NNRTI.6 ETV 
was designed for activity against wild-type HIV-1 and against strains harbouring 
NNRTI resistance-inducing mutations selected by nevirapine (NVP) or efavirenz 
(EFV). Its resistance-associated mutation (RAM) pattern is partially different from that 
of other NNRTIs and its genetic barrier, defined as the number of mutations required 
to confer full resistance, seems to be considerably higher.7, 8 Clinical studies showed 
that the presence of three or more ETV RAMs led to substantially decreased 
virological response.9-12 Current International AIDS Society-USA (IAS-USA) 
recommendations list the following 14 ETV RAMs: V90I, A98G, L100I, K101E/P, 
V106I, V179D/F/T, Y181C/I/V and G190A/S.13, 14 Recently, Vingerhoets et al.11 have 
updated the list of mutations and added K101H, E138A and M230L. Of note, this list 
does not include K103N, which confers high-level resistance to both EFV and NVP. 
The potential eligibility of patients for treatment with ETV in routine clinical practice 
has not been systematically assessed for large, well-characterized drug-naïve and 
treatment-experienced individuals. For this reason, we interrogated the resistance 
database from the Swiss HIV Cohort Study (SHCS) to determine the prevalence of 
ETV RAMs and to predict the potential eligibility of treatment-naïve and treatment-
experienced patients for treatment with ETV. Moreover, we compared different 
algorithms that predict susceptibility to ETV based on available genotypic resistance 
tests (GRTs). As it has been shown repeatedly that new antiretroviral drugs should 
be accompanied by at least two additional active compounds for optimal virological 
response to salvage treatment,15-19 we further identified patients who had failed 
NNRTIs previously with at least two remaining drugs for the background regimen in 
addition to ETV. 
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Methods 
Data and patient selection 
Our analysis included clinical and genotypic data collected up to May 2008. The 
SHCS is a nationwide, clinic-based cohort study with continuous enrolment and at 
least bi-annual study visits.20 The SHCS has been approved by ethical committees of 
all participating institutions and written informed consent has been obtained from 
participants. The SHCS resistance database contains all genotypic HIV resistance 
tests performed by the four authorized laboratories in Switzerland, stored in 
SmartGene’s (Zug, Switzerland) Integrated Database Network System (IDNS version 
3.4.0).21 Resistance tests performed between January 1999 and May 2008 were 
included in this study. Patients with recent infection were defined as presenting with 
either documented acute infection or a documented sero-conversion within 1 year as 
described in detail elsewhere.22 
 
Analysis 
Because GRTs were obtained under various circumstances, we stratified our 
analysis by whether patients were treatment naïve (group A) or antiretroviral therapy 
(ART) exposed at the time of resistance testing. Samples from treatment-
experienced patients were grouped further according to NNRTI exposure. Group B 
included resistance tests performed in treatment-experienced patients never exposed 
to any NNRTI, group C included resistance tests performed while patients were 
receiving NNRTI treatment and group D included tests performed after exposure to 
NNRTI (58.4% on treatment without NNRTIs, 41.6% off treatment). We only 
considered tests that were performed after at least 30 days of continuous exposure to 
ART since the last treatment modification. Patients could appear in more than one 
group, but only the latest resistance test of a patient was included if several tests per 
patient were available for the same group. 
Resistance mutations against ETV were defined according to the mutation list of the 
International AIDS Society-USA (IAS-USA).13, 14 We further classified ETV RAMs into 
ETV-specific mutations, which do not show cross-resistance to EFV or NVP based on 
the IAS-USA recommendations, and nonspecific mutations, which also confer 
resistance to NVP and EFV. The ETV-specific mutations included V90I, A98G, 
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K101E/H/P, V106I, E138A, V179D/F/T, Y181V and M230L, and ETV nonspecific 
mutations consisted of L100I, Y181C/I and G190S/A. 
GRTs were categorized into fully susceptible, intermediately resistant, and fully 
resistant to a specific antiretroviral drug with three frequently used interpretation 
algorithms: the Stanford algorithm, version 5.0.1,23 the RegaV7 1.1 algorithm24 and 
the Agence Nationale de recherches sur le sida et les hépatites virales (ANRS) 
(http://www.hivfrenchresistance.org/index.html) version 16 algorithm as implemented 
in the Stanford HIV Drug Resistance algorithm comparison tool 
(hivdb.stanford.edu/pages/algs/HIValg.html). As a fourth classification following the 
IAS-USA spring 2008 guidelines, we considered viruses with at least three IAS-USA 
ETV RAMs as fully resistant to ETV and viruses with one or two IAS-USA ETV RAMs 
as intermediately resistant. The newest update of IAS-USA guidelines, for December 
2008, has assigned relative weights to the following mutations based on in vitro and 
in vivo data: L100I, K101E/H/P and Y181C/I/V.13, 14 In analogy to major protease 
inhibitor (PI) mutations it has been shown that these weighted ETV mutations do 
induce a substantial reduction in phenotypic drug susceptibility compared with the 
other nonweighted ETV mutations.25-27 Thus, for simplicity, we will call ETV RAMs at 
these three positions as ‘major ETV mutations’. To assess the availability of active 
antiretroviral compounds for combination with ETV, results obtained using the 
Stanford interpretation algorithm were mapped to a genotypic sensitivity score (GSS) 
for all approved drugs except enfuvirtide, maraviroc and raltegravir. Drugs with a 
score of 0 were considered inactive because of full resistance of the virus to that 
compound, 0.5 indicated intermediate antiretroviral activity and 1 related to full 
activity based on GRTs. It was assumed that ETV-based salvage therapy following 
EFV or NVP failure should consist of the two highest scoring NRTI drugs and one of 
the highest scoring boosted PIs as background treatment. Thus a maximum score of 
3 could be achieved for a fully active background regimen and a score of 0 if all drugs 
were considered inactive. Virological failure was defined as viral rebound after 
previous suppression with two consecutive viral loads >500 HIV-1 RNA copies/mL or 
a single value >500 copies/mL followed by a stop or a modification of the current 
therapy. 
Statistical analysis was performed with Stata 10 SE (StataCorp, College Station, TX, 
USA). Proportions were compared with the Fisher’s exact test. All confidence 
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intervals (CIs) were two-sided 95% confidence intervals and calculated with the 
Clopper-Pearson method. The level of significance was set at P<0.05. 
Results 
Prevalence of RAMs for ETV  
We included 6072 resistance tests from the SHCS drug resistance database in our 
analyses: 3020 (49.7%) GRTs performed in treatment-naïve patients (group A), 1667 
(27.5%) in NNRTI-naïve patients exposed to ART without NNRTIs (group B), 639 
(10.5%) performed in patients on NNRTI treatment (group C) and 746 (12.3%) 
performed in patients with past NNRTI experience (group D) (Fig. 1). 
ETV RAMs occurred three times more frequently in NNRTI-experienced patients 
(groups C and D: 32.6%, CI 30.2-35.2%) compared with NNRTI-naïve patients 
(groups A and B: 10.0%, CI 9.1-10.9%, P<0.001). In patients with virological failure 
on EFV/NVP the prevalence was 51.9% (CI 45.7-58.2%). The prevalence of 
nonspecific ETV RAMs, which also confer resistance to other approved NNRTIs, was 
higher in NNRTI- experienced patients (groups C and D: 21.4%, CI 19.2-23.6%) than 
in NNRTI-naïve patients (groups A and B: 0.7%, CI 0.5-1.0%, P<0.001). The 
increase in frequency of specific ETV RAMs following exposure to NNRTI was less 
pronounced, but still highly significant (groups A and B: 9.5%, CI 8.7-10.4%; groups 
C and D: 19.9%, CI 17.9-22.1%, P<0.001). Among patients with at least one ETV 
RAM, single mutations were most common (84.8%, CI 83.9-85.7%). The acquisition 
of three or more ETV RAMs, which would indicate high level resistance to ETV 
according to IAS-USA, was most common in groups C and D (8.2%, CI 5.8-11.1%) 
and occurred significantly less frequently in NNRTI-naïve patients (groups A and B: 
0.9%, CI 0.2-2.2%, P<0.001). Also, the occurrence of at least one major ETV RAM 
according to IAS-USA (L100I, K101E/H/P, Y181C/I/V) was higher in groups C and D 
(18.8%, CI: 16.7-20.9%) compared with NNRTI-naïve patients (groups A and B: 
0.9%, P<0.001). 
As illustrated in Figure 2, the most prevalent mutations in NNRTI-naïve patients 
(groups A and B) were the ETV-specific mutations E138A (group A: 2.8%; 
group B: 2.8%), V106I (group A: 2.3%; group B: 1.7%) and V90I (group A: 2.1%; 
group B: 2.9%), whereas in patients tested while receiving NNRTIs (group C) or after 
NNRTI exposure (group D) mutations selected by EFV and NVP were mainly 
dominating: L100I (8.3%), Y181C (15.0%), G190A (12.5%) in group C and V90I 
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(3.9%), Y181C (5.0%) and G190A (3.2%) in group D. Interestingly, the two ETV 
RAMs V179F and Y181V were not found at all in our large study sample. 
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Association between ETV RAMs and HIV subtypes 
We further analysed associations between ETV RAMs and HIV subtypes based on 
genotypic tests from treatment-naïve patients (group A, n=3020). Most samples were 
subtype B (78.1%), followed by subtype CRF02_AG (6.2%), A (5.5%), C (5.4%) and 
CRF01_AE (4.7%). Based on Fisher’s exact test and Bonferroni-adjustment of P-
values for multiple testing, two mutations were found to be significantly different 
between subtypes, V90I and V179T (both P<0.001). V90I was most prevalent in 
subtype CRF02_AG (7.9%, CI 4.3-13.2%) compared with subtypes A (2.1%, CI 0.4-
5.9%) and B (1.9%, CI 1.4-2.6%) and did not occur in subtypes C. V179T was most 
common in subtypes A (4.1%, CI 1.5-8.7%) and CRF01_AE (3.2%, CI 0.9-8.1) and 
was not found in subtypes CRF02_AG, B and C. 
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Figure 2. Percentage of etravirine resistance-associated mutations (ETV RAMs) based on genotypic 
resistance tests from treatment-naïve patients (group A), nonnucleoside reverse transcriptase inhibitor 
(NNRTI)-naïve patients (group B), patients exposed to NNRTIs [group C] and patients who had 
stopped treatment with NNRTIs (group D). The following ETV RAMs did not occur: 179F and 181V. 
ART, antiretroviral therapy 
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ETV RAMs in patients experiencing virological failure with EFV or NVP 
We further focused our analysis on patients who had failed NVP- or EFV-containing 
therapies. In total, 258 GRTs were performed in patients with a virological failure, 182 
(70.5%) of whom were exposed to EFV and 76 (29.5%) to NVP. 
Frequencies of ETV-specific RAMs did not differ markedly according to exposure to 
EFV or NVP: V90I (4.9% on EFV vs. 5.3% on NVP, P=1.000), A98G (5.5% vs. 6.6%, 
P=0.773), K101E (8.2% vs. 11.8%, P=0.357), K101H (0.5% vs. 1.3%, P=0.503), 
K101P (3.3% vs. 0%, P=0.184), V106I (2.7% vs. 3.9%, P=0.697), E138A (1.6% vs. 
5.5%, P=0.200), V179D (4.4% vs. 1.3%, P=0.289), V179T (0.5% vs. 1.3%, P=0.503) 
and M230L (3.8% vs. 0%, P=0.109). Certain nonspecific ETV mutations, however, 
preferentially occurred on treatment with specific NNRTIs, such as L100I (14.8% on 
EFV vs. 1.3% on NVP, P=0.001), Y181C (9.3% on EFV vs. 28.9% on NVP, 
P<0.001), and G190A (10.4% vs. 22.4%, P=0.017). The mutations Y181I (0% on 
EFV vs. 1.3% on NVP, P=0.295) and G190S (8.8% on EFV and 3.9% on NVP, 
P=0.203) occurred at similar frequencies in the two treatment groups. 
 
Persistence of ETV RAMs following exposure to EFV or NVP 
To analyse the persistence of ETV RAMs, we selected patients with a virological 
failure on EFV or NVP who had received a GRT during exposure to NNRTI and a 
later GRT performed on a therapy not containing NNRTI or off treatment (n=87). The 
median time between stop of NNRTIs and the second GRT was 897 days 
[interquartile range (IQR): 356-1555 days]. 
The prevalence of one or more ETV RAMs significantly decreased after cessation of 
exposure to NNRTIs from 51.7% (CI 40.8-62.6%) to 34.5% (CI 24.6-45.4%, 
P=0.032). The appearance of ETV RAMs tended to be less frequent in patients who 
had stopped ART (25%, CI 7.3-52.4%, n=16) compared with patients who had 
continued ART without NNRTIs (36.6%, CI 25.5-48.9%, n=71). Overall, 55.6% (CI 
40.0-70.4%) of patients had lost at least one ETV RAM after the stop of NNRTIs. As 
shown in Figure 3, the frequency of almost all ETV RAM decreased after stop of 
NNRTI drugs. 
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Figure 3. Changes in frequency of etravirine resistance-associated mutations (ETV RAMs) and 
K103N after discontinuation of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy. 
Patients with two genotypic resistance tests (GRTs), one performed during exposure to NNRTIs and 
a second performed at least 30 days after discontinuation of NNRTI treatment, were included (n=87). 
For comparison, the NNRTI mutation K103N is listed. K103N does not affect the antiviral activity of 
ETV, but is known to disappear after discontinuation of NNRTI treatment.28 
 
Eligibility for ETV in the SHCS population based on different algorithms 
We further aimed to determine the potential eligibility for treatment with ETV for 6072 
GRTs performed based on the Stanford algorithm. Overall, ETV was considered fully 
active in 4599 (98.1%, CI 97.7-98.5%) NNRTI-naïve patients and in 518 (69.4%, 
CI 66.1-72.8%) patients with past NNRTI experience, but only in 262 (41.0%, 
CI 37.2-44.8%) patients with GRTs while being exposed to NNRTI.  
For further analysis, we focused on patients with GRTs obtained while receiving 
EFV/NVP. Of all four interpretation methods the Stanford algorithm predicted the 
highest proportion of intermediate/full resistance in GRTs (56.2%, CI 52.2-60.1%). 
The predictions obtained with the IAS-USA recommendations (44.7%, CI 40.8-
48.7%), Rega 7.1 algorithm (23.3%, CI 20.1-26.8%) and the ANRS algorithm (3.8%, 
CI 2.5-5.6%) were generally much lower (Fig. 4). The predicted frequency of full 
resistance was comparable across interpretation methods (Stanford: 3.8%, CI 2.5-
5.6%; IAS-USA: 4.4%, CI 3.0-6.3%; Rega: 5.7%, CI 4.0-7.8%), with the exception of 
the ANRS algorithm, which classified 0.5% (CI 0.1-1.4%) of the samples as fully 
resistant. As shown in Figure 4, taking either EFV or NVP did not have differential 
effect on the estimated antiviral activity of ETV. 
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Figure 4. Proportion of genotypic resistance tests (GRTs) indicating intermediate or full resistance 
against etravirine (ETV), efavirenz (EFV) or nevirapine (NVP) according to different interpretation 
algorithms. The analysis was stratified by whether the patient was receiving EFV (n=428) or NVP 
(n=203) at the time of sampling. ANRS, Agence Nationale de Recherches sur le Sida et les hépatites 
virales; HIVDB, Stanford HIV Drug Resistance Data Base; IAS-USA, International AIDS Society-USA 
 
Transmission of ETV drug resistance mutations 
We analysed the prevalence of ETV RAMs in 763 GRTs in recently infected, 
treatment-naïve patients.22 The prevalences of specific and nonspecific ETV 
mutations were 9.0% (CI 7.1-11.3%) and 0.9% (CI 0.3-1.9%), respectively, without 
any significant time trends (by the Cochran-Armitage test, not shown). Of note, the 
ETV RAMs V90I, A98G, E138A and V179D/T were detected in five of 51 (9.8%) 
plasma samples obtained before 1998, when NNRTIs were not yet registered in 
Switzerland. Thus, the detection of ETV RAMs in recently infected patients most 
probably reflects polymorphism rather than transmitted RAMs. 
 
Estimated benefit of ETV in patients with different effective background regimen 
Stratified by the GSS of the optimized background regimen, we aimed to identify the 
percentage of patients exposed to NNRTIs (group C) with a virus fully susceptible to 
ETV. The GSS of an optimized background treatment regimen was defined based on 
cumulative information from GRTs and consisting of the highest scoring of two NRTIs 
and one boosted PI. Based on the Stanford algorithm, only 22.9% (CI 15.4-32.0%) of 
samples with little residual antiviral activity of the background treatment (GSS<2) 
were fully susceptible to ETV, whereas significantly more viruses were susceptible 
(45.9%, CI 41.6-50.3%, P<0.001) in samples with more potent backbone regimens 
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(GSS≥2), indicating that the additional benefit of ETV may be limited for those in 
most need. As shown in Figure 5, other algorithms predicted higher benefits of ETV, 
however, and the frequency of patients with fully susceptible virus did not correlate 
with the magnitude of the GSS for the background regimens (ANRS algorithm, range 
86.7-98.3%; REGA algorithm, range 60.0-83.8%). Of note, 81.9-84.9% of patients 
achieved a GSS of ≥2 for the background regimen. 
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Figure 5: Proportion of patients with a genotypic resistance test performed while receiving nevirapine 
(NVP) or efavirenz (EFV) (n=631) and with a virus fully susceptible to etravirine (ETV). The analysis 
was stratified by a cumulative genotypic sensitivity score (GSS) for a hypothetical optimized 
background regimen consisting of two nucleoside reverse transcriptase inhibitor (NRTIs) and one 
protease inhibitor (PI). A GSS of 0 indicates full resistance and 1 indicates full susceptibility. ANRS, 
Agence Nationale de Recherches sur le Sida et les hépatites virales; HIVDB, Stanford HIV Drug 
Resistance Data Base; IAS-USA, International AIDS Society-USA 
 
Clinical response 
An intent-to-treat analysis (n=71) for the week 24 response showed an overall viral 
suppression rate of 71.8% (CI 59.9-81.9%). The presence of L100I, K101E/H/P or 
Y181C/I/V was more predictive for the short-term outcome (viral load <50 copies/mL 
after 24 weeks follow-up) than the GSS calculated using the Stanford algorithm. 
Patients with one of the above-mentioned mutations had a suppression rate of 52.9% 
(CI 27.8-77.1%) compared with 77.8% (64.4-88.0%) when these mutations were 
absent (P=0.065). In contrast, the GSS for ETV as estimated using the Stanford 
algorithm was not predictive for a virological response: response rates for fully 
susceptible viruses were 71.4% (CI 51.3-86.8%) compared with 72.1% (CI 56.3-
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84.7%, P=1.000) for those with intermediate/full resistance. This tendency was 
confirmed, by a multivariable logistic regression including HIV RNA at the start of 
ETV treatment, the GSS of the background regimen and the presence of L100I, 
K101E/H/P, or Y181C/I/V. Failure to achieve undetectable HIV RNA was better 
predicted by the presence of one of the abovementioned mutations [odds ratio (OR): 
2.8, CI 0.8-9.4] than by the Stanford algorithm (OR for intermediate/fully ETV-
resistant HIV 0.7, CI 0.2-2.2). 
Discussion 
In this data set from a highly representative cohort study, the prevalence of ETV 
RAMs was higher in NNRTI-treated patients compared with NNRTI-naïve patients. 
ETV RAMs were lost at a relatively high rate once NNRTI drugs were stopped. 
Uncertainty remains for predictions of ETV activity, because analyses with different 
algorithms led to widely varying results. 
The prevalence of ETV RAMs was 44.9% in patients tested while receiving NNRTIs, 
and 51.9% in patients failing on NNRTIs. Other studies have reported higher 
prevalence estimates of ETV RAMs in patients failing on NNRTIs, ranging between 
61.7% and 74.1%.29, 30 Also, the occurrence of three or more ETV RAMs was less 
common in our study.12, 30, 31 The most likely explanation for the lower frequency of 
ETV mutations found in the SHCS might be that treatment failures in the SHCS were 
managed aggressively early on and that NNRTIs were rarely maintained in failing 
drug regimens,15, 21 even when no other options were available. Two ETV mutations 
were associated with the largest impact on response, namely Y181I and Y181V.32 
The former mutation was rare and the later did not appear in our study sample. In 
addition, four mutations were also associated with a higher negative impact on 
response and their prevalence was increased with exposure to NNRTI treatment, 
namely L100I (8.3%), K101P (1.3%), Y181C (15.0%) and M230L (1.7%). It should be 
mentioned, that the prevalence of K101E increased under NNRTI treatment, even 
though K101E is not associated with NNRTI resistance.32 
The fact that certain ETV-specific IAS-USA mutations such as 90I or 106I were 
already present at relative high frequencies in samples from treatment-naïve patients 
and their persistence in longitudinal samples suggests that these represent 
polymorphisms. This hypothesis is further strongly supported by the high frequency 
of transmitted ETV RAMs in our large study group with documented recent infection, 
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especially as the prevalence of ETV RAMs did not differ before and after registration 
of NNRTIs in Switzerland. Whether these polymorphisms really have an impact on 
ETV activity in clinical practice has to be further investigated in datasets with longer 
follow-up. 
It should be noted that ETV RAMs that also affect other approved NNRTIs were lost 
at a relatively high rate once NNRTI drugs were stopped, as our analysis of GRTs 
performed on and off treatment containing NNRTIs has demonstrated. Overall, 
55.6% of patients with sequential GRTs lost at least one ETV RAM, and hence GRTs 
performed distantly from NNRTI-containing therapy should be interpreted with 
caution because of the possible presence of minor viral variants with drug resistance 
mutations. 
Overall, 631 GRTs were performed while patients were receiving EFV (n=428) or 
NVP (n=203). When analysed with Stanford algorithm, 67.5% of GRTs indicated full 
resistance to EFV and 76.9% to NVP, whereas full resistance against ETV was 
observed in 3.8% of GRTs. Full susceptibility to ETV was only predicted for 43.8% on 
EFV/NVP by the Stanford algorithm, suggesting considerable cross-resistance of 
ETV with approved NNRTIs. However, other interpretation methods such as ANRS 
and Rega or IAS-USA, gave less weight to the potential overlap of resistance 
mutations between ETV and EFV/NVP, thus yielding higher predictions for the 
proportion of viruses fully susceptible to ETV. Therefore, depending on interpretation 
methods used, we estimated that 43.8-96.2% of patients with a GRT performed while 
receiving potent NNRTI drug would be unaffected by the presence of resistance 
mutations and 3.3-54.9% could still get a partial benefit from treatment with ETV. 
This low concordance among interpretation methods for predicting antiviral activity of 
ETV reflects the current uncertainty about how much the resistance profiles of ETV 
and EFV/NVP are overlapping. Moreover, the set of mutations that may affect viral 
response to ETV have not yet been clearly defined outside of the Duett studies.9, 10 
All these issues are highly relevant for decision-making in clinical practice, and 
further studies are warranted. 
ETV is currently approved for use in salvage treatments. The application of a novel 
antiretroviral drug is especially interesting in patients with previous virological failure 
on NNRTIs and few alternative treatment possibilities. Depending on interpretation 
algorithm, our calculations showed that the effectiveness of ETV decreased almost 
Chapter 1 
45 
linearly in highly treatment-experienced patients with decreasing potency of an 
optimized background regimen. 
The presence of major ETV IAS-USA mutations (L100I, K101E/H/P, Y181C/I/V) 
reduced the treatment response at week 24. The occurrence of these mutations was 
more predictive for clinical outcome than the Stanford algorithm. Although our sample 
size was relatively small for this analysis (n=71) a recent study investigating short-
term responses at week 8 in a larger number of patients (n=243) supports our 
findings.33 
Because of its good tolerability, a further potential application for ETV could be in 
patients with intolerance to EFV and NVP. In our study sample, 11% of patients had 
to cease treatment within 90 days of NNRTI initiation because of intolerance. ETV 
may be a safer alternative for these patients, because adverse events such as 
rashes are less severe and their incidence is lower compared with EFV treatment8.  
This study has some limitations. Not all GRTs in ART experienced patients were 
performed because of virological failures. We repeated the main analyses for those 
patients who failed NNRTI-treatment virologically, with virological failure defined as 
two consecutive on-treatment viral load measurements >500 copies/mL after at least 
180 days of treatment. Of note, our results did not change. Moreover, as sequential 
GRTs were available for relatively few ART-exposed patients, eligibility may have 
been somewhat overestimated. However, the SHCS drug resistance database 
generally has a very high degree of completeness, with GRTs for more than 65% of 
all patients with a history of virological failures [von Wyl and Günthard, unpublished 
data]. 
In conclusion, here we clearly demonstrate that ETV RAMs in drug-naïve patients 
mainly reflect polymorphisms and probable do not confer high levels of resistance to 
ETV by themselves. Moreover, we have shown that only small differences exist in the 
prevalence of ETV RAMs among subtypes. Most importantly, caution is needed for 
the interpretation of GRTs performed off NNRTI treatment, because the frequency of 
ETV RAMs diminishes if the selection pressure is removed. Furthermore, 
considerable uncertainty remains in predicting the antiviral activity of ETV, underlined 
by widely discrepant results obtained using different interpretation systems. The 
newly defined weighted IAS-USA ETV mutations, however, were associated with 
enhanced clinical relevance when compared to the nonweighted mutations. Thus, the 
presence of these weighted mutations should particularly caution clinicians to use 
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ETV, in particular, in patients with extensive multidrug resistance. In this patient 
group, the predicted activity of ETV was the lowest, thus limiting the use of ETV in 
those patients most in need. 
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Abstract 
Background 
Raltegravir (RAL) achieved remarkable virological suppression rates in randomized-
clinical trials, but today efficacy data and factors for treatment failures in a routine 
clinical care setting are limited. 
Methods 
First, factors associated with a switch to RAL were identified with a logistic regression 
including patients from the Swiss HIV Cohort Study (SHCS) with a history of 3 class 
failure (n=423). Second, predictors for virological outcome were identified in an 
intent-to-treat analysis including all patients who received RAL. Last observation 
carried forward imputation was used to determine week 24 response rate (HIV-1 
RNA<50 copies/mL). 
Results 
The predominant factor associated with a switch to RAL in patients with suppressed 
baseline RNA was a regimen containing enfuvirtide [odds ratio: 41.9 (95%CI: 11.6-
151.6)]. Efficacy analysis showed an overall response rate of 80.9% (152/188), 
whereas 71.8% (84/117) and 95.8% (68/71) showed viral suppression when stratified 
for detectable and undetectable RNA at baseline, respectively. Overall CD4 cell 
counts increased significantly by 42 cells/µl (P<0.001). Characteristics of failures 
were a genotypic sensitivity score of the background regimen ≤1, very low RAL 
plasma concentrations, poor adherence and high viral load at baseline. 
Conclusions 
Virological suppression rates in our routine clinical care setting were promising and 
comparable to data from previously published randomized-controlled trials. 
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Introduction 
Currently, the strategy for HIV treatment is based on combination therapy to achieve 
durable viral suppression. Long-term use of HIV treatment can be jeopardized by the 
development of resistance and drug toxicity. Multi-drug resistance and cross-
resistance to agents within the same drug class lead to restricted treatment options.1-
3 The introduction of the integrase inhibitor raltegravir (RAL) has broadened the 
treatment possibilities for highly treatment experienced patients considerably.4-7 
In Switzerland, RAL has been registered since February 2008 for use only in highly 
antiretroviral treatment (ART) experienced patients with detectable HIV-1 RNA. 
Phase 2 and phase 3 clinical trials showed that RAL, together with an optimized 
background regimen, provided good HIV-1 suppression, in particular, in patients with 
triple-class drug failure and extensive drug resistance.5, 6, 8 Success rates were 
comparable with what has been achieved in earlier salvage studies.9-13 There are no 
major pharmacokinetic interactions known with other antiretroviral drugs, although 
atazanavir increases and tipranavir decreases the plasma concentration of RAL 
moderately.14-18 RAL is the last option to achieve complete viral suppression for many 
highly treatment experienced patients. Due to its good tolerance and high efficacy, 
RAL may also be an option for treatment simplification, for example to circumvent a 
regimen including enfuvirtide (T20), which is difficult to administer and causes allergic 
injection site reactions,19, 20 or potentially to reduce drug toxicity caused by other 
drugs, such as dyslipidemia or liver toxicity. 
Using data from the Swiss HIV Cohort Study (SHCS), we aimed to identify the main 
factors associated with a change of the ART to a regimen containing RAL. We further 
analyzed the outcome of this switch in terms of sustained undetectable viral loads 
and CD4 cell count recovery after 24 weeks of treatment. For patients with 
incomplete viral suppression after 24 weeks of RAL treatment, we attempted to 
identify factors associated with suboptimal treatment response by assessing 
adherence, results from therapeutic drug monitoring and HIV drug resistance.  
Methods 
Patient selection and study design 
The Swiss HIV cohort study (SHCS) is a nationwide, multicenter, clinic-based, highly 
representative cohort with continuous enrolment and at least semiannual study 
visits.21 The study has been approved by ethical committees of all participating 
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institutions, and written informed consent has been obtained from all participants 
(ClinicalTrials.gov, #NCT00904644). For the present analysis, we included patients 
with at least one SHCS study visit after February 1, 2008, and patients who 
participated in the expanded access program before the registration of RAL in 
Switzerland. Two analyses with different study populations were performed; one 
analysis aimed to assess factors associated with the switch to RAL, and the second 
analysis was an efficacy study. 
 
Patient selection for identification of factors associated with switching to RAL 
We identified factors for switching the previous ART to a regimen containing RAL. 
Because in Switzerland RAL is only approved for use in highly treatment experienced 
patients, we included only individuals who had experienced triple class failure on 
nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse 
transcriptase inhibitor (NNRTI), and protease inhibitor (PI). Virological failure was 
defined as viral rebound after previous suppression with 2 consecutive viral loads 
greater than 500 copies/mL or a single value greater than 500 copies/mL followed by 
a stop or a modification of the current therapy. In addition, we considered patients 
with evidence for triple class failure based on cumulative information from genotypic 
drug resistance testing, defined as the presence of at least 1 class-specific IAS-USA 
mutation against each of all 3 classes.22 
 
Patient selection for efficacy analysis 
Additionally, we aimed to study the efficacy of RAL, defined as an HIV-1 RNA<50 
copies/mL after 24 weeks (window 20-28 weeks) of continuous treatment with RAL. 
Contrary to the first analysis, in the efficacy analysis we included all patients who had 
started a treatment with RAL, irrespective of their treatment history or resistance 
pattern to obtain most representative estimates for RAL efficacy in a routine clinical 
care setting. 
Routinely performed measurements of RAL plasma levels were included in the study 
and compared to previous published levels, where logarithmic RAL plasma 
concentrations were approximately linear between the peak (1.7h) and 12h after 
administration. We considered plasma levels below the lower 90% confidence 
interval (CI) as too low.23 Drug levels were measured with liquid chromatography-
tandem mass spectrometry (LC-MS/MS).24 
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Statistical method 
Baseline was defined as the start of the first ART including RAL. Multivariable logistic 
regression was used to identify predictors for switching to a treatment containing 
RAL. The following baseline characteristics were considered in the model: sex, 
ethnicity, age, risk group, CD4 cell count, number of drugs in the last treatment, the 
presence of T20 in the last regimen, self-reported adherence, genotypic sensitivity 
score (GSS) of the optimized background regimen, lipid profile [triglycerides, high-
density lipoprotein (HDL), cholesterol, total cholesterol], and the Framingham risk 
score.25 Predictors were included in the multivariable analysis if the univariable P 
value was <0.2 and sex, ethnicity, risk group and age, irrespective of its P value. As 
an a priori hypothesis we postulated that for patients with detectable HIV-1 RNA at 
start of RAL the main factor for RAL initiation may be to achieve viral suppression, 
whereas switches to RAL in patients with prior undetectable HIV-1 RNA may be 
driven by the wish for treatment simplification and toxicity concerns. We therefore 
developed 2 separate logistic regression models for patients with undetectable 
baseline HIV-1 RNA (switch patients) and patients with detectable baseline viral load 
(salvage patients). 
An intent-to-treat analysis was performed to determine RAL efficacy. Two strategies 
were used to account for missing information on endpoints: missing values were 
considered failures (m = f), or we carried forward the last HIV-1 RNA measurement 
obtained before week 20 to impute the week 24 HIV-1 RNA [last observation carried 
forward (LOCF)]. Factors for a virological nonresponse to RAL after 24 weeks were 
assessed with logistic regression models using the same covariables for adjustment 
as in the prediction model for switching to RAL. In addition, we also included baseline 
HIV-1 RNA, CD4 nadir, coadministration of boosted PIs, GSS of the background 
regimen and central nervous system (CNS) penetration effectiveness (CPE) rank of 
the background regimen as covariables. The GSS was calculated based on the 
Stanford algorithm (version 6.0.1; HIV Drug Resistance Database, Stanford, CA) for 
all approved NRTI, NNRTI, and PI drugs. Viral susceptibility to T20 and maraviroc 
(MVC) was considered to be intact if these drugs had not been included in a previous 
failing regimen. Genotypic data were obtained from the SHCS resistance database 
which contains all genotypic HIV resistance tests performed by the 4 authorized 
laboratories in Switzerland, stored in SmartGene’s (Zug, Switzerland) Integrated 
Database Network System (IDNS version 3.5.4).26 
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A CPE of 0, 0.5 or 1 indicated low, intermediate or high CNS penetration, 
respectively. The CPE of MVC was estimated as 1 and the CPE of etravirine (ETV) 
as 0.5.27-29  
Mixed-effects linear regression was performed to estimate the increase in CD4 cell 
count after week 24. 
Statistical analysis was performed with Stata 10 SE (StataCorp, College Station, TX, 
USA). The level of significance was set at P<0.05. 
Results 
Factors associated with a switch to RAL 
We identified 423 patients who had experienced triple class failures and were actively 
participating in the SHCS in February 2008 of whom 238/423 (56.3%) had 
undetectable viral loads at the last HIV-1 RNA measurement and 185/423 (43.7%) 
had detectable viral loads, respectively. In total, 123 (29.1%) patients changed the 
ART to a regimen containing RAL, 48/238 (20.2%) of whom had undetectable and 
75/185 (40.5%) had detectable viral loads (HIV-1 RNA>50 copies/mL) at the time of 
treatment change. Mentionable, 48/123 (39.0%) of patients who started RAL had an 
undetectable viral load.  
As shown in Table 1, in patients with undetectable viral load at baseline (n=238) the 
multivariable model indicated that low CD4 cell counts (<200cells/µL), exposure to 
T20 and increased triglycerides (>2.3 mmol/L) were important factors to change the 
current ART to a RAL-containing regimen. Heterosexual patients received RAL less 
likely compared with homosexual men. Additionally, age, more than 5 drugs in the 
last regimen, decreased HDL cholesterol (<0.9 mmol/L), increased Framingham 
score and low GSS of the background regimen were significantly associated with 
RAL administration in the univariable model. 
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Table 1. Univariable and multivariable logistic regression to identify factors associated with a switch to 
RAL (n=48) in patients with triple-class failure (n=238) and undetectable HIV-1 RNA (<50 copies/mL). 
  Univariable analysis Multivariable analysis 
Characteristics N (%) (on RAL/TCF) OR 95% CI P  OR 95% CI P 
Sex         
Male 40/172 (23.3) Ref       
Female 8/66 (12.1) 0.5 (0.2-1.0) 0.060  2.3 (0.6-9.5) 0.251 
Ethnicity         
White 46/206 (22.3) Ref       
Other 2/32 (6.3) 0.2 (0.1-1.0) 0.051  1.0 (0.1-7.3) 0.990 
Risk         
Homosexual 28/98 (28.6) Ref       
Intravenous drug use 9/42 (21.4) 0.7 (0.3-1.6) 0.381  1.2 (0.3-4.9) 0.800 
Heterosexual 9/86 (10.5) 0.3 (0.1-0.7) 0.003  0.2 (0.1-0.8) 0.026
Other 2/12 (16.7) 0.5 (0.1-2.4) 0.390  1.5 (0.2-12.1) 0.700 
Age per year older  1.5 (1.1-2.0) 0.009  1.4 (0.8-2.2) 0.227 
CD4 cell count         
≥200 cells/µL 40/222 (18.0) Ref       
<200 cells/µL 8/16 (50.0) 4.6 (1.6-12.8) 0.004  5.4 (1.0-29.0) 0.050
No. drugs in last regimen         
0-3 8/74 (10.8) Ref       
4-5 28/133 (21.1) 2.2 (0.9-5.1) 0.067  0.5 (0.1-1.7) 0.254 
Over 5 12/31 (38.7) 5.2 (1.9-14.6) 0.002  0.4 (0.1-1.8) 0.214 
Self-reported adherence         
Never missed a dose 39/190 (20.5) Ref       
1 dose per month 7/37 (18.9) 0.9 (0.4-2.2) 0.824     
1 dose per week 2/11 (18.2) 0.9 (0.2-4.1) 0.851     
Exposure to T20 in last regimen         
Unexposed 10/175 (5.7) Ref       
Exposed 38/63 (60.3) 25.1 (11.0-56.6) <0.001  41.9 (11.6-151.6) <0.001
Total cholesterol         
Normal 39/191 (20.4) Ref       
High (>6.2mmol/L) 9/47 (19.1) 0.9 (0.4-2.1) 0.846     
HDL cholesterol         
Normal 28/168 (16.7) Ref       
Low (<0.9mmol/L) 20/70 (28.6) 2.0 (1.0-3.9) 0.039  0.7 (0.2-2.0) 0.473 
Triglycerides         
Normal  16/134 (11.9) Ref       
High (> 2.3 mmol/L) 32/104 (30.8) 3.3 (1.7-6.4) <0.001  4.0 (1.5-11.0) 0.006
Framingham score per 10% increase  1.9 (1.2-2.8) 0.004  0.8 (0.4-1.5) 0.439 
GSS optimized background regimen         
GSS <2 42/149 (27.7) Ref       
GSS ≥2 6/80 (8.6) 0.2 (0.1-0.5) 0.001  0.4 (0.1 -1.1) 0.084 
Unknown 0/9 (0) - - -  - - - 
Bold values indicate P <0.05 
TCF patients who experienced triple class failure, OR odds ratio. 
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In patients with detectable viral load, the multivariable model showed that exposure 
to T20 in the previous regimen, low CD4 cell counts, self-reported adherence and low 
GSS of the optimized background regimen were associated with the decision to 
include RAL in the salvage ART (Table 2). Intravenous drug users received RAL less 
likely compared to homosexual men. Additionally, in the univariable model also 
heterosexual patients received RAL less likely. In contrast to patients with 
suppressed viremia, lipid abnormalities were not correlated with the change in 
patients with detectable viral load. 
 
Efficacy analysis 
We performed an intent-to-treat analysis to investigate whether the change to RAL 
was successful in patients with detectable (salvage patients) or suppressed (switch 
patients) viral load at baseline, respectively. In total, 243 patients had started a 
regimen containing RAL since February 2008. Three (1.2%) patients were excluded 
because of missing baseline data and 52 patients were excluded, because RAL was 
started within less than 20 weeks before the cut-off date for this analysis (28 
February 2009). Thus, for the efficacy analysis, we included 188 patients, of whom 
184 still were on RAL after 24-week follow-up. A total of 117 patients were salvage 
patients and 71 switch patients. During follow-up, 4 patients interrupted ART for a 
median time of 25 days (range: 1-136) and four patients interrupted the intake of RAL 
for a median time of 57 days (range: 10-61), but all except 1 continued with a 
regimen including RAL later on. Additionally, 25 patients changed their background 
regimen during the follow-up. Further, 1 patient (0.5%) died because of AIDS, 1 
committed suicide (0.5%) and 1 patient died of unknown reasons (0.5%) within the 
first 20 weeks of follow-up and 36/188 (19.2%) patients had no available HIV-1 RNA 
measurement within week 20 and 28 after RAL start. 
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Table 2. Univariable and multivariable logistic regression to identify factors associated with a switch to 
RAL (n=75) in patients with triple-class failure (n=185) and detectable HIV-1 RNA (≥50 copies/mL). 
  Univariable analysis  Multivariable analysis 
Characteristics N (%) (on RAL/TCF) OR 95% CI P  OR 95% CI P 
Sex        
Male 58/135 (43.0) Ref    Ref   
Female 17/50 (34.0) 0.7 (0.3-1.3) 0.271  1.3 (0.4-4.0) 0.649 
Ethnicity       
White 65/154 (42.2) Ref    Ref   
Other 10/31 (32.3) 0.7 (0.3-1.5) 0.306  0.4 (0.1-1.5) 0.168 
Risk       
Homosexual 47/86 (54.7) Ref    Ref   
Intravenous drug use 4/23 (17.4) 0.2 (0.1-0.6) 0.003  0.1 (0.0-0.4) 0.001
Heterosexual 20/64 (31.3) 0.4 (0.2-0.7) 0.005  0.5 (0.2-1.4) 0.194 
Other 4/12 (33.3) 0.4 (0.1-1.5) 0.176  0.4 (0.1-2.5) 0.338 
Age per year older  1.2 (0.9-1.5) 0.232  0.8 (0.5-1.3) 0.458 
CD4 cell count       
≥200 cells/µL 42/138 (30.4) Ref    Ref   
<200 cells/µL 33/47 (70.2) 5.4 (2.6-11.1) <0.001  9.2 (3.4-24.4) <0.001
No. drugs in last regimen       
0-3 31/94 (33.0) Ref    Ref   
4-5 36/79 (45.6) 1.7 (0.9-3.2) 0.091  1.3 (0.6-2.9) 0.575 
Over 5  8/12 (66.7) 4.1 (1.1-14.5) 0.031  1.3 (0.2-6.8) 0.783 
Self-reported adherence       
Never missed a dose 55/122 (45.1) Ref    Ref   
1 dose per month 8/26 (30.8) 0.5 (0.2-1.3) 0.184  0.4 (0.1-1.5) 0.182 
1 dose per week 8/32 (25.0) 0.4 (0.2-1.0) 0.044  0.3 (0.1-0.9) 0.036
Unknown 4/5 (80.0) 4.9 (0.5-44.9) 0.162  3.2 (0.2-68.2) 0.449 
Exposure to T20 in last regimen       
Unexposed 46/142 (32.4) Ref    Ref   
Exposed 29/43 (67.4) 4.3 (2.1-9.0) <0.001  4.3 (1.6-11.7) 0.004
Total cholesterol       
Normal 65/163 (39.9) Ref       
High (>6.2 mmol/L) 10/22 (45.5) 1.3 (0.5-3.1) 0.618     
HDL cholesterol       
Normal 43/118 (36.4) Ref    Ref   
Low (<0.9 mmol/L) 32/67 (47.8) 1.6 (0.9-2.9) 0.133  1.0 (0.4-2.5) 0.915 
Triglycerides       
Normal  42/105 (40.0) Ref       
High (>2.3 mmol/L) 33/80 (41.3) 1.1 (0.6-1.9) 0.864  Ref   
Framingham score per 10% increase 1.6 (1.0-2.6) 0.051  1.1 (0.5-2.5) 0.781 
GSS optimized background regimen        
GSS <2 61/115 (53.0) Ref    Ref   
GSS ≥2 14/68 (20.6) 0.2 (0.1-0.5) <0.001  0.3 (0.1-0.8) 0.010
Unknown 0/2 (0) - - -  - - - 
Bold values indicate P <0.05 
TCF patients who experienced triple class failure, OR odds ratio. 
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In switch patients, the median number of drugs in the background regimen was 3 
(range: 1-7). 40.9% had an NNRTI, 84.5% at least 1 NRTI and 60.1% a boosted PI. 
Unboosted PIs were coadministered in 5 (7.4%) cases. At baseline, 46.5% had T20, 
which was replaced in almost all patients (n=30, 90.9%). 22.5% were treated with 
ETV, the latest approved NNRTI, and 5.6% with MVC.  
Salvage patients had a median number of 3 (range: 1-7) coadministered drugs. The 
background regimen included an NNRTI in 45.3% of the patients, an NRTI in 76.1%, 
a boosted PI in 70.9%. Unboosted PIs were rarely coadministered (6.8%). At 
baseline 16 (13.6%) patients were treated with T20, which was replaced in most 
cases (75%). The newer drugs, ETV and MVC were administered in 37.6% and 
13.7%, respectively.  
Many salvage and switch patients had a documented 3 class failure before starting 
RAL, 57.3% and 59.2%, respectively. 
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Figure 1. Percentage of patients with plasma HIV-1 RNA levels less than 50 copies/mL after 24 
weeks of RAL combined with a background regimen. Percentages are shown for patients with 
undetectable (HIV-1 RNA <50 copies/mL), detectable HIV-1 RNA at baseline, and the overall 
response rate. Intent-to-treat analysis was performed for 2 imputation methods, missing equal failure 
[closed circle] and LOCF (n=188) [open square]. Error bars represent 95% CIs. 
 
Salvage patients had median plasma HIV-1 RNA of 3.8 log10 copies/mL [interquartile 
range (IQR): 2.9-4.7] at baseline. Results from the intent-to-treat analysis are shown 
in Figure 1 according to the 2 imputation methods, which were missing equal failure 
(m = f) and LOCF. The overall week 24 response rates were 69.2% (m = f) and 
80.9% (LOCF), respectively. Response rates for switch patients were 76.1% (m = f) 
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and 95.8% (LOCF), respectively. For salvage patients, the estimates were 65.0% 
(m = f) and 71.8% (LOCF), respectively. Median baseline CD4 cell counts at baseline 
were 226 cells/µL (IQR: 134-328) and 351 cells/µL (IQR: 252-483) for salvage and 
switch patients, respectively. The CD4 cell count increased within 24 weeks by 51 
cells/µL (95% CI: 39-64, P<0.001) and by 22 cells/µL (95% CI: 7-37, P=0.003), 
respectively. The overall increase was 42 cells/ µL (95% CI: 32-52, P=<0.001). 
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Figure 2. Plasma concentration of RAL after at least 10 days with twice daily doses of 400 mg. 
Patients with detectable [closed circle] (HIV-1 RNA ≥50 copies/mL) and undetectable HIV-1 RNA 
[open square] after 24 weeks follow-up were distinguished. Expected drug levels, mean [▬] and 
upper and lower 90% confidence interval [--] were indicated, based on previous pharmacokinetic 
studies.23 
 
Characteristics of failures 
Univariable and multivariable logistic regressions (not shown) including risk group, 
ethnicity, sex, self-reported adherence, CPE, baseline HIV-1 RNA and the GSS of 
the background regimen did not show any significant factor for treatment success. 
The number of patients with failure to achieve undetectable viral loads at week 24 
was low, (n=36, 33 salvage patients, 3 switch patients). As shown in table 3, 
characteristics for failure were identified descriptively. Patients classified as failures 
because of insufficient follow-up time (n=15) were excluded. Six of the 21 patients 
listed in the table (#5, #6, #14, #17, #18, #20) had a low GSS ≤1 of the background 
regimen, 6 had very low plasma concentrations of RAL (#1, #2, #7, #11, #12, #20), 
Chapter 2 
61 
 
C
P
E
 
1.
5 
0.
5 3 2.
5 
1.
5 1 1.
5 2 1 2.
5 
2.
5 2 1.
5 
0.
5 1 1.
5 
0.
5 
0.
5 1 3.
5 1 
G
S
S
 
O
B
T§
 
2 2 1.
5 3 0.
5 
0.
5 
2.
5 
2.
5 2 3 3 2 1.
5 1 1.
5 2 0.
5 1 2 1 1.
5 
R
AL
 
m
ut
at
io
ns
 
-     
no
ne
 
  
Q
14
8R
 
 
no
ne
 
   
Y1
43
C
 
     
 
R
AL
 p
la
sm
a 
co
nc
en
tra
tio
n+
 
lo
w
 
lo
w
 
- 
no
rm
al
 
- - lo
w
 
- 
no
rm
al
 
no
rm
al
 
lo
w
 
lo
w
 
- - - - - - 
no
rm
al
 
lo
w
 
- 
S
el
f-r
ep
or
te
d 
ad
he
re
nc
e 
go
od
 
go
od
 
po
or
 
go
od
 
go
od
 
- 
go
od
 
go
od
 
po
or
 
go
od
 
po
or
 
go
od
 
go
od
 
- 
po
or
 
go
od
 
go
od
 
po
or
 
go
od
 
- 
go
od
 
                       
W
ee
k 
24
 
1.
8 
1.
7 
3.
5 
2.
1 
2.
0 
5.
0 
1.
7 
1.
9 
2.
9 
3.
0 
5.
4 
2.
0 
2.
3 
5.
1 
4.
7 
1.
9 
4.
3 
3.
2 
2.
1 
2.
1 
1.
8 
Lo
g 
H
IV
-1
 R
N
A
 
(c
op
ie
s/
m
l) 
Ba
se
lin
e 
2.
0 
3.
4 
2.
9 
2.
0 
3.
1 
5.
2 
0.
0 
5.
4 
3.
3 
5.
2 
4.
1 
4.
8 
2.
4 
4.
7 
5.
2 
5.
2 
4.
6 
4.
2 
1.
9 
2.
1 
2.
2 
                       
W
ee
k 
24
 
25
0 
46
2 
15
6 
47
7 
57
5 
11
 
76
9 
29
5 
19
1 
19
4 
30
 
71
1 
25
8 
19
0 
63
 
25
3 
32
0 
17
0 
19
1 
59
2 
65
0 
C
D
4 
co
un
t 
(c
el
ls
/µ
l) 
Ba
se
lin
e 
20
6 
59
1 
12
1 
68
3 
41
3 
28
 
60
6 
19
0 
28
1 
64
 
11
6 
39
6 
26
9 
16
7 
14
 
12
5 
28
4 
28
 
14
7 
60
0 
59
2 
                       
on
 R
AL
 
TD
F 
R
TV
 R
A
L 
FT
C
 D
R
V
 
T2
0 
R
AL
 D
R
V
 
TD
F 
T2
0 
R
TV
 R
A
L 
D
R
V
 
ZD
V
 A
B
C
 3
TC
 
R
A
L 
LP
V
 Z
D
V
 3
TC
 
R
A
L 
LP
V
 E
TV
 
R
A
L 
E
TV
 3
TC
 
TD
F 
R
A
L 
FT
C
 E
FV
 
R
TV
 R
A
L 
M
V
C
 E
TV
 D
R
V
 
R
TV
 R
A
L 
E
TV
 D
R
V
 
TD
F 
R
TV
 R
A
L 
E
TV
 D
R
V
 
A
B
C
 3
TC
 
R
TV
 R
A
L 
E
TV
 D
R
V
 A
B
C
 
3T
C
 
TD
F 
R
TV
 R
A
L 
E
TV
 F
TC
 
D
R
V 
TD
F 
T2
0 
R
TV
 R
A
L 
FT
C
 D
R
V
 
R
TV
 R
A
L 
A
TV
 
TP
V
 R
TV
 R
A
L 
E
TV
 D
R
V
 
TD
F 
R
TV
 R
A
L 
FT
C
 A
TV
 
TD
F 
R
A
L 
E
FV
 
R
A
L 
A
TV
 
TD
F 
R
A
L 
N
V
P
 
TD
F 
R
TV
 R
A
L 
M
V
C
 E
TV
 
D
R
V
 Z
D
V
 3
TC
 
R
TV
 R
A
L 
E
TV
 D
R
V
 
Tr
ea
tm
en
t* 
pr
e-
R
A
L 
TD
F 
R
TV
 E
TV
 F
TC
 D
R
V
 
S
Q
V
 R
TV
 D
D
I Z
D
V
 
TD
F 
T2
0 
R
TV
 D
R
V
 Z
D
V
 
A
B
C
 3
TC
 
LP
V
 E
FV
 Z
D
V
 3
TC
 
TP
V
 R
TV
 E
TV
 
M
VC
/p
la
ce
bo
‡  T
D
F 
T2
0 
A
B
C
 3
TC
 
TD
F 
T2
0 
FT
C
 E
FV
 
LP
V
 F
P
V
 A
B
C
 
R
TV
 A
TV
 A
B
C
 3
TC
 
TD
F 
N
V
P
 A
B
C
 3
TC
 
T2
0 
R
TV
 E
TV
 D
R
V
 A
B
C
 
3T
C
 
TD
F 
R
TV
 F
TC
 A
TV
 
TP
V
 T
D
F 
T2
0 
R
TV
 L
P
V
 
ZD
V
 A
B
C
 3
TC
 
TD
F 
R
TV
 F
TC
 A
TV
 
TP
V
 T
D
F 
D
D
I 3
TC
 
  TD
F 
N
V
P
 F
TC
 
N
V
P
 Z
D
V
 A
B
C
 3
TC
 
TP
V
 T
D
F 
T2
0 
R
TV
 M
V
C
 
ZD
V
 A
B
C
 3
TC
 
TD
F 
R
TV
 F
TC
 A
TV
 
Ta
bl
e 
3.
 P
at
ie
nt
s 
(n
=2
1)
 w
ith
 a
 d
oc
um
en
te
d 
fa
ilu
re
 (H
IV
-1
 R
N
A
>5
0 
co
pi
es
/m
L)
 a
t w
ee
k 
24
 a
fte
r R
A
L 
st
ar
t 
P
at
ie
nt
 
 
#1
 
#2
 
#3
 
#4
 
#5
 
#6
 
#7
 
#8
 
#9
 
#1
0 
#1
1 
#1
2 
#1
3 
#1
4 
#1
5 
#1
6 
#1
7 
#1
8 
#1
9 
#2
0 
#2
1 
*T
D
F,
 te
no
fo
vi
r; 
R
T,
V
 ri
to
na
vi
r; 
S
Q
V
, s
aq
ui
na
vi
r; 
FT
C
, e
m
tri
ci
ta
bi
ne
; D
R
V
, d
ar
un
av
ir;
 D
D
I, 
di
da
no
si
ne
; Z
D
V
, z
id
ov
ud
in
e;
 A
B
C
, a
ba
ca
vi
r; 
3T
C
, l
am
iv
ud
in
e;
 L
P
V
, 
lo
pi
na
vi
r; 
E
FV
, e
fa
vi
re
nz
; T
P
V
, t
ip
ra
na
vi
r; 
FP
V
, f
os
am
pr
en
av
ir;
 N
V
P
, n
ev
ira
pi
ne
; A
TV
, a
ta
za
na
vi
r. 
+ b
as
ed
 o
n 
ph
ar
m
ac
ok
in
et
ic
 s
tu
di
es
 23
 ; 
§ G
SS
 O
BT
 g
en
ot
yp
ic
 
se
ns
iti
vi
ty
 s
co
re
 o
f t
he
 o
pt
im
iz
ed
 b
ac
kg
ro
un
d 
tre
at
m
en
t, 
‡ b
lin
de
d 
cl
in
ic
al
 tr
ia
l, 
co
de
 n
ot
 b
ro
ke
n 
ye
t. 
 
Chapter 2 
62 
five patients had a poor self-reported adherence (#3, #9, #11, #15, #18), and 5 
patients had a very high HIV-1 RNA (>100,000 copies/mL) at baseline (#6, #8, #10, 
#15, #16) and for 4 patients there was no clear explanation for the failure (#4, #13, 
#19, #21). Four patients had a genotypic resistance test performed while failing on 
RAL 1 patient had the Q148R mutation and one the Y143C mutation; the other two 
patients had no known RAL resistance-associated mutation (Table 3). 
Drug levels were measured for 54 patients, and 46.3% had a lower RAL plasma 
concentration than expected. Six of 25 (24.0%) patients with low and 4/29 (13.8%) 
with normal RAL plasma concentration were not suppressed after 24 weeks follow-
up. However, drug levels showed very large inter-patient variation (Fig. 2). 
Discussion 
In our study population, the main reasons to include RAL in an antiretroviral regimen 
were low CD4 cell counts and replacement of T20. Treatment success, defined as an 
HIV-1 RNA<50 copies/mL after 24 weeks of follow-up, was analyzed with an intent-
to-treat approach using LOCF imputation and yielded estimates of 95.8% for switch 
patients and 71.8% for salvage patients. 
Our study reflects the introduction of the newly available drug RAL into a routine 
clinical care setting within the SHCS, a highly representative study for the Swiss HIV-
infected population. 74% of all NRTI compounds sold within Switzerland are 
prescribed within the SHCS (B. Ledergerber, personal communication). Despite the 
knowledge that RAL has almost no interaction potential with other drugs and has a 
very favourable lipid profile, RAL received a very restricted approval by the Swiss 
health authorities, most likely because RAL prices are high compared with most 
licensed drugs. Interestingly, however, our study clearly demonstrates that 39% of 
RAL use was not within the approved indication (replicating virus), and among those 
the main reason for switching to RAL was the replacement of T20 (60.3%). Thus, 
health insurers in Switzerland were quite supportive with regards to approving the 
formal requests that had to be individually written for each patient by the treating 
physician if a drug is used outside the approved indication. As an a priori hypothesis, 
we postulated that for patients with detectable HIV-1 RNA at start of RAL the main 
factor for RAL initiation may be a low GSS of the background regimen, whereas 
switches to RAL in patients with prior undetectable HIV-1 RNA may be driven by the 
wish for treatment simplification and toxicity concerns. This hypothesis was partially 
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confirmed by our results. Low GSS of the optimized background regimen and good 
self-reported adherence were associated with switching to RAL in patients with 
detectable viral load, whereas increased triglycerides were significantly associated in 
patients with undetectable viral load. In both models, exposure to T20, low CD4 cell 
counts were positively associated with the treatment change, being an intravenous 
drug user was negatively associated. 
This is a comprehensive observational study presenting efficacy data of RAL in 
routine clinical practice for salvage and switch patients. We implemented an intent-to-
treat analysis with 2 strategies to handle missing data, which were to consider 
patients with missing endpoints as failures and to carry the LOCF and yielded an 
overall efficacy of 69.2% and 80.9%, respectively. In this observational dataset, 
results from the LOCF imputation method are more meaningful, because the rate of 
missing values was quite high (19.5%). The efficacy when performing the LOCF 
imputation were slightly lower compared to the efficacy estimates including only 
patients with a HIV-1 RNA measurement between week 20 and 28 were included 
(86.1%), which were 98.2% and 79.2% (data not shown) for switch and salvage 
patients, respectively.  
Based on the data from LOCF imputation, a switch from a previous treatment to a 
regimen containing RAL in patients with suppressed viral loads seemed highly 
effective because 95.8% of these study subjects had an HIV-1 RNA <50 copies/mL 
at week 24. Only 3 highly treatment experienced patients had detectable viral loads 
at week 24. This is comparable with results from a study by Harris et al, which 
showed that 34/35 patients who switched from RAL to T20 were virologically 
suppressed after 7-month follow-up time.20, 30 The SWITCHMRK trials studied the 
replacement of lopinavir/ritanovir-based regimens to a RAL-based regimen and 
obtained slightly lower efficacy estimates compared to the switch patients in our 
study, however 60% of our patients were kept on a boosted PI containing regimen in 
contrast to the SWITCHMRK trials.30 A replacement of T20 with RAL would have 
considerable advantages for patients concerning manageability and tolerance of the 
treatment. 
After 24 weeks of follow-up, 71.8% of salvage patients had no detectable viral 
replication, which is comparable to previous published phase 3 randomised-control 
trials (BENCHMARK 1, 2) where approximately 78% of patients attained suppression 
of viral replication at week 16.5, 6 
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A careful in depth analysis of factors potentially associated with RAL failure did not 
reveal clear predictors for failure. In the first place, this may be surprising, however, 
due to the low overall number of documented failures (n=21) in our study and due to 
multifactorial reasons for treatment failures in ART this finding makes sense. Of note 
is our observation of low RAL drug levels in more than 46% of patients, which clearly 
demonstrates that more knowledge is needed for useful interpretation of RAL drug 
levels in the context of virological response. Although low RAL drug levels did not 
predict virological failure in our and in other studies it has to be noted that 60% of our 
failures indeed showed very low RAL drug levels compared to 43% of patients with 
successful viral suppression.5, 6 To date it is not known how well RAL penetrates into 
the central nervous system. Thus, we speculated that if RAL would not penetrate 
well, failures would potentially be associated with a lower CPE score of the 
background regimen compared with nonfailures. However, our results do not support 
this hypothesis.  
This study has some limitations. At this point we looked at 24-week efficacy, and in 
the future also long-term efficacy and safety of RAL in clinical practice will need to be 
further analyzed. This is an observational study, treatments were not randomized and 
patients had very different treatment histories, and as in all observational studies, 
residual confounding can not be excluded. The particular indication to measure drug 
levels was unknown and the selection of the 54 drug levels measured might be 
biased. A strength of this study is the very comprehensive assessment of clinical and 
laboratory data, including adherence, genotypic resistance data and data from 
therapeutic drug monitoring in a highly representative cohort. 
In summary, this study demonstrated very good week 24 efficacy of RAL in patients 
with previous triple-class failure with detectable or undetectable viral load at baseline. 
The main reason for the selection of RAL in patients with undetectable viral load was 
to replace T20, although to date only little is known about the effectiveness of such 
changes. Moreover, RAL plasma concentration levels were lower than expected in a 
large proportion of patients but failed to predict clinical outcomes in our statistical 
analyses. Further studies are needed to analyze long-term efficacy of RAL. 
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Abstract 
Background 
Nucleoside reverse transcriptase inhibitors (NRTIs) are often administered in salvage 
therapy even if genotypic resistance tests (GRTs) indicate high-level resistance, but 
little is known about the benefit of these additional NRTIs. 
Methods 
The effect of <2 compared to 2 NRTIs on viral suppression (HIV-1 RNA <50 
copies/mL) at week 24 was studied in salvage patients receiving raltegravir. Intent-to-
treat and per-protocol analyses were performed; last observation carried forward 
imputation was used to deal with missing information. Logistic regressions were 
weighted to create a pseudo-population in which the probability of receiving <2 and 2 
NRTIs was unrelated to baseline factors predicting treatment response.  
Results 
One-hundred thirty patients were included, of whom 58.5% (n=76) received <2 
NRTIs. NRTIs were often replaced by other drug classes. Patients with 2 NRTIs 
received less additional drug classes compared to patients with <2 NRTIs [median 
(IQR): 1 (1-2) compared with 2 (1-2), P Wilcoxon <0.001]. The activity of non-NRTI 
treatment components was lower in the 2 NRTIs group compared with the <2 NRTIs 
group [median (IQR) genotypic sensitivity score: 2 (1.5-2.5) compared with 2.5 (2-3), 
P Wilcoxon<0.001]. The administration of <2 NRTIs was associated with a worse 
viral suppression rate at week 24. The odds ratios were 0.34 (95% confidence 
interval: 0.13 to 0.89, P=0.027) and 0.19 (95% confidence interval: 0.05 to 0.79, 
P=0.023) when performing the last observation carried forward and the per-protocol 
approach, respectively.  
Conclusion 
Our findings showed that partially active or inactive NRTIs contribute to treatment 
response, and thus the use of 2 NRTIs in salvage regimens that include raltegravir 
seems warranted. 
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Introduction 
The treatment options for patients infected with highly drug-resistant HIV markedly 
improved with the introduction of new antiretroviral compounds, such as fusion 
inhibitors, second-generation nonnucleoside reverse transcriptase inhibitors 
(NNRTIs), or new boosted protease inhibitors (PIs), CCR5 antagonists, and integrase 
inhibitors.1-7 To date, knowledge about the optimal combination of these compounds 
in salvage therapy is lacking. Nucleoside reverse transcriptase inhibitors (NRTIs) are 
often co-administered in salvage therapy, even if genotypic resistance tests (GRTs) 
indicate high-level resistance. A therapeutic benefit is assumed because of the 
possible residual activity of these NRTIs and the maintenance of a resistant virus with 
reduced replicative capacity.8-12 On the other hand, costs, drug-drug interactions, 
tolerability and toxicity of these additional NRTIs have to be taken into account. 
NRTIs can cause mitochondrial dysfunction by inhibiting the DNA γ-polymerase 
resulting in plasma hyperlactataemia and variable clinical syndromes, such as 
lipoathrophy and peripheral neuropathy.13-21 
The clinical benefit of NRTIs with decreased activity due to drug resistance mutations 
to date has not been properly assessed. The number of antiretroviral compounds has 
increased, and additional drug classes have become available, making NRTIs 
potentially expendable in salvage therapy. 
Here, we focused on salvage regimens including raltegravir (RAL) because this drug 
is now frequently used in Switzerland to treat patients with highly resistant viruses.22 
Using data from the highly representative Swiss HIV Cohort Study (SHCS),23, 24 we 
report on the genotypic activity and composition of salvage therapies with RAL and 
the effect of partially active or inactive NRTIs on the viral suppression rate. 
Methods 
Data and patient selection 
Data from the SHCS were included for our analysis (up to June 30, 2010). The SHCS 
is a nationwide, clinic-based cohort study with continuous enrolment and at least 
semi-annual study visits (www.shcs.ch).24 It has been approved by ethical 
committees of all participating institutions, and written informed consent has been 
obtained from participants. The SHCS drug resistance database contains all HIV 
resistance tests performed by the 4 authorized laboratories in Switzerland using 
commercial assays (Viroseq Vs.1 PE Biosystems, Rotkreuz, Switzerland; Virsoseq 
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Vs. 2, Abbott AG, Baar, Switzerland; vircoTYPE HIV-1 Assay, Virco Lab, Mechelen, 
Belgium) and in-house methods.25 Sequences are stored in SmartGene’s (Zug, 
Switzerland) Integrated Database Network System (IDNS version 3.5.8).26 
 
Study population 
To analyze the effect of partially active or inactive NRTIs in salvage therapy, the 
SHCS was screened for patients who started a regimen containing RAL. Inclusion 
criteria were GRT on antiretroviral therapy (ART) prior to the RAL start and baseline 
HIV-1 RNA >500 copies/mL. Patients receiving more than 2 NRTIs were excluded 
from the study due to the small number of cases (n=12). For further analyses, 
patients receiving 0 or 1 NRTI were considered as one group and compared to 
patients receiving 2 NRTIs beside RAL. This classification turned out to be 
appropriate because patients treated with 0 and 1 NRTI had similar characteristics, 
and results did not differ markedly when analyzing these two groups separately (not 
shown). 
 
Baseline characteristics and estimated activity of available treatment options 
Patient characteristics were compared between patients receiving <2 NRTIs and 2 
NRTIs with Fisher’s exact test (categorical variables) and Wilcoxon rank-sum test 
(continuous variables). The baseline was set at the date of RAL start. The self-
reported adherence was categorized in 2 groups: patients who never missed a drug 
and patients who missed ≥1 drug in the 4 weeks preceding the study visit.27 To 
assess the availability of active antiretroviral compounds, results from Stanford 
interpretation algorithm (version 6.0.8) were mapped to a genotypic sensitivity score 
(GSS) for all approved drugs except enfuvirtide (T20), maraviroc (MAR), and RAL. 
The 5 resistance categories from the Stanford algorithm were regrouped as follows: 
viruses with a GSS less than 15 were considered as fully susceptible (GSS=1), those 
with a GSS between 15 and 59 were considered to have intermediate resistance 
(GSS=0.5), and those with a GSS greater than 59 were considered to be fully 
resistant (GSS=0). If T20 and MAR have not previously been included in a failing 
regimen, they were considered fully susceptible because transmission of HIV with 
resistance to T20 is very rare and coreceptor tropism testing was always performed 
prior to MAR prescription (Trofile assay, Monogram Biosciences, San Francisco, 
CA).28 
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Virological outcome 
The effect of NRTIs in salvage therapies with RAL was assessed at week 24. The 
viral suppression rate (HIV-1 RNA <50 copies/mL) was analyzed and different 
approaches were implemented as follows: an intent-to-treat analysis was performed 
with two different methods dealing with missing information, last observation carried 
forward (LOCF) and missing equal failure (m = f), and a per-protocol analysis. For the 
per-protocol analysis, only patients who did not change, stop, or interrupt treatment 
until week 24 and who had a viral load measurement between week 18 and week 30 
were included. 
Logistic regressions were performed and adjusted for ethnicity, age, sex, the GSS of 
the treatment (without NRTIs), number of drug classes, HIV-1 RNA and CD4 cell 
count before RAL treatment start. In the present study, confounding by indication 
must be addressed, because many factors, for example, number of drug classes in 
the background regimen, GSS of available drugs, or adherence, may influence not 
only the suppression rate, but also the number of NRTIs physicians chose for the 
salvage therapy. A solution to overcome a selection bias is to perform a marginal 
structural model.29 Weights were defined as the inverse of the probability for 
receiving <2 NRTIs as estimated by multivariable logistic regression including the 
following possible confounders: sex, adherence, age, transmission category, 
ethnicity, MAR, etravirine (ETV), or darunavir (DRV) in the background treatment, 
GSS of available NRTIs, GSS of PIs and NNRTIs in the salvage therapy, CD4 nadir, 
baseline HIV-1 RNA, year of treatment, and whether the patient was ever treated with 
mono/dual NRTI therapy. This method creates a pseudo-population, in which the 
probability for receiving <2 or 2 NRTIs is unrelated to baseline factors which are also 
prognostic for the treatment response (Appendix 1). Multicollinearity was checked 
and a variance inflation factor (VIF) <3 was tolerated for regression models. To check 
whether single observations had a disproportionately large impact on our results due 
to the weighting, the analysis was repeated 1000 times on bootstrapped data sets. 
To confirm results, an additional analysis was performed assessing time to viral 
suppression with a Cox regression model. The same covariables were included as in 
the logistic regression described above and the same procedure was followed to 
calculate the weights. Patients were included when they had at least 1 HIV-1 RNA 
measured and they were censored when they changed, stopped, or interrupted 
therapy. 
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Statistical analyses were performed with Stata 11 SE (StataCorp, College Station, 
TX), all confidence intervals (CI) are 95% CI and the level of significance was set at 
P=0.05. 
Results 
Study population and baseline characteristics 
A total of 142 patients who had a viral load >500 copies/mL, a GRT performed before 
RAL treatment start and follow-up HIV-1 RNA measurements were considered for 
analysis. Patients who received more than 2 NRTIs were excluded from further 
analysis (11 with 3 NRTIs, 1 with 4 NRTIs). Patients who received no NRTI (n=38, 
26.8%) or 1 NRTI (n=38. 26.8%) were handled as one group and compared to 
patients receiving 2 NRTIs (n=54, 38.0%). 
Most baseline characteristics were similar between patients with <2 NRTIs and 2 
NRTIs (Table 1), but patients with 2 NRTIs were younger, had more often baseline 
HIV-1 RNA >100,000 copies/mL and tended to have started the first ART later. The 
self-reported adherence during the 4 weeks proceeding the study visit before RAL 
start was similar: 72.2% (2 NRTIs group) and 71.1% (<2 NRTIs group). Additional 
factors that might be a sign of non-adherence were tested as follows: the number of 
therapies patients started, the number of treatment interruptions (cessation of ART 
and resumption at a later date), psychiatric treatment in the past, alcohol abuse, 
current intravenous drug use or smoking. All these characteristics were similar 
among groups (data not shown). 
The median number of NRTI, NNRTI and PI mutations (International AIDS Society 
[IAS-USA] drug resistance mutations printed in bold)30 was comparable between 
patients with <2 and 2 NRTIs, 9 [interquartile range (IQR): 5-13] and 10 (7-14.5) 
(P=0.100), respectively. Of note, the median number of NRTI mutations was lower in 
the 2 NRTIs group, 4 (1-5) compared to 5 (3-5) in the <2 NRTIs group (P=0.040). The 
number of major PI and NNRTI mutations was not significantly different. 
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Tabelle 1. Baseline characteristics of patients who started salvage treatment with raltegravir 
 <2 NRTIs (n=76)* 2 NRTIs (n=54)* P* 
Socio-demographic factors  
Median (IQR) age (in yrs) 49 (42.5-51) 43 (40-48) 0.009 
Sex    
female 28.9% (19.1-40.5) 25.9% (15.0-39.6) 0.704 
male 71.0% (59.5-80.9) 74.1% (60.4-85.0)  
Ethnicity    
white 82.9% (72.5-90.6) 87.0% (75.1-94.6) 0.519 
other 17.1% (9.4-27.5) 13.0% (5.4-24.9)  
Risk group    
MSM 51.3% (39.6-63.0) 55.6% (41.4-69.1) 0.972 
HET 28.9% (19.1-40.5) 25.9% (15.0-39.6)  
IDU 15.8% (8.4-26.0) 14.8% (6.6-27.1)  
other 4.0% (0.8-11.1) 3.7% (0.5-12.8)  
Immunological and virological factors    
Baseline HIV-1 RNA (copies/mL)    
500-9,999 43.4% (32.1-55.3) 37.0% (24.3-51.3) 0.068 
10,000-99,999 44.7% (33.3-56.6) 35.2% (22.7-49.4)  
≥100,000 11.8% (5.6-21.3) 27.8% (16.5-41.6)  
Median (IQR) CD4 (cells/µL) 226 (128.5-302.5) 256 (94-314) 0.962 
Median (IQR) CD4 nadir (cells/µL) 71.5 (18.5-176) 82 (33-172) 0.498 
Subtype    
B 80.3% (69.5-88.5) 87.0% (75.1-94.6) 0.310 
other 19.7% (11.5-30.5) 13.0% (5.4-24.9)  
CDC stage    
A 23.7% (14.7-34.8) 18.5% (9.3-31.4) 0.702 
B 38.2% (27.3-50.0) 44.4% (30.9-58.6)  
C 38.2% (27.3-50.0) 37.0% (24.3-51.3)  
Treatment history    
Median (IQR) year of therapy start 1995 (1993-1996) 1996 (1994-1998) 0.037 
Ever mono/dual NRTI therapy 88.2% (78.7-94.4) 79.6% (66.5-89.4) 0.184 
Prior DRV 2.6% (0.3-9.2) 9.3% (3.1-20.3) 0.099 
Prior ETV 5.3% (1.5-12.9) 3.7% (0.5-12.8) 0.676 
Prior MAR 2.6% (0.3-9.2) 0.0% (0.0-6.6) 0.230 
Prior T20 18.4% (10.4-29.0) 18.5% (9.3-31.4) 0.989 
*Percentage (95% confidence interval) or median (IQR), P value based on Fisher’s exact test 
(categorical variables) or Wilcoxon rank-sum test. 
MSM, men who have sex with men. 
 
Available treatment options based on genotypic data 
Some treatment options differed between patients with 2 and <2 NRTIs and were 
important reasons to perform a weighted logistic regression. The GSS of the best two 
NRTIs was <1, 1 and >1 in 29.6%, 20.4% and 50.0% of patients with 2 NRTIs, 
slightly higher than in the <2 NRTIs group (43.4%, 26.3% and 30.3%, P=0.075). As 
shown in Table 2, the NRTI with the highest estimated activity was tenofovir (TDF), 
with only 3.7% (2 NRTIs group) and 11.8% (<2 NRTIs group) being fully resistant. In 
contrast, full resistance against the following NRTI groups was common in patients 
with 2 and <2 NRTIs: zidovudine/stavudine (37.0% and 59.2%), emtricitabine 
(FTC)/lamivudine (3TC) (81.5 and 85.5%) and abacavir (ABC)/didanosine (DDI) 
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(37.0% and 52.6%). Resistance against the new NNRTI ETV was rare 1.9% (2 
NRTIs group) and 5.3% (<2 NRTI group). In contrast, full resistance against first line 
NNRTIs (EFV and NVP) was common in patients with 2 and <2 NRTIs, 63.0% and 
68.4%, respectively. DRV was the best PI with an estimated full activity in 73.9% of 
the cases, followed by tipranavir (48.5%), lopinavir (43.9%), saquinavir (39.2%), and 
indinavir (38.5%). 
 
Table 2. Genotypic activity of potential antiretroviral compounds for salvage 
treatment 
Estimated activity* <2 NRTIs 2 NRTIs P
GSS of NRTIs  
ZDV/D4T    
1 23.7% (14.7-34.8) 33.3% (21.1-47.5) 0.041
0.5 17.1% (9.4-27.5) 29.6% (18.0-43.6)  
0 59.2% (47.3-70.3) 37.0% (24.3-51.3)  
FTC/3TC    
1 6.6% (2.2-14.7) 14.8% (6.6-27.1) 0.212
0.5 7.9% (3.0-16.4) 3.7% (0.5-12.8)  
0 85.5% (75.6-92.5) 81.5% (68.6-90.8)  
ABC/DDI    
1 9.2% (3.8-18.1) 35.2% (22.7-49.4) 0.001
0.5 38.2% (27.3-50.0) 27.8% (16.5-41.6)  
0 52.6% (40.8-64.2) 37.0% (24.3-51.3)  
TDF    
1 18.4% (10.4-29.0) 42.6% (29.2-56.8) 0.006
0.5 69.7% (58.1-79.8) 53.7% (39.6-67.4)  
0 11.8% (5.6-21.3) 3.7% (0.5-12.8)  
GSS of NNRTIs    
EFV/NVP    
1 28.9% (19.1-40.5) 35.2% (22.7-49.4) 0.735
0.5 2.6% (0.3-9.2) 1.9% (0.1-9.9)  
0 68.4% (56.8-78.6) 63.0% (48.7-75.7)  
ETV    
1 50.0% (38.3-61.7) 61.1% (46.9-74.1) 0.347
0.5 44.7% (33.3-56.6) 37.0% (24.3-51.3)  
0 5.3% (1.5-12.9) 1.9% (0.1-9.9)  
GSS of PIs    
Highest scoring PI    
1 73.7% (62.3-83.1) 79.6% (66.5-89.4) 0.423
0.5 23.7% (14.7-34.8) 20.4% (10.6-33.5)  
0 2.6% (0.3-9.2) 0.0% (0.0-6.6)  
*A GSS of 1 denotes full susceptibility, 0.5 intermediate resistance and 0 full 
resistance. GSS was calculated with Stanford algorithm version 6.0.8. 
D4T, stavudine; ZDV, zidovudine 
 
Composition of the salvage therapy with RAL 
The composition of the non-NRTI treatment patients received together with RAL 
differed markedly between groups. The number of non-NRTI drugs beside RAL was 
lower in the 2 NRTIs group. The percentage of patients with ≤1, 2 and 3 drugs was 
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68.5%, 27.8% and 3.7% compared to 30.3%, 56.6% and 13.2% (P<0.001). Also the 
number of drug classes beside NRTIs and RAL was lower in the 2 NRTIs group 
[median IQR: 1 (1-2) compared with the <2 NRTI group: median (IQR): 2 (1-2), P 
Wilcoxon<0.001). 
As shown in Figure 1, most patients with 2 and <2 NRTIs additionally received a 
boosted PI, 66.7% and 80.3% (P=0.102). Most patients with a boosted PI received 
DRV (74.3%). NNRTIs also were often co-administered, in 44.4% (2 NRTIs group) 
and 68.4% (<2 NRTIs group) of cases (P=0.007). Patients with a NNRTI most often 
had ETV (88.2%). MAR and T20 were rarely administered (3.7% and 18.4%, 
P=0.014; 3.7% and 6.6%, P=0.699). 
In the 2 NRTIs group, the predominant NRTI combination was 3TC/FTC and TDF 
(38/54, 70.4%), followed by ABC and 3TC (14.8%), ABC and TDF (11.1%), TDF and 
DDI, and 3TC and zidovudine (each 1.9%). Patients with 1 NRTI most often received 
3TC (16/38, 42.1%) or TDF (15/38, 39.5%). Three patients received ABC (7.9%), 2 
DDI (5.3%) and 1 each zidovudine and stavudine (2.6%). 
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Figure 1. Background regimen of patients who receive <2 and 2 NRTI in addition to RAL. A, 
Percentage of patients who received NNRTI or PI, the proportions of drugs of full resistance, 
intermediate resistance, or full susceptibility are indicated in italics. B, Percentage of patients who 
received MAR or T20, the proportions of prior exposure are indicated in italics. 
 
Estimated genotypic activity of the salvage therapy 
The GSS of all non-NRTI drugs in the salvage therapy was lower in the 2 NRTIs 
group with a median GSS of 2 (1.5-2.5) compared with 2.5 (2-3) (P<0.001). However, 
when also considering the GSS of NRTIs the overall GSS of the treatment tended to 
be higher in the 2 NRTIs group 3 (2.5-3.0) compared with 2.5 (2-3, P=0.059). 
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The contribution to the GSS of each NRTI was similar in the <2 NRTIs and the 2 
NRTIs group, the GSS was <0.5, 0.5 and >0.5 in 46.3%, 31.5% and 22.2% 
compared with 47.4%, 31.6% and 21.1% (P=1.000) cases. Most patients (47/63, 
74.6%) receiving 3TC/FTC had viral strains carrying the M184I/V mutations, in the <2 
and 2 NRTIs group 81.3% and 76.6%, respectively. 
 
 
Figure 2: Logistic regression was performed to compare the viral suppression rate at week 24 
between patients treated with <2 NRTIs or 2 NRTIs in a salvage treatment with RAL. Different 
approaches were compared: intent-to-treat analysis with missing equal failure (ITT m=f), ITT LOCF 
and a per-protocol analysis. 
 
Virological outcome 
The described differences in salvage therapy composition and in particular the higher 
number of drug classes included in the <2 NRTIs group are possibly interfering with 
our aim to measure the effect of partially active or inactive NRTIs. For this purpose a 
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marginal structural model was performed. The model creates a “pseudo-population” 
in which group differences in salvage treatment composition are balanced.  
With the LOCF approach, the crude percentages of patients who achieved viral 
suppression at week 24 were 72.2% and 71.0% for patients with 2 and <2 NRTIs, 
respectively. The median (IQR) week of measurement was 24 (20-27) and similar 
between patients with 2 and <2 NRTIs [24.1 (19.9-26.6) compared with 23.9 (20.1-
27.5)]. About 2.6% (2 NRTIs group) and 5.6% (<2 NRTIs group) had no RNA 
measurement performed. A similar number of patients stopped, interrupted, or 
changed treatment before week 24, 22.2% (12 of 54) and 29.0% (22 of 76) in the 2 
and <2 NRTIs group, respectively (P=0.425). Toxicity was the reason for the change 
among 16.7% (2 of 12) and 36.4% (8 of 22) of the cases. (P=0.430). As shown in 
Figure 2, multivariable logistic regressions showed that patients treated with <2 
NRTIs compared with 2 NRTIs had a decreased chance to achieve viral suppression 
[multivariable odds ratio (OR): 0.59, P=0.269; weighted multivariable OR: 0.34, 
P=0.027] (table 3). The robustness of the results was tested with a bootstrap analysis 
(1000 replications), it yielded a similar result [mean multivariable weighted OR: 0.41 
(fifth and 95th percentiles: 0.11-0.98)], suggesting that the observed differences were 
not hinging on a few specific observations in our dataset, but were broadly 
consistent. 
The crude percentage of patients with suppressed viral load was slightly lower when 
using the m = f approach (2 NRTIs: 64.8%, <2 NRTIs: 59.2%). The beneficial effect 
of 2 NRTIs was confirmed in multivariable (OR: 0.47, P=0.099), and in weighted 
multivariable models (OR: 0.33, P=0.027) (Fig. 2). Also the per-protocol analysis 
confirmed results. Eighty-three patients were included who did not change, stop, or 
interrupt treatment until week 24 and who had a viral load measurement performed 
within the given time frame (multivariable OR: 0.54, P=0.337, weighted multivariable 
OR: 0.19, P=0.023). 
Different sensitivity analyses were performed to verify the results. Because the higher 
GSS of NRTIs in the 2 NRTIs group might partially explain the results, a sub-analysis 
including only patients with a cumulative NRTI GSS ≤0.5 in the regimen was 
performed (n=93 ITT LOCF, n=60 per-protocol). It was confirmed that additional 
NRTIs with low activity are beneficial for virological outcome (ITT LOCF: weighted 
multivariable OR: 0.13, 95% CI: 0.03-0.55; per-protocol: OR: 0.06, 95% CI: 0.01-
0.38). Because the last GRT was not always performed immediately before RAL 
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start, the estimation of the GSS might be imprecise. Therefore, a logistic regressions 
including exclusively patients who had a GRT on the last failing regimen was 
performed [ITT LOCF (n=104): weighted multivariable OR: 0.36, 95% CI: 0.11-1.18, 
per-protocol (n=65): OR: 0.07, 95% CI: 0.01-0.46]. 
As an additional analysis time to viral suppression was studied. Patients were 
included if they had at least 1 RNA measurement performed before treatment 
change, stop, or interruption (n=109). The frequency of RNA measurements after 
RAL start was similar between groups (data not shown). Compared with patients with 
2 NRTIs, patients with <2 NRTIs had a longer time to viral suppression. The hazard 
ratio with the multivariable and weighted multivariable regression was 0.63 (95% CI: 
0.39-1.03, P=0.064) and 0.54 (95% 0.37-0.80, P=0.002), respectively. 
 
Table 3. Weighted multivariable logistic regression analyzing virological suppression at week 24. 
Characteristics 
HIV-1 RNA<50 
copies/mL 
(n=93) 
HIV-1 RNA ≥50 
copies/mL 
(n=37) 
Weighted 
multivariable OR 
(95% CI) 
P 
Number of NRTIs     
2 39 (72.2%) 15 (27.8%) 1 (ref)  
<2 54 (71.0%) 22 (28.9%) 0.34 (0.13 to 0.89) 0.027 
Sex    
Male 66 (70.2%) 28 (29.8%) 1 (ref)  
Female 27 (75.0%) 9 (25.0%) 2.19 (0.57 to 8.45) 0.254 
Ethnicity    
White 79 (71.8%) 31 (28.2%) 1 (ref)  
Other 14 (70.0%) 6 (30.0%) 1.10 (0.30 to 4.01) 0.887 
Risk    
IDU 14 (70.0%) 6 (30.0%) 1.38 (0.41 to 4.65) 0.608 
Other 79 (71.8%) 31 (28.2%) 1 (ref)  
Median (IQR) age (in yrs) 48 (41-51) 44 (41-48) 1.10 (1.03 to 1.17) 0.002 
Median (IQR) HIV-1 RNA 
(log10 copies/mL) 4.2 (3.3-4.7) 4.7 (3.8-5.1) 0.51 (0.29 to 0.87) 0.015 
CD4 count (cells/µL)    
<200 39 (69.6%) 17 (30.4%) 1 (ref)  
≥200 54 (73.0%) 20 (27.0%) 0.91 (0.36 to 2.32) 0.850 
GSS of the treatment (without 
NRTIs)    
0-1.5 14 (56.0%) 11 (44.0%) 1 (ref)  
2-2.5 54 (77.1%) 16 (22.9%) 3.17 (0.83 to 12.1) 0.092 
≥3 25 (71.4%) 10 (28.6%) 4.04 (0.55 to 29.9) 0.172 
Median (IQR) drug classes 3 (2-3) 3 (2-3) 1.17 (0.50 to 2.74) 0.711 
MSM, men who have sex with men 
 
Discussion 
The availability of second-line antiretroviral agents and the introduction of new drug 
classes increased the options for salvage treatment markedly and raised the question 
of the optimal combination of compounds. Particularly, the role of genotypic partially 
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or completely inactive NRTIs in such situations is unknown. In our study, we saw that 
NRTIs were often replaced by other drug classes, such as second-line NNRTIs, 
boosted PIs, T20 or MAR. Importantly, patients who received two inactive or partially 
active NRTIs were more likely to achieve viral suppression at week 24. These NRTIs 
might have a residual antiretroviral activity or select viruses with reduced replicative 
capacity which might be favourable to achieve viral suppression.9 The presence of 2 
NRTIs increased the chance to achieve viral suppression three times. Single NRTIs 
did not significantly increase the chance to achieve viral suppression but tended to 
show an additional benefit compared to NRTI-sparing regimen (data not shown). Also 
the time to viral suppression was faster when 2 NRTIs were given. A short time to 
suppression might be beneficial because it may decrease the chance to accumulate 
resistance associated mutations in the very early phase of therapy. These finding 
were consistent and were confirmed with different approaches and sensitivity 
analyses. 
The use of NRTIs in salvage therapies has several potential advantages. In contrast 
to new compounds, NRTIs are well studied after 20 years of use: Their long-term 
toxicities are well characterized and the potential for drug-drug interactions is low. 
Costs are much lower compared with newer antiretroviral compounds, which are 
particularly relevant for developing countries and will become more important in the 
future when generic antiretroviral agents will be available.  
Previous studies showed that NRTI-sparing regimens suppress viremia in treatment-
naïve and treatment-experienced patients but increase the probability to select for 
drug resistance mutations. They reduce the frequency of lipoatrophy, but other 
adverse events occurred when combining remaining drug classes (eg, PIs and 
NNRTIs.31-35 
Preliminary results from another study addressing the effect of inactive NRTIs in 
salvage therapy are in contradiction with our findings. However, in contrast to our 
study, no adherence data were available, no weighting was performed, the number of 
patients with <2 NRTIs was very small (27 compared to 76 in our study) and it was 
not differentiated between patients receiving salvage treatment with RAL, MAR or 
ETV.36 
We used marginal structural models to overcome confounding by indication. The 
model performed in this study simulated a hypothetical randomized controlled trial in 
which patients were randomly assigned to receive a treatment with <2 or 2 NRTIs. As 
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in any observational studies, it is impossible to exclude unmeasured confounding. In 
particular, we cannot fully exclude that there were additional factors, which led 
physicians to choose a treatment with <2 NRTIs, but which were also associated with 
a worse treatment outcome. However, in absence of a randomized controlled trial, 
observational studies represent the best available evidence. To analyze long-term 
effects and NRTI-related toxicities large cohort collaborations will be needed.  
The possibility to maintain NRTI in the salvage regimen despite the presence of 
major drug resistance mutation is of high relevance because the drug pipeline of new 
antiretroviral agents starts to decline and on a global scale resistance will continue to 
accumulate. 37-40 
To summarize, our study demonstrated that partially active or inactive NRTIs showed 
a beneficial effect on the short-term virological outcome in patients receiving RAL. 
Therefore, our study supports the strategy to administer two NRTIs in salvage 
therapy with RAL even if inactive or only partially active according to GSS. The 
negative impact on viral fitness by maintaining drug resistance mutations and the 
residual activity of NRTIs must not be underestimated. However, the benefit of these 
NRTIs should be balanced with potential complications because complex 
antiretroviral regimens can be associated with increased toxicity or poor adherence. 
Further studies and collaborations are needed to support our findings and to analyze 
the long-term benefit of partially active or inactive NRTIs. 
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Appendix 1* 
The standard approach to study the impact of partially active or inactive NRTIs on 
viral suppression is a logistic regression model, but Robins41 showed that this 
approach may be biased when there is a (1) time-dependent covariate that is a 
predictor for both, the event of interest and the exposure, and (2) past treatment 
history predicts the level of the covariate. In our study, the GSS of available non-
NRTIs is such an example, patients with a high GSS of non-NRTIs are more likely to 
achieve viral suppression (event of interest) and patients with a low GSS of non-
NRTIs tended to receive more NRTIs (exposure), and the level of the GSS of non-
NRTIs is influenced by the treatment history. The marginal structural model (MSM) is 
one possibility to deal with this problem. The parameters of the MSM can be 
estimated with using inverse-probability-of-treatment weights. The crude logistic 
regression is modified by weighting each subject i by ωi. For example, if a given 
patient has a weight of ωi=5, the patient contributes five copies of him- or herself to 
the pseudo-population. Thus, the model simulates a randomized controlled trial in 
which patients were randomly assigned to receive a treatment with <2 or 2 NRTIs.29, 
41, 42 
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On the basis of the study of Fewell et al,43 we performed the following analysis in 
Stata to estimate the MSM: 
 
The weights were derived using a logistic regression model: 
xi: logit number_nrti sex adherence age i.transmission ethnicity background_maraviroc /// 
background_etravirine background_darunavir background_t20 gss_nrti gss_nnrti_pi /// 
cd4_nadir log_bl_rna i.bl_cd4 year_of_treatment i.monodual_nrti, or 
 
Probability of receiving 0 or 1 NRTIs: 
predict pw if e(sample) 
Probability of the treatment patients actually got: 
replace pw = (1-pw) if number_nrti==0 
Inverse probability of treatment weights: 
gen ipw= 1/pw 
Examination of the distribution of the weights: 
summ ipw,detail 
Marginal structural model: 
xi: logistic supression_week24 i.number_nrti ethnicity sex age i.transmission /// 
i.gss_of_no_nrtis log_bl_rna i.bl_cd4 number_of_drug_classes [pweight=ipw] 
 
* Appendix 1 is not included in the published version of the manuscript. The journal 
did not provide enough space to add it. However, in the framework of the thesis it is 
valuable to explain the used methods in more detail. 
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Abstract 
The 69 insertion and Q151M mutations are multi-nucleoside/nucleotide resistance 
mutations (MNR). The prevalence among 4078 antiretroviral (ART)-experienced 
individuals was <1.3%. Combined ART fully prevented MNR in subtype B infections. 
Case-control studies were performed to identify risk factors. Control subjects were 
patients with ≥3 thymidine-analogue mutations. The 69 insertion study (27 control 
subjects, 14 case patients) identified didanosine exposure as a risk (odds ratio, 5.0 
per year, P=0.019), whereas the Q151M study (which included 44 control subjects 
and 25 case patients) detected no associations. Following detection, individuals with 
Q151M tended to have lower suppression rates and higher mortality rates, relative to 
control subjects. Additional studies are needed to verify these findings in non-subtype 
B infections.  
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Introduction 
The introduction of highly-active antiretroviral therapy (HAART) reduced morbidity 
and mortality of human immunodeficiency virus (HIV) infected patients. However, 
drug resistance continues to emerge in association with treatment failure.1  
The 69 insertion and Q151M mutation are multi-nucleoside/nucleotide resistance 
(MNR) mutations on the reverse transcriptase that affect the activity of all approved 
nucleoside reverse transcriptase inhibitors (NRTIs). While 69 insertion confers full 
resistance to all drugs, tenofovir retains some activity when Q151M is present.2-4 
MNR mutations occur rarely in European settings (prevalence <1% to 3.6%). The 
prevalence in resource-limited countries has not been analyzed, but recent reports 
indicate that it has increased.5-8 The possible increase in MNR HIV strains is of great 
concern because of the very limited options for salvage treatment in resource-limited 
settings and the general lack of understanding as to how to optimally treat patients 
who have MNR infections.9 
We aimed to identify predictors for the emergence of the 69 insertion and Q151M 
mutation in the Swiss HIV Cohort Study (SHCS) and studied outcomes of salvage 
regimens applied for treatment of MNR HIV infections. 
Methods 
Data and patient selection 
Our analysis included data from the SHCS and the SHCS drug resistance database 
up to February 2010.10, 11 The SHCS has been approved by ethical committees of all 
participating institutions, and written informed consent has been obtained from 
participants. 
 
Prevalence of acquired and transmitted MNR mutations 
The prevalence of the 69 insertion and the Q151M mutation was analyzed among 
treatment-experienced (at least 30 days exposure) and treatment-naïve patients. 
Among treatment-naïve patients, possible transmission clusters were identified 
through phylogenetic methods. These analyses were performed with PHYLIP 3.6 
(distributed by J. Felsenstein), using the F84 nucleotide substitution model and the 
neighbor-joining tree algorithm with 1000 bootstraps. To avoid interference of 
treatment history, all major International AIDS Society-USA drug resistance-
associated amino acid positions were deleted from the sequences prior to analysis.12 
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Case-control study to determine predictors for MNR 
We compared patients with MNR detected with patients who carried viruses with ≥3 
thymidine analogue mutations (TAMs), either from the TAM 1 (M41L, L210W, T215Y) 
or the TAM 2 pathway (D67N, K70R, T215F, K219K/E). The rationale was to 
establish a control group consisting of highly NRTI-experienced individuals with 
comparable characteristics, except for the occurrence of 69 insertion or Q151M. 
Separate matched case-control studies were performed for each of the 2 MNR 
mutations. Control patients were matched 2:1 on the basis of the fist antiretroviral 
treatment (ART) received and the time between ART initiation and the detection of 
MNR mutations (for case patients) or ≥3 TAMs (for control subjects). Inclusion was 
restricted to individuals infected with HIV subtype B who started ART with single-
class NRTI therapy. 
Conditional logistic regression analyses were performed to identify risk factors for the 
emergence of 69 insertion and Q151M. Variables tested included the time spent on 
specific NRTIs and adjustments for the following potential confounders: sex, age, 
ethnicity, risk group, HIV-1 RNA level, and CD4+ cell count at time of detection of 
MNR mutations (for case patients) or >3 TAMs (for control subjects). 
 
Factors associated with attaining undetectable viral loads after detection of MNR 
mutations 
Virological outcomes after detection of MNR were analyzed for patients from the 
case-control studies with >1 follow-up HIV-1 RNA measurement. Characteristics and 
treatments were compared between patients who ever achieved 2 consecutive 
undetectable HIV-1 RNA levels <50 copies/mL and patients who did not. Fisher’s 
exact test (categorical) and Wilcoxon rank-sum test (continuous variables) were 
used. 
 
Association of all-cause mortality with detection of MNR mutations 
Cox proportional hazard models for matched case-control data were estimated to 
analyze the time to all-cause mortality after detection of MNR mutations (case 
patients) or >3 TAMs (control subjects). Models were stratified by years of detection 
of MNR mutations or >3 TAMs (1998, 1999-2003, after 2003). The proportional 
hazard assumption was verified by analyzing Schoenfeld residuals.  
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Statistical analyses were performed with Stata 11 SE (StataCorp), all confidence 
intervals (CI) are 95% CIs, and the level of significance was set at P=0.05.  
Results 
Prevalence of MNR in treatment-experienced patients 
The SHCS included 19 (0.5%) of 4078 and 34 (0.8%) of 4078 treatment-experienced 
patients who carried viruses with the 69 insertion and Q151M mutation, respectively. 
Most patients in the 69 insertion and Q151M group were treated with mono- or dual 
NRTI therapy (14 [73.7%] of 19 and 30 [88.2%] of 34), respectively. MNR was never 
detected in patients who were exclusively treated with HAART (2 NRTIs and 1 
boosted protease inhibitor [PI]/nonnucleoside reverse transcriptase inhibitor 
[NNRTI]). The median duration of ART until detection was 6.8 for the 69 insertion 
group and 5.5 years for the Q151M group. The median years of detection were 
2000.5 (range: 1995-2007) and 2000 (range: 1995-2006), respectively. Most 
individuals who carried viruses with MNR were infected with subtype B viruses (18 
[94.7%] of 19 and 29 [85.3%] of 34, respectively). All additional analyses were 
restricted to this subtype. 
 
Evidence for MNR transmission among treatment-naïve patients 
We screened 5692 sequences from treatment-naïve patients and detected the 69 
insertion 3 times (0.05%) and Q151M once (0.02%). The phylogenetic analysis 
provided strong evidence of forward transmission of the 69 insertion from 1 index to 2 
patients (100% bootstrap support). All these patients were men who had sex with 
men from the same study center. For Q151M, no transmission cluster was detected. 
 
Predictors for the emergence of MNR in patients infected with HIV subtype B 
For the 69 insertion case-control study, matching criteria fitted for 14 case patients 
(69 insertion) and 27 control subjects (≥3 TAMs). Interestingly, years spent receiving 
didanosine were significantly associated with the emergence of 69 insertion in 
univariable (odds ratio [OR], 3.4; 95% CI, 1.2-9.6; P=0.019) and multivariable models 
(OR, 5.0; 95% CI, 1.3-19.3; P=0.019).  
For the Q151M case-control study, 25 case patients and 44 control subjects (≥3 
TAMs) were matched, but conditional logistic regressions failed to identify predictors 
for the emergence of Q151M.  
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Virological response to salvage treatment upon emergence of MNR 
Virological outcomes of patients with >1 follow-up HIV-1 RNA measurement following 
MNR detection were analyzed. The probability of ever achieving viral suppression 
was comparable between the 69 insertion group (9 [69.2%] of 13; 95% CI, 38.6%-
90.9%) and the respective control subjects (15 [75.0%] of 20; 95% CI, 50.9%-91.3%). 
A large proportion of patients who received previously unseen drug classes achieved 
viral suppression (87.5% compared to 40.0% of other patients; P=0.217). As shown 
in table 1, all patients detected without major NNRTI or PI mutations achieved viral 
suppression (patients 1, 4, and 8). Five of 7 patients with either NNRTI or PI 
mutations achieved viral suppression with the remaining active non-NRTI drug class 
(patients 2, 5, 6, 7, and 11).  
Viral suppression rates between the Q151M group (14 [56.0%] of 25; 95% CI, 34.9%-
75.6%) and respective control subjects (27 [73.0%] of 37; 95% CI, 55.9%-86.2%) 
were similar. Generally, patients who achieved viral suppression had a higher median 
CD4+ cell count at detection (241 cells/µL vs 61 cells/µL; P=0.030), a lower viral load 
(median log10 RNA level, 4.5 copies/mL vs 5.1 copies/mL; P=0.089), a higher 
percentage of a previously unseen drug classes (88.9% vs 37.5%; P=0.033) and 
were detected later (median year, 1997 vs 2001; P=0.027). As illustrated in Table 1, 
most patients with Q151M detected before the introduction of HAART never achieved 
viral suppression (patients 1-3 and 6-8). Four of 11 patients detected in the HAART 
era prior to the approval of enfuvirtide (T20) (1998-2002) never had a successful 
treatment (patients 10, 11, 13, and 15). All of these patients had low CD4+ cell 
counts (<50 cells/µL) and extensive PI and/or NNRTI mutations. Most of the other 
patients had PI mutations but achieved viral suppression with a regimen containing 
NNRTIs (patients 12, 14, and 16-20). 
 
Survival after detection of MNR 
The crude incidence of mortality after detection of the 69 insertion was 1.9 deaths 
(95% CI, 0.2-6.9) per 100 person-years of follow-up, compared with 6.3 deaths (95% 
CI, 2.9-12.0) per 100 person-years of follow-up among control subjects (≥3 TAMs) 
[figure 1]. Of the 2 deaths noted in the 69 insertion group, 1 death was HIV-related 
and the other cause of the other death was unknown. The risk of mortality was not 
significantly different between patients with the 69 insertion and those with ≥3 TAMs 
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(univariable hazard ratio [HR], 0.3 [95% CI, 0.1-1.6]; P=0.178). The small number of 
events did not allow stratified or multivariable models. 
Patients with Q151M detected tended to have a higher crude incidence of 9.8 deaths 
per 100 person-years (95% CI, 5.3-16.4) compared with 5.8 deaths per 100 person-
years (95% CI, 3.3-9.4) in control subjects (≥3 TAMs) [Figure 1]. HIV infection was 
the cause of death for 6 (42.9%) of14 patients from the Q151M group and 7 (43.8%) 
of 16 control subjects. Additional causes of death reported in the Q151M group were 
neoplasm (14.3%), cardio-vascular diseases (14.3%), chronic hepatitis C (7.1%), 
suicide (7.1%) or unknown (14.3%). The detection of Q151M was associated with 
increased mortality but was of marginal statistical significance in the univariable (HR, 
2.7 [95% CI, 0.9-8.0]; P=0.075) and multivariable model, adjusted for sex, ethnicity, 
risk group, CD4+ cell count, and age (HR, 7.5 [95% CI, 0.9-64.6]; P=0.068). 
Sensitivity analyses including only those deaths associated with HIV infection 
(univariable HR, 2.6 [95% CI, 0.6-10.4]; P=0.189) or by additionally matching case 
patients and control subjects by CD4+ cell count at time of detection of Q151M or >3 
TAMs showed similar results (univariable HR, 3.2 [95% CI: 1.0-10.9]; P=0.058; 
multivariable HR: 6.2 [95% CI, 0.7-56.0]; P=0.105). 
Discussion 
Because the prevalence of MNR is increasing in resource-limited countries, and 
because 69 insertion and Q151M affect the activity of an entire drug class, it is of 
great importance to identify risk factors and to optimize treatment strategies. 
Our study currently represents the largest longitudinal dataset with full treatment 
history available. We found high evidence of forward transmission of 69 insertions. 
This finding is of relevance, because the presence of 69 insertion results in a 
substantial reduction of treatment options, which can be devastating in settings with 
limited access to potent salvage therapies. 
Moreover, our study identified a significant association of ddI exposure with the 
emergence of the 69 insertion.13 No specific NRTI was associated with the 
emergence of Q151M. Our study did not confirm a previously reported negative 
association of lamivudine with Q151M,2, 14 nor was d4T exposure correlated with an 
increased risk for Q151M (data not shown). 
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Figure 1. Kaplan-Meier curves showing survival after detection of 69 insertion (a) or Q151M (b). 
Patients detected with ≥3 thymidine analogue mutations (TAMs) were matched (2:1) for comparison. 
Log-rank test was stratified for matched pairs. 
 
 
Of note, MNR mutations were never detected in patients who were exclusively 
treated with HAART. This is in contrast to the high prevalence of MNR mutations 
observed in resource-limited settings.7, 8 Free access to potent antiretroviral drugs in 
Switzerland and close monitoring are the most likely explanations for this difference. 
Moreover, this study widened the very limited knowledge for treatment strategies of 
patients detected with MNR. These patients can be successfully treated if potent 
drugs, such as boosted PI, raltegravir or T20 are available. The descriptive analysis 
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of therapy success further suggests that extensive resistance to NNRTIs and PIs, as 
well as a low CD4+ cell count at the time of detection of MNR mutations, were 
prognostic unfavourable.15  
Patients with viruses possessing Q151M tended to have an increased mortality risk 
compared with patients with ≥3 TAMs. Although this finding was robust throughout 
several sensitivity analyses, conclusions regarding causality between Q151M and 
death should be drawn with care. 
This study has some limitations. Even though our sample is the largest study so far 
addressing MNR, it is still limited in power.11 Our study was restricted to subtype B-
infected individuals, and results may therefore not be readily transferable to other 
subtypes. 
Taken together, our data indicate that modern antiretroviral therapies in combination 
with adequate viral monitoring are able to prevent the emergence of MNR mutations 
in developed settings. In Switzerland, detected MNR mutations are mainly a relic of 
the mono- or dual-NRTI therapy era, although 2 cases of transmitted MNR were 
observed. This analysis further demonstrates that salvage treatment can be 
successful even when MNR mutations are present if at least 1 previously unseen 
drug class is available. Today, the development of MNR seems to be becoming an 
emerging problem in resource-limited settings, where most patients are infected with 
non-subtype B strains. Thus, additional studies are needed to investigate whether 
our findings are also true for non-subtype B infections. 
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Abstract 
Background 
We hypothesized that polymorphic mutations exist that are associated with the 
emergence of the multi-nucleoside resistance mutations (MNR), 69 insertion and 
Q151M. 
Methods 
The Swiss HIV Cohort Study (SHCS) was screened and the frequencies of 
polymorphic mutations in HIV-1 (subtype B) were compared between patients 
detected with the 69 insertion (n=17), Q151M (n=29), ≥2 thymidine analogue 
mutations (TAM) 1 (n=400) or ≥2 TAM 2 (n=249). Logistic regressions adjusted for 
the antiretroviral treatment history were performed to analyze the association of the 
polymorphic mutations with MNR. 
Results 
The 69 insertion and TAM 1 were strongly associated and occurred in 94.1% (16/17) 
together. The 69 insertion seemed to emerge as a consequence of the TAM 1 
pathway (median years until detection: 6.8 compared to 4.4 for ≥2 TAM 1, P 
Wilcoxon=0.009). Frequencies of 8 polymorphic mutations (K43E, V60I, S68G, 
S162C, T165I, I202V, R211K, F214L) were significantly different between groups. 
Logistic regression showed that F214L and V60I were associated with the 
emergence of Q151M/TAM 2 opposed to 69 insertion/TAM 1. S68G, T165I and 
I202V were associated with Q151M instead of TAM 2. 
Conclusion 
Besides antiretroviral therapy polymorphic mutations may contribute to the 
emergence of specific MNR mutations. 
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Introduction 
The emergence of resistance mutations during antiretroviral therapy (ART) of human 
immunodeficiency virus type 1 (HIV-1) infections is an important cause for treatment 
failure. The 69 insertion and the Q151M mutation are two rare drug-associated 
genotypic modifications causing multi-nucleoside/tide resistance (MNR).1-5 The 
prevalence among several European studies was <3.5%, but recent studies from 
resource-limited countries reported a higher prevalence.6-9 Earlier studies showed 
that the 69 insertion often co-occurred with mutations from the thymidine analogue 
mutation (TAM) 1 pathway (M41L, L210W and T215W).10, 11 Q151M has a 
completely different resistance pattern and is usually accompanied by two or more 
accessory mutations (A62V, V75I, F77L, and F116Y) that compensate the negative 
impact of Q151M on viral replication.1 A possible association of the Q151M and the 
TAM pathways was discussed controversially.10, 12, 13 In developed countries, MNR 
mutations mostly have occurred during outdated single class nucleoside reverse 
transcriptase inhibitor (NRTI) therapy. In addition, the 69 insertion has been 
associated with didanosine exposure.5, 14, 15 Otherwise very little is known about risk 
factors for the emergence of MNR, mostly due to the rare occurrence of MNR 
mutations and hence the limited sample size for analysis.13, 14 
Previous studies have already demonstrated the existence of polymorphic mutations 
that are strongly associated with the emergence of TAM 1 as opposed to TAM 2 (e.g. 
F214L).16-18 Therefore, we hypothesized that, besides exposure to specific drugs, the 
emergence of the different MNR profiles, 69 insertion and Q151M, may also depend 
on particular genomic signatures of the virus in the polymerase region. We aimed to 
identify such mutations using data from the Swiss HIV Cohort study (SHCS) and the 
SHCS drug resistance data base. 
Methods 
General procedure 
To identify mutations associated with the emergence of MNR, we proceeded as 
follows: First, we determined whether the emergence of the two MNR profiles, 69 
insertion and Q151M, are linked to specific TAM patterns. In particular, we were 
interested in finding out whether the MNR mutations could occur independently from 
TAMs or whether they mark an endpoint of a specific TAM pathway (analysis step 1). 
The result from this analysis then allowed us to form appropriate groupings for 
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MNR/TAM pathways to be used in subsequent analyses (henceforth named 
MNR/TAM groups). Next we identified polymorphic mutations, which were not 
significantly more prevalent in patients with treatment exposure compared to 
individuals without treatment exposure. This initial set of polymorphic mutations was 
further restricted to mutations, which were present at significantly different 
proportions across the MNR/TAM groups defined in the first analysis, thus suggesting 
an accumulation of polymorphic mutations in certain MNR/TAM groups (analysis step 
2). In a final analysis, the predictive values of the found polymorphic mutations were 
studied (analysis step 3). 
Statistical analyses were performed with Stata 11 SE (StataCorp, College Station, 
TX). All confidence intervals (CI) are 95% CI and the level of significance was set at 
0.05 unless indicated otherwise.  
 
Data and study population 
Data from the SHCS resistance data base were analyzed, which contains all 
genotypic HIV resistance tests performed by the four authorized laboratories in 
Switzerland, stored in SmartGene’s (Zug, Switzerland) Integrated Database Network 
System (IDNS version 3.5.7).19 Additionally, clinical data came from the SHCS, which 
is a nationwide, clinic-based cohort study with continuous enrolment and semi-annual 
study visits.20, 21 The SHCS has been approved by ethical committees of all 
participating institutions and written informed consent has been obtained from 
participants. Only sequences from therapy exposed individuals infected with subtype 
B viruses were considered for analysis, because of very low numbers of 69 insertion 
(n=1) and Q151M (n=5) among non-B strains. 
 
Association of the 69 insertion and Q151M with TAMs (analysis step 1) 
To start with, we built four groups representing the particular resistance pathways: 1) 
patients with the 69 insertion detected, 2) patients with the Q151M detected, 3) 
patients with ≥2 TAM 1 (M41L, L210W, T215Y), and 4) patients with ≥2 TAM 2 
(D67N, K70R, T215F, K219K/E) detected. Sequences with both, TAM 1 and TAM 2, 
were excluded (n=495). Sequences with 69 insertion and TAMs were allocated to the 
69 insertion group and sequences with Q151M and TAMs to the Q151M group.  
In order to assess whether MNR mutations can emerge independently of TAMs, the 
percentage of co-occurrence of the 69 insertion or Q151M with TAMs of group 1 or 2 
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was compared. In addition, we investigated the possible chronological order of the 
TAM and MNR mutations. For this purpose, the time from therapy initiation until 
detection of either TAMs or MNR mutations was compared between the different 
MNR profiles and the two TAM pathways. In particular, we aimed to study whether 
MNR mutations tended to follow TAMs, which would support the hypothesis that the 
MNR mutations emerge as the end point of the respective TAM pathway. Empirical 
distributions of time until mutation detection (described by median and interquartile 
ranges) were compared by use of the Wilcoxon rank sum test. Based on these 
analyses we regrouped the four initial MNR or TAM groups to represent possible 
pathways. 
 
Identification of polymorphic mutations associated with different MNR/TAM groups 
(analysis step 2) 
To identify polymorphic mutations, we compared the frequency of all reverse 
transcriptase (RT) mutations between treatment-exposed patients (detected with 69 
insertion, Q151M, ≥2 TAM 1 or ≥2 TAM 2) and an equal number of randomly 
selected sequences from treatment-naïve patients. For the definition of a 
polymorphism, only amino acid changes with a prevalence of at least 3% among 
treatment-naïve patients were considered. In addition, the prevalence of the 
respective mutation among treatment-experienced patients was not allowed to be 
significantly higher compared to the frequency among treatment-naïve patients. 
Analogous to algorithms used in analyses of non-inferiority clinical trials 22, an upper 
limit for an allowed difference in prevalence of specific mutations between treatment-
naive and treatment-exposed individuals was determined to still be considered 
equivalent (or non-superior), which was set at 5% in this study. If the 95% CI of the 
difference in prevalence did not include this margin (i.e. was superior) then this 
mutation was discarded from the list of potential polymorphisms, otherwise the 
mutation was included. To verify that the identification of polymorphisms were not 
influenced unduly by our dataset, we applied the same selection criteria (i.e. >3% 
frequency among treatment-naive and <5% difference) to genotypic data from the 
Stanford database by querying the Genotype-Treatment Correlations tool 
(http://hivdb.stanford.edu/cgi-bin/RTMutSummary.cgi). 
Of this initial set of polymorphic mutations those were selected that varied 
significantly across the MNR/TAM groups defined in step 1. Significance was 
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assessed by use of Fisher’s exact tests and Benjamini-Hochberg correction with a 
false-discovery rate of 5% to adjust for multiple testing. 
The associations of polymorphic mutations with specific MNR/TAM groups were 
checked further by use of multivariable logistic regression models adjusted for the 
exposure to specific NRTIs (ever exposed). Variables (polymorphic mutations and 
treatment exposure) were included in the multivariable model if the P value in the 
univariable model was <0.1. 
 
Predictive values of polymorphic mutations (analysis step 3) 
The predictive values of the identified polymorphic mutations were assessed by 
performing non-parametric receiver operating characteristic (ROC) analyses defining 
the sensitivity, specificity, number of correctly classified and the area under ROC 
curve (AUC). 
To further validate the predictive value of polymorphisms identified in analysis step 2, 
we queried the Stanford database Genotype-Treatment Correlations tool for 
sequence pairs consisting of one genotype performed before treatment exposure and 
one obtained after any exposure to zidovudine and/ or stavudine (see results). 
Sequence pairs were included in the analysis if the sequence taken after treatment 
exposure either carried the 69 insertion, ≥2 TAM 1, ≥2 TAM 2, or Q151M, analogous 
to our initial selection criteria for sequences from the SHCS drug resistance 
database. The same analytic methods for prediction performance assessment were 
used as for the SHCS dataset.  
Results 
Association of TAM 1, TAM 2, 69 insertion and Q151M (analysis step 1) 
The SHCS was screened for genotypic resistance tests (GRT) from treatment-
experienced patients. A total of 3335 subtype B sequences were selected. The 69 
insertion and the Q151M mutation occurred very rarely, the prevalence was 0.5% 
(n=17/3335) and 0.9% (n=29/3335), respectively. 
Previous studies suggested an association of the 69 insertion with the TAM 1 
pathway. This finding was confirmed in our study. As shown in table 1, the 69 
insertion co-occurred in 16/17 cases (94.1%) with ≥1 TAM 1 and rarely with ≥1 TAM 
2 (2/17, 11.8%). In contrast to the 69 insertion, the Q151M mutation co-occurred very 
rarely with ≥1 TAM 1 (5/29, 17.2%), whereas TAM 2 were found frequently (16/29, 
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55.2%). These impressions were reinforced when checking the actual nucleotide 
sequences for ambiguous base calls at positions associated with TAM, 69 insertion 
and Q151M.23 The presence of both wild type and mutant virus is suggestive for the 
presence of separate viral strains, which has been described previously for 
incompatible mutations such as TAM 1 and K65R.24 Indeed, 2 out of 5 patients with 
Q151M and TAM 1 also harboured virus with wild type at these amino acid positions. 
The infrequent co-occurrence of Q151M and TAM 1 on the same strain (3 of 29, 
10%) indicates strong fitness interactions between these mutations. For the 
sequences containing the 69 insertion no ambiguous base calls were detected at 
relevant positions. Of further note, while the 69 insertion only once occurred in the 
absence of TAM 1, there were 12 (41%) cases of Q151M without the presence of any 
TAMs (and TAM 2 in particular). This finding indicates that Q151M emergence may 
be independent of the TAM 2 pathway.  
 
Table 1. Occurrence of the 69insertion, Q151M and thymidine-
analogue mutations (TAM) 1 and TAM 2. 
Mutation 69 insertion(n=17) Q151M (n=29) 
TAM 1 (≥1 mutation) 16 (94.1%) 5 (17.2%) 
M41L 16 (94.1%) 4 (13.8%) 
L210W 10 (58.8%) 2 (6.9%) 
T215Y 16 (94.1%) 2 (6.9%) 
TAM 2 (≥1 mutation) 2 (11.8%) 16 (55.2%) 
D67N 1 (5.9%) 14 (48.3%) 
K70R 2 (11.8%) 6 (20.7%) 
T215F 0 (0.0%) 3 (10.3%) 
K219E 0 (0.0%) 6 (20.7%) 
K219Q 1 (5.9%) 5 (17.2%) 
No TAMs 0 (0%) 12 (41.4%) 
 
Next, to better understand the chronological order of the emergence of resistance 
mutations, the time until detection of MNR and ≥2 TAMs was analyzed. Given the 
results from above we hypothesized that the 69 insertions may result from the TAM 1 
pathway after prolonged exposure to ART. The empirical distributions of time to 
occurrence of the 69 insertion or ≥2 TAM 1 (figure 1a) showed that the overall time 
on ART until detection of 69 insertion (median [IQR]: 6.8 years [4.7-9.4]) was longer 
compared to ≥2 TAM 1 (median [IQR]: 4.4 years [2.3-6.9], P Wilcoxon=0.009). These 
findings support the notion that the 69 insertion results out of the TAM 1 pathway. 
The same type of analysis however showed no time dependent difference between 
the occurrence of Q151M and TAM 2 mutations: 5.5 years (IQR: 3.9-6.4) and 5.1 
years (IQR: 2.9-7.0, P=0.566), respectively (figure 1b). Additionally, no difference 
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was found between patients detected exclusively with mutations from the Q151M 
pattern (median years [IQR]: 5.0 [1.9-6.1]) and patients detected with a combination 
of the Q151M and TAM 2 mutations (median years [IQR]: 5.9 [4.5-8.8, P=0.136]). 
On the basis of these results we established the following hypotheses for the 
dependencies between TAM and MNR. The 69 insertion emerges out of the TAM 1 
pathway and is strongly discriminated against by TAM 2 mutations. In contrast, 
Q151M is selected against by TAM 1 mutations, but there is no strict association with 
TAM 2 mutations. Thus, in the following analyses we considered TAM 2 and Q151M 
as separate MNR/TAM categories, and a third group consisting of TAM 1 and 69 
insertion. 
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Figure 1. Time on antiretroviral treatment until the detection of 69 insertion (n=17) and ≥2 thymidine 
analogue mutations 1 (TAM 1, n=400) [a], or Q151M (n=29) and ≥2 TAMs 2 (n=249) [b] 
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Polymorphic mutations associated with the emergence of MNR mutations (analysis 
step 2) 
To identify polymorphic mutations associated with the emergence of MNR mutations, 
we screened all RT mutations and compared their frequencies between treatment-
naive individuals and all treatment-experienced individuals from the three MNR/TAM 
groups combined. 
We identified 95 mutations which fulfilled the criteria for a polymorphic mutation, 
meaning that the frequency among treatment-naïve patients was >3% and the 95% 
CI of the difference between treatment-exposed and treatment-naïve patients did not 
contain the 5% margin. Out of these 95 mutations, 8 (8.4%) showed statistically 
significant differences in proportions across the three MNR/TAM groups after 
adjustment for multiple testing: K43E, V60I, S68G, S162C, T165I, I202V, R211K and 
F214L (table 2). We checked these findings with data from the Stanford database, 
which included 12,172 sequences from treatment-naïve and 9,101 sequences from 
treatment-experienced patients. With the exception of K43E all mutations classified 
as polymorphisms by our algorithm were confirmed, meaning that they showed a 
prevalence of >3% among treatment-naïve patients and the differences in prevalence 
relative to treatment-exposed sequences was <5%. 
 
Table 2. Polymorphic mutations associated with the 69 insertion/ thymidine-analogue mutations (TAM) 1, 
Q151M or TAM 2. 
Mutation 
 
69 insertion/ 
≥2TAM 1 
(n=417) 
Q151M 
(n=29) 
≥2 TAM 2 
(n=249) P exact
Treatment 
experienced 
(n=696) 
Treatment naïve 
(n=696) 
Difference 
(95% confidence 
interval) 
K43E 38 (9.1%) 0 (0.0%) 4 (1.6%) <0.001 42 (6.0%) 27 (3.9%) 2.2% (-0.1 to 4.4) 
V60I 61 (14.6%) 7 (24.1%) 63 (25.3%) 0.002 131 (18.9%) 145 (20.9%) -2.0% (-6.2 to 2.2) 
S68G 28 (6.7%) 8 (27.6%) 4 (1.6%) <0.001 40 (5.8%) 32 (4.6%) 1.2% (-1.2 to 3.5) 
S162C 51 (12.2%) 3 (10.3%) 11 (4.4%) 0.002 65 (9.3%) 119 (17.1%) -7.8% (-1.1 to -4.2) 
T165I 5 (1.2%) 5 (17.2%) 5 (2.0%) <0.001 15 (2.2%) 38 (5.5%) -3.3% (-.5.3 to -1.3) 
I202V 30 (7.2%) 12 (41.4%) 36 (14.5%) <0.001 78 (11.2%) 78 (11.2%) 0.0% (-3.3to 3.3) 
R211K 230 (55.2%) 13 (44.8%) 91 (36.5%) <0.001 334 (48.1%) 361 (51.9%) -3.9% (-9.1 to 1.4) 
F214L 9 (2.2%) 8 (27.6%) 77 (30.9%) <0.001 94 (13.5%) 115 (16.6%) -3.0% (-6.8 to 0.7) 
 
The polymorphism F214L showed the most pronounced difference between the 
MNR/TAM groups. It occurred very rarely (2.2%) in the 69 insertion/TAM 1 group, but 
frequently in the Q151M (27.6%) or TAM 2 group (30.9%), which provides evidence 
that F214L might direct viral evolution towards the Q151M- and TAM 2-pathways as 
opposed to the TAM 1 pathway. Compared with the 69 insertion/TAM 1- and the TAM 
2-group, S68G and I202V co-occurred frequently with Q151M, in 27.6% and 41.4% 
of cases, but only at 6.7% and 7.2% in the 69 insertion/TAM 1 group and at 1.6% and 
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14.5% in the TAM 2 group, respectively. From these comparisons and the results 
shown in table 1 we inferred that there may exist a similarity between the Q151M and 
the TAM 2 group, but a pronounced dissimilarity between these two groups with the 
69 insertion/TAM 1 group in terms of polymorphism profiles. We hypothesized that 
there may exist an early split in pathways between TAM 1 and the other two 
MNR/TAM groups, and a later split between TAM 2 and Q151M, as outlined 
graphically in figure 2. Accordingly, modelling was performed in two sequential steps. 
The first step consisted of a multivariable comparison of the 69 insertion group with a 
pooled group of TAM2 and Q151M with respect to polymorphisms and therapy 
exposures. Subsequently, factors separating the TAM 2 and Q151M groups were 
identified by repeating the multivariable modelling analysis on these two groups only.  
 
Table 3. Univariable and multivariable logistic regression comparing patients detected with 69 
insertion/≥2 thymidine-analogue mutations (TAM) 1 (reference) with Q151M/ ≥2 TAM 2. 
 69 insertion / 
≥2 TAM 1 
(n=417) 
 Q151M /  ≥2 
TAM 2 
(n=278) 
Univariable Multivariable 
Characteristics    OR (95% CI) P OR (95% CI) P 
K43E 38 (9.1%)  4 (1.4%) 0.1 (0.1-0.4) <0.001 0.1 (0.0-0.4) 0.001 
V60I 61 (14.6%)  70 (25.2%) 2.0 (1.3-2.9) 0.001 1.9 (1.2-2.9) 0.006 
S68G 28 (6.7%)  12 (4.3%) 0.6 (0.3-1.3) 0.187 -   
S162C 51 (12.2%)  14 (5.0%) 0.4 (0.2-0.7) 0.002 0.4 (0.2-0.8) 0.016 
T165I 5 (1.2%)  10 (3.6%) 3.1 (1.0-9.1) 0.042 2.3 (0.6-8.4) 0.217 
I202V 30 (7.2%)  48 (17.3%) 2.7 (1.7-4.4) <0.001 2.5 (1.5-4.4) 0.001 
R211K 230 (55.2%)  104 (37.4%) 0.5 (0.4-0.7) <0.001 0.5 (0.4-0.8) 0.001 
F214L 9 (2.2%)  85 (30.6%) 20.0 (9.8-40.5) <0.001 19.0 (9.0-40.1) <0.001
Ever used 3TC 297 (71.2%)  211 (75.9%) 1.3 (0.9-1.8) 0.174 -   
Ever used ABC 79 (18.9%)  69 (24.8%) 1.4 (1.0-2.0) 0.064 1.2 (0.8-1.9) 0.373 
Ever used ZDV 387 (92.8%)  254 (91.4%) 0.8 (0.5-1.4) 0.488    
Ever used D4T 239 (57.3%)  178 (64.0%) 1.3 (1.0-1.8) 0.077 1.3 (0.9-2.0) 0.137 
Ever used ddC 117 (28.1%)  58 (20.9%) 0.7 (0.5-1.0) 0.033 0.6 (0.4-1.0) 0.034 
Ever used ddI 262 (62.8%)  157 (56.5%) 0.8 (0.6-1.0) 0.094 0.7 (0.5-1.0) 0.061 
Ever used TDF 29 (7.0%)  17 (6.1%) 0.9 (0.5-1.6)  0.663 -   
OR, odds ratio; CI confidence interval; 3TC, lamivudine; ABC, abacavir; ZDV, zidovudine; D4T, stavudine; ddC, 
zalcitabine; ddI, didanosine; TDF, tenofovir 
 
 
The first logistic regression comparing the pooled 69 insertion/TAM 1 groups with the 
pooled Q151M/TAM 2 groups (table 3) confirmed the strong association of the 
polymorphic mutation F214L with the emergence of Q151M and or ≥2 TAM 2 
(univariable odds ratio (OR): 20.0, 95% CI: 9.8-40.5, P<0.001; multivariable OR: 
19.0, 95% CI: 9.0-40.1, P<0.001). Moreover, V60I and I202V were also associated 
with the emergence of Q151M/≥2 TAM 2, whereas K43E and R211K were negatively 
associated. In the second step aiming at finding polymorphisms which may influence 
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the emergence of Q151M as opposed to TAM 2 mutations, S68G was strongly 
associated with the occurrence of Q151M (univariable OR: 23.2, 95% CI: 6.5-83.9, 
P<0.001; multivariable OR: 18.1, 95% CI: 4.0-81.3, P<0.001). Additionally, S162C 
and I202V were positively associated with the occurrence of Q151M. Of note, this 
analysis also suggests a role of stavudine use and possibly also zalcitabine in the 
emergence of the MNR mutation Q151M (table 4). 
 
Table 4. Univariable and multivariable logistic regression comparing patients detected with ≥2 
thymidine-analogue mutations (TAM) 2 (reference) and Q151M. 
 ≥2 TAM 2 
(n=249) 
 Q151M  
(n=29) 
Univariable Multivariable 
Characteristics    OR (95% CI) P OR (95% CI) P 
K43E 4 (1.6%)  0 (0%) -   -   
V60I 63 (25.3%)  7 (24.1%) 0.9 (0.4-2.3) 0.891 -   
S68G 4 (1.6%)  8 (27.6%) 23.3 (6.5-83.9) <0.001 18.1 (4.0-81.3) <0.001
S162C 11 (4.4%)  3 (10.3%) 2.5 (0.7-9.5) 0.181 -   
T165I 5 (2.0%)  5 (1.2%) 10.2 (2.7- 37.6) 0.001 9.2 (2.0-42.4) 0.005 
I202V 36 (14.5%)  12 (41.4%) 4.2 (1.8-9.5) 0.001 6.2 (2.2-17.6) 0.001 
R211K 91 (36.6%)  13 (44.8%) 1.4 (0.6-3.1) 0.385    
F214L 77 (30.9%)  8 (27.6%) 0.9 (0.4-2.0) 0.712 -   
Ever used 3TC 188 (75.5%)  23 (79.3%) 1.2 (0.5-3.2) 0.650 -   
Ever used ABC 60 (24.1%)  9 (31.0%) 1.4 (0.6-3.3) 0.415 -   
Ever used ZDV 228 (91.6%)  26 (89.7%) 0.8 (0.2-2.9) 0.729 -   
Ever used D4T 152 (61.0%)  26 (89.7%) 5.5 (1.6-18.8) 0.006 6.3 (1.5-25.9) 0.011 
Ever used ddC 46 (18.5%)  12 (41.4%) 3.1 (1.4-7.0) 0.006 4.3 (1.6-11.7) 0.005 
Ever used ddI 134 (53.8%)  23 (79.3%) 3.3 (1.3-8.4) 0.012 1.5 (0.5-4.3) 0.500 
Ever used TDF 14 (5.6%)  3 (10.3%) 1.9 (0.5-7.2) 0.323 -   
OR, odds ratio; CI confidence interval; 3TC, lamivudine; ABC, abacavir; ZDV, zidovudine; D4T, stavudine; ddC, 
zalcitabine; ddI, didanosine; TDF, tenofovir 
 
Predictive values of polymorphic mutations (analysis step 3) 
The polymorphism with the highest sensitivity (30.6%) and specificity (97.8%) to 
predict Q151M/TAM 2 as opposed to 69 insertion/TAM 1 was F214L, with an area 
under the curve (AUC) of 0.64. Having this mutation predicted the correct pathway 
(i.e. Q151M/TAM 2) in 71.0% of cases. The sensitivity, specificity and the percentage 
of correctly classified of V60I and I202V were 17.3% and 25.2%, 92.8% and 85.4%, 
and 62.6% and 61.3%, respectively. 
In the second analysis comparing only the TAM 2 and Q151M groups, the sensitivity 
and specificity of S68G to predict the TAM 2 pathway was 27.6% and 98.4%, 
respectively. The percentage of correctly classified was 91.0% and the area under 
ROC curve 0.74. For T165I and I202V were sensitivity 17.2% and 41.4%, specificity 
98.0% and 85.5%, and percentage of correctly classified 89.6% and 80.9%, 
respectively. 
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For the external validation 36 sequence pairs from the Stanford database could be 
included , of which 8 had the Q151M mutation, 21 had ≥2 TAM 1, 22 ≥2 TAM 2. The 
69 insertion was not observed. Interestingly, the polymorphisms F214L and V60I also 
showed the best prediction performance in this new sample for Q151M/TAM 2 
(supplementary table 1), with 64% and 67% of samples correctly classified, 
respectively. Due to the very small numbers of S68G (n=1), T165I (n=1), and I202V 
(n=0) mutations in treatment-naive samples no meaningful comparisons could be 
performed between the Q151M and the TAM 2 group. 
 
TAM 2TAM 1
S68G
T165I
I202V
Q151M
F214L 
I202V
V60I
69 insertion
K43E
S162C
R211K
 
Figure 2. Polymorphic mutations associated with different resistance pathways. 
 
Discussion 
The present study aimed to better characterize possible viral genetic signatures 
associated with the emergence of MNR profiles. Specifically, it was investigated 
whether particular polymorphic mutations are associated with the occurrence of 69 
insertion and Q151M. The study confirmed the cluster of the 69 insertion with the 
TAM 1 pathway. Among others, the polymorphism F214L was found to be strongly 
positively associated with the Q151M/TAM 2 pathway, but negatively with the 69 
insertion/TAM 1 pathway. S68G, T165I and I202V were more common among 
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patients detected with Q151M in contrast to patients with TAM 2. In figure 2, the 
suggested resistance pathways are summarized. 
F214L is a polymorphism known to direct resistance pathways.16, 25 This is the first 
study showing an association with the emergence of Q151M. The high percentage of 
F214L in samples detected with the Q151M mutation is probably due to the negative 
association with the TAM 1 pathway. On a structural level, F214L is too far away from 
the Q151M pattern to interact directly. However, indirect effects via other amino acids 
can not formally be excluded. We showed a strong correlation between S68G and 
Q151M.13 S68G was commonly observed together with the Q151M mutations. The 
prevalence of S68G among treatment-naïve patients was 4.5% compared to 5.8% 
among treatment-experienced patients, we can not definitively exclude an 
association with the treatment.13, 26 S68G is known to partially compensate the 
negative impact on the viral replication of Q151L that is a potential intermediate of 
the Q151M mutation with a strongly decreased viral replication capacity.27, 28 The 
polymorphic mutation I202V was found to be positively associated with the Q151M 
pathway. T165I and I202V might be an important factor directing viral evolution 
towards Q151M in contrast to TAM 2.  
Our study is limited by the small sample size, but to date it is the largest study 
addressing the topic of MNR.13, 14 Overall, the predictive values of polymorphisms for 
the emergence of specific pathways were quite low. This is not so surprising, given 
that the emergence or resistance mutations is also strongly influence by antiretroviral 
therapy, which was difficult to adjust for in this analysis. It should be noted however 
that we have been able to reproduce some of our main findings in an independent, 
strictly selected dataset, namely the negative associations of the polymorphisms 
F214L and V60I with the TAM 1/69 insertion pathway. Whether polymorphic 
mutations can favour the emergence of Q151M mutation is less clear from this 
analysis. While we found solid evidence for a distinct 69 insertion/TAM 1 pathway, 
there was no clear separation between Q151M and TAM 2 mutations. Although 
Q151M and TAM 2 can occur independently, these mutations do not seem mutually 
exclusive, and the emergence of Q151M may largely be driven be factors like 
treatment. 
To conclude, this is the first study which found evidence for a dependency of MNR 
emergence on the genomic background of the HIV polymerase. The polymorphisms 
F214L and V60I were found to direct viral evolution towards Q151M- and TAM 2-
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pathway in contrast to the 69 insertion/TAM 1-pathway. Other genotypic changes, 
such as S68G, T165I and I202V, were strongly associated with the emergence of 
Q151M, but their role was less clear. Nevertheless, a better understanding of the 
processes leading up to the emergence of MNR mutations is of great relevance in 
light of their negative clinical impact and the increasing MNR prevalence in resource 
limited settings.29, 30 Similar studies in less developed settings and with subtypes 
other than subtype B are clearly warranted. 
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Supplementary  
Supplementary table 1. Validation of polymorphisms predicting for the thymidine analogue 
mutation (TAM) 1 pathway. Sequences were obtained from the Stanford database Genotype-
Treatment Correlations tool consisting of one genotype performed before treatment exposure 
and one obtained after any exposure to zidovudine and/ or stavudine. 
 TAM 1 (n=21 ) no TAM 1 (n=15) Sensitivity Specificity % Correctly classified AUC
K43E  0 0 - - - - 
V60I 1 (6.7%) 4 (19%) 26.7% 95.2% 66.7% 0.61
S68G 1 (6.7%) 0 - - - - 
S162C 3 (20%) 2 (9.5%) 13.3% 85.7% 55.6% 0.50
T165I 1 (6.7%) 1 (4.8%) 7.0% 95.2% 58.3% 0.51
I202V 1 (6.7%) 0 - - - - 
R211K 7 (46.7%) 2 (9.5%) 13.0% 66.7% 44.4% 0.40
F214L 1 (6.7%) 3 (14.3%) 20.0% 95.2% 63.9% 0.58
AUC, area under ROC curve 
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Abstract 
Background 
Antiretroviral compounds were predominantly studied in HIV-1 subtype B, but only 
approximately 10% of infections worldwide are caused by this subtype. Analyzing the 
impact of different HIV subtypes on treatment outcome is important. 
Methods 
The effect of subtype B and non-B on the time to virological failure while taking 
combination antiretroviral therapy (cART) was analyzed. Previous studies addressing 
this question were limited by the strong correlation of subtype and ethnicity. Our 
analysis was restricted to Caucasians from the Swiss HIV Cohort Study who started 
cART between 1996 and 2009. Cox regression models were performed, adjusted for 
age, sex, transmission category, first cART, baseline CD4 cells and HIV RNA, and 
stratified for previous mono/dual nucleoside reverse transcriptase inhibitor treatment. 
Results 
4729 patients infected with subtype B and 539 with non-B were included. Most 
prevalent non-B subtypes were CRF02_AG (23.8%), A (23.4%), C (12.8%) and 
CRF01_AE (12.6%). The incidence of a virological failure was higher in patients with 
subtype B (4.3 [95% CI: 4.0-4.5] failures/100 person-years) compared with non-B 
(1.8 [1.4-2.4]). Cox regression models confirmed that patients infected with non-B 
subtypes had a lower risk for virological failure compared with subtype B (univariable 
HR: 0.39 [0.30-0.52], P<0.001; multivariable HR: 0.68, [0.51-0.91], P=0.009). In 
particular, subtype A and CRF02_AG revealed improved outcomes (multivariable 
HR: 0.54 [0.29-0.98] and 0.39 [0.19-0.79], respectively). 
Conclusions 
Improved virological outcomes among patients infected with non-B subtypes 
invalidate concerns that these individuals are at disadvantage because drugs were 
designed mostly for subtype B infections. 
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Introduction 
The HIV epidemic is characterized by a high genotypic diversity with multiple distinct 
viral subtypes and circulating recombinant forms (CRFs).1 In North America, Europe 
and Australia, where most antiretroviral compounds were designed and initially 
tested, subtype B is predominant.2 However, only approximately 10% of global HIV 
infections are caused by subtype B. The most prevalent subtype is C which occurs 
mainly in South and East Africa.1 
With the introduction of combination antiretroviral therapy (cART) HIV/AIDS-related 
morbidity and mortality was markedly reduced,3, 4 but concerns rose that antiviral 
susceptibility derived from studies with subtype B may not be applicable to non-B 
infections.5 It was suggested that pretreatment genetic variation in the HIV reverse-
transcriptase and protease among different subtypes may affect treatment response.6 
Studies in areas where non-B infections are predominant, mostly resource-limited 
settings, showed promising results, but these data can not be directly compared with 
data derived from resource-rich settings. To reduce biases, it is essential to perform 
inter-subtype comparisons in single settings.7 A few studies were performed in 
Western countries analyzing the effect of viral subtype on treatment response.8-15 
However, all these studies had limitations and suffered either from a short follow-up 
time, a small sample size or the strong correlation of ethnicity and subtype. 
We aimed to analyze short- and long-term effects of HIV subtype on the viral 
response after cART initiation in the Swiss HIV Cohort Study (SHCS). The SHCS 
provides the unique opportunity to study different subtypes in a single ethnic group, 
namely Caucasian. This is advantageous, because HIV subtype and ethnicity are 
strongly correlated and ethnicity is potentially associated with treatment response 
and with a different natural history of HIV.16-20 Furthermore, it allows excluding 
potential bias due to different host genetic backgrounds.21 
Methods 
Study population 
Data from the SHCS up to January 12, 2011 were included. The SHCS is a 
nationwide, multicenter, clinic-based cohort with continuous enrolment and semi-
annual study visits 22. The SHCS has been approved by ethical committees of all 
participating institutions, and written informed consent has been obtained from all 
participants. The present study was restricted to Caucasians with known HIV 
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subtype. Subtyping was based on sequences from the SHCS drug resistance 
database that are stored in SmartGene’s (Zug, Switzerland) Integrated Database 
Network System (IDNS version 3.6.0).23 Systematic retrospective sequencing was 
performed to obtain one sequence for each patient enrolled in the SHCS after 1995. 
Subtyping was performed using the REGA 2 System and if the results were 
inconclusive, we repeated subtyping with the Star analyzer 
(http://www.vgb.ucl.ac.uk/starn.shtml).24 Sequences were excluded if the subtype 
remained unequivocal undetermined.  
 
Study design 
cART was defined as any antiretroviral therapy consisting of at least two different 
drug classes. Detection limits of HIV RNA assays changed in the course of time 
(<400 copies/mL before 1999, <50 copies/mL afterwards). Therefore, we performed 
two separate analyses with different definitions for viral suppression and virological 
failure. Analysis A included patients who initiated cART between January 1, 1996 
and December 31, 2009. The definition of viral suppression was at least one viral 
load below the detection limit (<400 copies/mL) between day 90 and 365 after cART 
initiation. Virological failure was defined as: i) two consecutive viral loads >1000 
copies/mL after previous suppression to <400 copies/mL on an uninterrupted 
treatment, or ii) one viral load >1000 copies/mL after previous suppression to <400 
copies/mL followed by a treatment change or interruption, or iii) one viral load >1000 
copies/mL after 180 days of treatment without previous suppression. If patients 
changed the cART regimen when viral load was suppressed, e.g. due to toxicity 
reasons, the definition of a virological failure for i) and ii) was adapted: Previous 
suppression to <400 copies/mL was not required during the new treatment. The 
analysis B included a subset of patients from analysis A. Analysis B was limited to 
treatment-naïve patients who started cART between January 1, 1999 and December 
31, 2009. In 1999, all SHCS laboratories had changed their HIV RNA assays and 
achieved detection limits of 50 copies/mL. Viral load measurements with higher 
detection limits in this transition period occurred rarely and were excluded from 
analysis. The definition of viral suppression and virological failure was adapted in 
analysis B. Viral suppression was achieved when HIV RNA was <50 copies/mL and 
for the definition of virological failures the viral load limits in i), ii) and iii) were 
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changed: The lower limit was <50 copies/mL (instead of <400 copies/mL) and the 
upper limit >500 copies/mL (instead of >1000 copies/mL). 
 
Statistical analysis 
Baseline characteristics at cART initiation were analyzed with Fisher’s exact test 
(categorical variables) and Wilcoxon rank-sum test (continuous variables). Baseline 
HIV RNA and CD4 cell counts were considered when measured within 180 days prior 
to cART initiation. 
The short-term virological response (viral suppression) was analyzed using 
univariable and multivariable logistic regressions. Multivariable models were adjusted 
for sex, age, transmission category, baseline HIV RNA, baseline CD4 cell count, 
initial cART (unboosted PI, PI/r, NNRTI or other), calendar period (analysis A: 1996-
1998, 1999-2003, 2004-2009; analysis B: 1999-2002, 2003-2006, 2007-2009), and 
previous treatment with mono/dual NRTI therapy (only analysis A). Continuous 
variables were categorized if likelihood-ratio tests indicated significant departures 
from linearity. 
To study the long-term virological outcome, the virological failure rates were analyzed 
with Kaplan-Meier curves and log-rank tests. Additionally, univariable and 
multivariable Cox regression models were performed and adjusted for the same 
potential confounders described above. The proportional hazard assumption was 
checked with Schoenfeld residuals and by using graphical methods. While being pre-
treated with mono/dual NRTI therapy in analysis A, did not satisfy the proportional 
hazard assumption, we stratified the Cox models for this variable. Co-linearity was 
checked and a variance inflation factor (VIF) <3 was tolerated for regression models. 
All analyses assumed intention to continue treatment and did not consider treatment 
changes after starting cART. Patient’s follow-up was censored when the treatment 
was changed to a non-cART regimen. Periods of treatment interruptions were 
subtracted from the exposure time and viral loads measured off-treatment were not 
considered for analysis.  
Self-reported adherence is measured since May 2003 in the SHCS and has been 
validated for treatment outcome.25 We compared the lowest self-reported adherence 
between cART initiation and censoring or virological failure. 
Statistical analyses were performed with Stata 11 SE (StataCorp, College Station, 
TX). All P values were two-sided and the level of significance was set at 0.05. 
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Results 
Study population and baseline characteristics 
Analysis A (cART start 1996-2009) included 4729 of 5268 patients (89.8%) with 
subtype B infections and 539 (10.2%) with non-B subtypes (table 1). The most 
common non-B subtypes were CRF02_AG (23.8%), A (23.4%), C (12.8%), 
CRF01_AE (12.6%) or other (27.5%). Most patients infected with “other” subtypes 
had a subtype F (29.1%, n=43), subtype G (28.4%, n=42), or subtype D infection 
(16.9%, n=25). CD4 cell count at baseline tended to be lower in patients infected with 
subtype B compared with non-B (median (IQR): 223 (106-357) cells/µl compared with 
243 (134-366) cells/µl, P=0.088). The median log10 HIV RNA at baseline was similar 
between groups (subtype B: 4.7 [IQR: 3.9-5.2], non-B: 4.7 [3.9-5.3]). 
In analysis B (cART start 1999-2009), 2166 of 2549 patients (85.0%) had subtype B 
infections and 383 non-B infections (15.0%). Most baseline characteristics were 
similar to analysis A (table 1). 
 
First cART 
In analysis A, 34.3% and 13.7% of patients infected with subtype B and non-B were 
pre-treated with mono/dual NRTIs, respectively (table 2). The median [IQR] year of 
cART initiation was earlier in patients infected with subtype B (1999 [1997-2004]) 
compared with non-B (2003 [1999-2007]), and they received more often unboosted 
PIs, 52.0% compared with 30.2% of non-B infections. 
In analysis B, no difference between cART was present between groups (table 2). 
The median [IQR] year of cART start was similar: 2004 [2001-2007] and 2005 [2002-
2007], respectively. 
In both analyses, the most frequent NRTI combination was lamivudine and 
zidovudine. Efavirenz was the most common NNRTI and lopinavir the most 
frequently used PI/r. Patients with an unboosted PI received mostly nelfinavir or 
indinavir. 
Patients of whom the treatment was not classified into the categories PI, PI/r or 
NNRTI had often combinations of PIs and NNRTIs (analysis A: 90/95, analysis B: 
33/35).  
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Table 1. Patients characteristics at combination antiretroviral therapy (cART) initiation. 
 Analysis A: cART start between 1996-2009 
Subtype 
 
B 
n (%) 
non-B 
n (%) P
1 01_AE n (%) 
02_AG 
n (%) 
A 
n (%) 
C 
n (%) 
other 
n (%) P
2 
Sex    <0.001      <0.001
Male  3768 (79.7) 363 (67.3)  43 (63.2) 121 (94.5) 60 (47.6) 47 (67.1) 93 (62.4)  
Female  961 (20.3) 176 (32.6)  25 (36.8) 7 (5.5) 66 (52.4) 23 (32.9) 56 (37.6)  
Median age (IQR)  47(43-53) 50 (41-61) <0.001 47.5 (42-59.5) 51.5 (43-58) 56 (45-67) 51 (45-61) 45.5 (39.5-59.5) <0.001
Transmission category  <0.001      <0.001
HET  1082 (22.9) 388 (72.0)  58 (85.3) 84 (65.6) 101 (80.2) 50 (71.4) 96 (64.4)  
MSM  2253 (47.6) 91 (16.9)  7 (10.3) 36 (28.1) 10 (7.9) 10 (14.3) 28 (18.8)  
IDU  1250 (26.4) 37 (6.9)  1 (1.5) 4 (3.1) 8 (6.3) 5 (7.1) 20 (13.4)  
Other  144 (3.0) 23 (4.3)  2 (2.9) 4 (3.1) 7 (5.6) 5 (7.1) 5 (3.4)  
CDC stage    <0.001      <0.001
A  2536 (53.6) 366 (67.9)  47 (69.1) 93 (72.7) 79 (62.7) 50 (71.4) 98 (65.8)  
B  1255 (26.5) 101 (18.7)  16 (23.5) 13 (10.2) 25 (19.8) 14 (20.0) 34 (22.8)  
C  938 (19.8) 72 (13.4)  5 (7.3) 22 (17.2) 22 (17.5) 6 (8.6) 17 (11.4)  
CD4 count (cells/µL)  0.081      0.182
CD4 <200  1861 (44.4) 193 (40.2)  22 (37.9) 55 (48.3) 41 (36.9) 22 (34.9) 53 (39.3)  
CD4 ≥200   2330 (55.6) 287 (59.8)  36 (62.1) 59 (51.8) 70 (63.1) 41 (65.1) 82 (60.7)  
CD4 missing  538 (11.4) 59 (10.9) 0.830 10 (14.7) 14 (10.9) 15 (11.9) 7 (10.0) 14 (9.4) 0.910
HIV-1 RNA count (copies/mL)  0.884      0.193
<10,000  1258 (28.5) 141 (27.4)  14 (22.2) 23 (18.6) 43 (35.5) 19 (28.4) 43 (30.5)  
10,000-99,999   1583 (35.9) 187 (36.4)  25 (39.7) 47 (37.9) 44 (36.4) 27 (40.3) 45 (31.9)  
≥100,000  1571 (35.6) 186 (36.2)  24 (38.1) 54 (43.5) 34 (28.1) 21 (31.3) 53 (37.6)  
missing  317 (6.7) 25 (4.6) 0.065 5 (7.3) 4 (3.1) 5 (4.0) 3 (4.3) 8 (5.4) 0.415
  Analysis B: cART start between 1999-2009 
Sex    <0.001      <0.001
Male  1801 (83.2) 268 (70.0)  33 (61.1) 95 (97.9) 40 (48.8) 30 (68.2) 70 (66.0)  
Female  365 (16.9) 115 (30.0)  21 (38.9) 2 (2.1) 42 (51.2) 14 (31.8) 36 (34.0)  
Median age (IQR)  45 (39-51) 50 (40-61) <0.001 46 (41-60) 52 (42-57) 55 (40-65) 51.5 (40-61) 46 (39-60) <0.001
Transmission category  <0.001      <0.001
HET  533 (24.6) 265 (69.2)  44 (81.5) 63 (65.0) 62 (75.6) 30 (68.2) 66 (62.3)  
MSM  1147 (53.0) 76 (19.8)  7 (13.0) 32 (33.0) 6 (7.3) 7 (15.9) 24 (22.6)  
IDU  409 (18.9) 28 (7.3)  1 (1.9) 2 (2.1) 8 (9.8) 3 (6.8) 14 (13.2)  
Other  77 (3.5) 14 (3.7)  2 (3.7) 0 (0.0) 6 (7.3) 4 (9.1) 2 (1.9)  
CDC stage    0.044      0.050
A  1390 (64.2) 269 (70.2)  39 (72.2) 73 (75.3) 53 (64.6) 33 (75.0) 71 (67.0)  
B  422 (19.5) 68 (17.8)  12 (22.2) 8 (8.3) 16 (19.5) 8 (18.2) 24 (22.6)  
C  354 (16.3) 46 (12.0)  3 (5.6) 16 (16.5) 13 (15.9) 3 (6.8) 11 (10.4)  
CD4 count (cells/µL)  0.284      0.813
CD4 <200  819 (42.5) 134 (39.3)  17 (37.0) 37 (43.5) 27 (37.0) 16 (41.0) 37 (37.8)  
CD4 ≥200   1108 (57.5) 207 (60.7)  29 (63.0) 48 (56.5) 46 (63.0) 23 (59.0) 61 (62.2)  
CD4 missing  239 (11.0) 42 (11.0) 1.000 8 (14.8) 12 (12.4) 9 (11.0) 5 (11.4) 8 (7.5) 0.809
HIV-1 RNA count (copies/mL)  0.528      0.546
<10,000  450 (21.5) 89 (24.1)  11 (21.6) 15 (16.1) 25 (30.9) 10 (23.8) 28 (27.2)  
10,000-99,999   764 (36.5) 132 (35.7)  20 (39.2) 36 (38.7) 27 (33.3) 17 (40.5) 32 (31.1)  
≥100,000  882 (42.1) 149 (40.3)  20 (39.2) 42 (45.2) 29 (35.8) 15 (35.7) 43 (41.8)  
missing  70 (3.2) 13 (3.4) 0.876 3 (5.6) 4 (4.1) 1 (1.2) 2 (4.5) 3 (2.8) 0.774
1 Fisher’s exact test comparing subtype B and non-B infections, 2 Fisher’s exact test comparing all particular subtypes  
HET, heterosexual; MSM, men who have sex with men; IDU, injecting drug user; CDC, centers for disease control and prevention 
 
Short-term virological outcome 
In analysis A, 4433 of 4729 (93.7%) and 516 of 539 patients (95.7%) infected with 
subtype B and non-B had at least one viral load measured between day 90 and 365 
after cART initiation (P=0.070). 3870 of 4433 (87.3%) and 481 of 516 (93.2%, 
P<0.001) achieved viral suppression. The probability to achieve viral suppression 
was higher in patients infected with non-B subtypes in the univariable logistic 
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regression model (odds ratio (OR): 2.0 [95% CI: 1.4-2.8]), but not in the multivariable 
model (OR: 1.2 [0.8-1.8]). Including patients without viral load measurement as 
failures did not alter conclusions. Results were similar in analysis B: 2076 of 2166 
patients (95.8%) infected with subtype B and 375 of 285 (97.9%, P=0.060) with non-
B subtypes had a viral load measured, of whom 1856 of 2076 (89.4%) and 338 of 
375 patients (90.1%) achieved viral suppression (P=0.715). Compared with subtype 
B, non-B infected patients had a comparable probability to achieve viral suppression. 
The ORs in the univariable and multivariable models were 1.1 [0.8-1.6] and 1.0 [0.7-
1.5], respectively. Considering missing values as treatment failures yielded similar 
results. Differentiating between the specific non-B subtypes did not alter conclusion. 
Compared with subtype B, probabilities to achieve viral suppression were not 
significantly different (data not shown). 
 
Table 2. First combination antiretroviral therapy (cART) 
 
 Analysis A: cART start between  
1996-2009 
 Analysis B: cART start between 
1999-2009 
Subtype 
 B 
n (%) 
non-B 
n (%) P*  
B 
n (%) 
non-B 
n (%) P* 
Year of cART initiation (analysis A | B)    <0.001   0.001
1996-1998 | 1999-2002  2198 (46.5) 113 (21.0)   617 (28.5) 75 (19.6)  
1999-2003 | 2003-2006  1164 (24.6) 165 (30.6)   660 (30.5) 138 (36.0)  
2004-2009 | 2007-2009  1367 (28.9) 261 (48.4)   889 (41.0) 170 (44.4)  
Pre-treated with mono/dual NRTIs  1624 (34.3) 74 (13.7) <0.001  0 (0.0) 0 (0.0) - 
Treatment included:    <0.001    0.062 
NNRTI  1035 (21.9) 177 (32.8)   863 (39.8) 157 (41.0)  
PI/r  1143 (24.2) 197 (36.5)   896 (41.4) 171 (44.6)  
PI  2458 (52.0) 163 (30.2)   373 (17.2) 54 (14.1)  
other  93 (2.0) 2 (0.4)   34 (1.6) 1 (0.3)  
NRTI backbone    <0.001    0.087 
ETC TDF  644 (13.6) 114 (21.1)   598 (27.6) 108 (28.2)  
3TC AZT  1994 (42.2) 247 (45.8)   956 (44.1) 188 (49.1)  
3TC D4T  857 (18.1) 44 (8.2)   114 (5.3) 11 (2.9)  
D4T DDI  387 (8.2) 30 (5.6)   81 (3.7) 6 (1.6)  
3TC ABC  172 (3.6) 31 (5.8)   152 (7.0) 29 (7.6)  
3TC TDF  177 (3.7) 25 (4.6)   146 (6.7) 24 (6.3)  
Other NRTIs  498 (10.5) 48 (8.9)   119 (5.5) 17 (4.4)  
NNRTI    0.895    1.000 
EFV  880 (85.5) 149 (84.2)   758 (87.8) 138 (87.9)  
NVP  148 (14.3) 27 (15.3)   103 (11.9) 19 (12.1)  
other NNRTI  7 (0.7) 1 (0.6)   2 (0.2) 0 (0.0)  
PI/r    <0.001    0.083 
LPV  625 (54.7) 136 (69.0)   589 (65.7) 127 (74.3)  
ATV/r  224 (19.6) 37 (18.8)   195 (21.8) 33 (19.3)  
IDV/r  92 (8.1) 7 (3.6)   70 (7.8) 6 (3.5)  
Other PI/r  202 (17.7) 17 (8.6)   42 (4.7) 5 (2.9)  
Unboosted PI    <0.001    0.629 
NFV  910 (37.0) 93 (57.1)   307 (82.3) 47 (87.0)  
IDV  949 (38.6) 42 (25.8)   31 (8.3) 5 (9.3)  
RTV  402 (16.4) 12 (7.4)   2 (0.5) 0 (0.0)  
Other PI  197 (8.0) 16 (9.8)   33 (1.1) 2 (3.7)  
*Fisher’s exact test. NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, 
protease inhibitor; PI/r, ritonavir boosted protease inhibitor; ETC, emtricitabine; TDF, tenofovir; 3TC, lamivudine; D4T, stavudine; 
DDI, didanosine; ABC, abacavir; EFV, efavirenz; NVP, nevirapine; LPV, lopinavir; ATV, atazanavir; IDV, indiniavir; RTV, ritonavir 
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Long-term virological outcome 
In analysis A, 5268 patients contributed 29,446 person-years follow-up. The 
incidence of a virological failure was higher in patients infected with subtype B (4.3 
[95% CI: 4.0-4.5] failures/100 person-years) compared with non-B (1.8 [1.4-2.4]). 
Incidences were smaller in analysis B, but patients infected with subtype B also had a 
higher incidence (2.6 [2.3-3.0] compared with 1.4 [0.9-2.1] failures/100 person-years; 
2549 patients contributed 10,803 person-years follow-up). 
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Figure 1. Kaplan-Meier curves differentiated by the first combination antiretroviral treatment (cART): 
unboosted protease inhibitor (PI), boosted PI (PI/r) or a nonnucleoside reverse transcriptase inhibitor 
(NNRTI). Analysis A and B included patients who started cART between 1996-2009 and 1999-2009, 
respectively. 
 
Kaplan-Meier curves illustrate the time to virological failure differentiated by types of 
treatment (figure 1). As shown in Cox regression models, the probability to 
experience a virological failure was lower among patients infected with non-B  
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subtypes compared with subtype B (table 3). In analysis A, the univariable hazard 
ratio (HR) was 0.39 (95% CI: 0.30-0.52, <0.001) and the multivariable HR 0.68 (0.51-
0.91, P=0.009). Analysis B retained similar results. The univariable HR was 0.54 
(0.35-0.82, P=0.004) and the multivariable HR 0.63 (0.40-0.96, P=0.041). We 
additionally differentiated between the particular subtypes (figure 2). The 
multivariable Cox regression of analysis A showed that subtype A (P=0.042) and 
CRF01_AG (P=0.009) had significantly better long-term virological outcomes 
compared with patients infected with subtype B. No differences were found in 
analysis B, however sample sizes were small. 
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Figure 2. Univariable [●] and multivariable [□] Cox regression analyses comparing time to virological 
failure between patients infected with different HIV subtypes and circulating recombinant forms. 
Multivarible analyses are adjusted for age, sex, transmission category, first combination antiretroviral 
therapy (cART), baseline CD4 cells and HIV RNA. Analysis A is additionally stratified for previous 
mono/dual nucleoside reverse transcriptase inhibitor treatment. Hazard ratios below 1 indicate a 
better virological response compared with patients infected with subtype B. 95% confidence intervals 
are indicated. 
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Table 3. Cox regression models analyzing the time to virological failure. 
Analysis A: cART initiation between 1996-2009 
 No. failures No. at risk % failures 
Univariable HR 
(95% CI) P 
Multivariable* HR 
(95% CI) P 
Subtype    
B 1140 4729 24.11 Ref Ref  
non-B 52 539 9.65 0.39 (0.30-0.52) <0.001 0.68 (0.51-0.91) 0.009
Age (per 10  1.09 (1.03-1.15) 0.003 0.92 (0.86-0.99) 0.021
Sex    
Male 946 4131 22.90 Ref  Ref 
Female 246 1137 21.64 0.90 (0.78-1.03) 0.132 0.75 (0.64-0.87) <0.001
Transmission  <0.001   0.355
MSM 496 2344 21.16 Ref Ref  
HET 280 1470 19.05 0.86 (0.75-1.00) 1.09 (0.92-1.29) 
IDU 387 1287 30.07 1.43 (1.25-1.63) 1.11 (0.96-1.28) 
OTH 29 167 17.37 0.79 (0.54-1.15) 0.87 (0.60-1.27) 
CD4 cell count  <0.001   <0.001
CD4 <200 596 2054 29.02 Ref Ref  
CD4 ≥200 415 2617 15.86 0.53 (0.47-0.60) 0.62 (0.54-0.71) 
CD4 missing 181 597 30.32 1.06 (0.90-1.25) 1.11 (0.79-1.55) 
HIV RNA  <0.001   <0.001
< 10,000  252 1399 18.01 Ref Ref  
10,000-99,999  409 1770 23.11 1.36 (1.16-1.59) 1.65 (1.40-1.93) 
≥100,000 387 1757 22.03 1.24 (1.06-1.45) 1.59 (1.34-1.89) 
missing 144 342 42.11 2.39 (1.95-2.93) 1.32 (0.90-1.93) 
Treatment  <0.001   <0.001
PI 951 2621 36.28 Ref Ref  
PI/r 126 1340 9.40 0.27 (0.23-0.33) 0.66 (0.54-0.82) 
NNRTI 97 1212 8.00 0.22 (0.18-0.27) 0.61 (0.47-0.79) 
Other 18 95 18.95 0.53 (0.33-0.84) 0.71 (0.44-1.15) 
cART initiation  <0.001   <0.001
1996-1998 899 2311 38.90 Ref Ref  
1999-2003 239 1329 17.98 0.43 (0.37-0.49) 0.73 (0.60-0.87) 
2004-2009 54 1628 3.32 0.10 (0.07-0.13) 0.21 (0.15-0.30) 
 
While adherence to treatment is a potential bias, the self-reported adherence was 
similar between groups. In analysis A, 71.5% and 87.4% of patients had at least one 
documented self-reported adherence between cART initiation and the date of 
censoring or virological failure. Patients infected with subtype B and non-B had 
similar adherence: 45.7% and 49.9% never missed a dose, 27.7% and 28.2% missed 
a maximum of one dose per month, and 26.6% and 21.9% missed more than one 
dose per month (P=0.073). In analysis B, 87.6% (subtype B) and 93.5% (non-B) of 
patients had at least one reported adherence. Results were similar as in analysis A. 
Other factors potentially associated with a low adherence are high rates of treatment 
changes or an increased number of treatment interruptions. Both factors were similar 
between groups (data not shown). 
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Table 3. (continued) 
Analysis B: cART initiation between 1999-2009 
 No. failures No. at risk % failures 
Univariable HR 
 (95% CI) P 
Multivariable* HR 
(95% CI) P 
Subtype    
B 240 2166 11.08 Ref Ref  
non-B 23 383 6.01 0.54 (0.35-0.82) 0.004 0.63 (0.40-0.98) 0.041
Age (per 10  0.97 (0.86-1.09) 0.614 0.86 (0.75-0.99) 0.030
Sex    
Male 215 2069 10.39 Ref Ref  
Female 48 480 10.00 0.96 (0.70-1.32) 0.808 0.76 (0.54-1.07) 0.110
Transmission  <0.001   0.099
MSM 101 1223 8.26 Ref Ref  
HET 81 798 10.15 1.17 (0.88-1.57) 1.23 (0.89-1.72) 
IDU 72 437 16.48 2.05 (1.52-2.78) 1.52 (1.09-2.10) 
OTH 9 91 9.89 1.15 (0.58-2.28) 1.40 (0.70-2.80) 
CD4 cell count  0.002   0.055
<200  129 953 13.54 Ref Ref  
≥200  100 1315 7.60 0.65 (0.50-0.84) 0.74 (0.56-0.97) 
missing 34 281 12.10 1.04 (0.71-1.52) 1.11 (0.66-1.84) 
HIV RNA  0.063   0.838
< 10,000  45 539 8.35 Ref Ref  
10,000-99,999 85 896 9.49 1.09 (0.76-1.57) 1.02 (0.71-1.47) 
≥100,000 117 1031 11.35 1.20 (0.85-1.69) 1.13 (0.79-1.62) 
missing 16 83 19.28 2.27 (1.28-4.02) 1.21 (0.59-2.48) 
Treatment  <0.001   <0.001
PI 116 427 27.17 Ref Ref  
PI/r 70 1067 6.56 0.27 (0.20-0.37) 0.51 (0.36-0.73) 
NNRTI 69 1020 6.76 0.25 (0.19-0.34) 0.46 (0.33-0.65) 
Other 8 35 22.86 0.82 (0.40-1.68) 0.94 (0.45-1.95) 
cART initiation  <0.001   <0.001
1999-2002 164 692 23.70 Ref Ref  
2003-2006 65 798 8.15 0.33 (0.25-0.44) 0.48 (0.34-0.68) 
2007-2009 34 1059 3.21 0.19 (0.13-0.28) 0.30 (0.19-0.47) 
*Multivarible analyses are adjusted for age, sex, transmission category, first combination antiretroviral therapy (cART), baseline 
CD4 cells and HIV RNA. Analysis A is additionally stratified for previous mono/dual nucleoside reverse transcriptase inhibitor 
treatment. NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor; PI/r, ritonavir boosted protease inhibitor; HET, heterosexual; MSM, men who have sex with men; IDU, intravenous drug 
user; cART, combination antiretroviral treatment; HR, hazard ratio; CI, confidence interval 
 
To assess the robustness of the finding that non-B subtypes have a better long-term 
virological outcome compared with subtype B, we performed several sensitivity 
analyses. In analysis A, results were similar if we excluded patients who were treated 
with mono/dual NRTIs prior to cART initiation (univariable HR: 0.46 [95% CI: 0.32-
0.65], multivariable HR: was 0.58 [0.40-0.84]). If limiting analysis A and B to patients 
with known CD4 and RNA values at baseline, univariable HRs were 0.40 [0.29-0.53] 
and 0.56 [0.36-0.87], respectively. Multivariable HRs were 0.71 [0.52-0.97] and 0.66 
[0.41-1.06], respectively. Results remained robust if we censored the follow-up when 
a treatment interruption occurred (analysis A, univariable HR: 0.38 [0.28-0.52]; 
multivariable HR: 0.62 [0.45-0.86]; analysis B: univariable HR: 0.62 [0.39-.99], 
multivariable HR: 0.69 [0.42-1.13]). The frequency of HIV RNA measurements was 
comparable between patients infected with subtype B and non-B, the median (IQR) 
days between measurements were 96 (79-119) and 92 (77-115) in analysis A, and 
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93 (79-117) and 91 (77-112) in analysis B, respectively. However, irregular or long 
durations without HIV RNA measurements might bias the results. Therefore we 
censored patients’ follow-up if the time span between two HIV RNA measurements 
was longer than 180 days. Results remained robust (analysis A: univariable HR: 0.38 
[0.28-0.50]; multivariable HR: 0.68 [0.50-0.93]); analysis B: univariable HR: 0.56 
[0.37-0.85]; multivariable HR: 0.63 [0.40-0.98]). Moreover, the mode of transmission 
may be a critical issue. However, limiting the analysis to heterosexual patients did not 
alter conclusions (analysis A, univarable HR: 0.41 [0.29-0.59], multivariable HR: 0.61 
[0.43-0.88]; analysis B: univariable HR: 0.41 [0.23-0.73], multivariable HR: 0.46 [0.26-
0.83]). It was previously shown that transmitted antiretroviral resistance levels differ 
by subtype.26 To assess whether our results could be due to differential baseline 
resistance, we performed a sensitivity analysis in a subset of patients who had a 
genotypic resistance performed prior to cART initiation (analysis A: n=3137 [59.6%], 
analysis B: n=2121 [83.2%]). The number of patients with transmitted mutations 
affecting the initial cART was slightly higher in the subtype B group (analysis A: 5.4%, 
analysis B: 4.3%) compared with non-B (each 2.4%). Point estimates of the 
multivariable Cox model for the effect of viral subtype (analysis A: 0.66 [0.40-1.10], 
analysis B: 0.80 [0.48-1.33]) were not substantially altered when adding information 
on transmitted resistance in multivariable models (analysis A: 0.68 [0.41-1.14], 
analysis B: 0.83 [0.50-1.39]). 
Discussion 
In the SHCS, we showed that Caucasians infected with HIV non –B subtypes had an 
improved virological success rate while treated with cART compared with patients 
infected with B subtype. In particular, subtype A and CRF01_AG infections were 
associated with an improved virological long-term response. The short-term 
virological response did not differ between subtypes. 
In the last decade a vivid debate rose whether antiretroviral compounds are less 
active against non-B infections, since most antiretroviral drugs were designed to be 
used against subtype B infections.7 Findings of this study indicate that these 
previously raised concerns are unwarranted. 
This is the first study analyzing the impact of different HIV subtypes on treatment 
response in a single ethnicity, namely in Caucasians. Restricting the analysis to a 
single ethnic group is advantageous and avoids potential serious biases caused by 
Chapter 6 
133 
the association of ethnicity and subtype. Ethnic differences in host genetic factors 
influence the natural history of HIV, and the tolerability and potentially the efficacy of 
cART.27 Furthermore, cultural differences between diverse ethnicities could influence 
virological outcome. The homogeneity of our cohort with regard to genetic and 
cultural backgrounds allows the assessment of the impact of viral subtypes on 
virological response independent of ethnical variability.8, 16-19 Although, most patients 
infected with non-B subtypes are non-Caucasians, the question of susceptibility to 
cART among Caucasians infected with non-B subtypes becomes more and more 
important, since the prevalence of non-B infections is increasing in Western 
Countries.26, 28 
Several in vitro studies were conducted to test the drug susceptibility of non-B 
subtypes. Overall, most non-B subtypes possessed similar susceptibilities to those of 
subtype B (reviewed in6). However, one study showed that CRF02_AG samples were 
more susceptible to nelfinavir and ritonavir.29 In our study, the proportion of patients 
receiving these PIs was quite high which could partially explain our findings. 
Our results differ from other previous published observational studies.8-15, 18, 30 
However, most of these studies were limited either by a small sample size, a short 
follow-up time, missing adherence data or the correlation of ethnicity and 
transmission category with the HIV subtype. So far, Geretti et al. published the 
largest study analyzing the effect of HIV subtype on cART response. They found no 
significant inter-subtype differences on long-term treatment response.14 However, 
due to the strong correlation of HIV subtype with the ethnicity and the transmission 
group, they could not adjust their model for these two potential confounders.16, 17, 21 In 
contrast, our study is unbiased by ethnicity and a sensitivity analysis clearly 
demonstrated that results remained robust if the analysis was limited to patients with 
heterosexual transmission. Furthermore, we used more restrictive criteria for 
virological failures. Geretti et al. did not ignore virological failures during treatment 
interruptions in the main analysis, only in a sensitivity analysis with highly reduced 
statistical power. However, both studies exhibit a rather small number of virological 
failures among patients infected with specific non-B subtypes. Contrary to Geretti et 
al., our study comprised a higher proportion of patients infected with subtype A, 
CRF01_AE and CRF02_AG and lower numbers of patients infected with subtype C 
and D.  
Chapter 6 
134 
Although, this is the largest study addressing the question of cART response among 
different subtypes in a single ethnic group, the sample sizes of some particular non-B 
subtypes were small and therefore confidence intervals of HRs remained wide. 
Larger cohort collaborations will be necessary to strengthen our findings. In our 
study, some baseline and treatment characteristics that are predictive for response to 
cART (e.g. treatment with unboosted PI) differed between patients infected with 
subtype B and non-B, especially in analysis A. However, results remained robust 
when adjusting the models for these factors. A sensitivity analysis excluded that our 
findings were substantially biased by differential resistance levels of transmitted 
viruses.  
Previous concerns that antiretroviral treatment response might be hampered due to 
development and testing of antiretroviral compounds in resource-rich countries with 
high subtype B prevalence are not tenable anymore.  
In conclusion, concerns that cART is less susceptible in non-B infections are 
unwarranted. In contrast, patients infected with particular non-B subtypes had a 
better long-term virological outcome in Switzerland. 
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In the last few years several new antiretroviral drugs were licensed in Switzerland 
that are highly efficient against multi-drug resistant viruses, e.g. the new generation 
nonnucleoside reverse transcriptase inhibitor etravirine, the first integrase inhibitor 
raltegravir or the co-receptor antagonist maraviroc. The introduction of these drugs 
ushered a new era in HIV treatment. Its registration was probably the greatest 
breakthrough in HIV treatment since the introduction of the combination antiretroviral 
therapy. For the first time, highly treatment-experienced patients had the possibility to 
achieve long-lasting viral suppression with salvage regimens consisting of fewer pills 
and of drugs with less toxicity. Although the treatment options improved, it is highly 
relevant to closely monitor HIV drug resistance, especially in new salvage treatments, 
to early identify risk factors for the emergence of drug resistance and to ensure long-
lasting treatment success. In resource-limited settings, the situation is different 
because the access to these new antiretroviral drugs is restricted. The quality of 
therapeutic monitoring mostly is very limited, viral load measurements are often not 
or less frequently performed, monitoring is often solely based on CD4+ cell counts, 
and HIV drug resistance tests are hardly ever performed in routine clinical care. 
Thus, the time on failing regimens can be very long and highly drug resistant strains 
can accumulate.  
The Swiss HIV Cohort Study (SHCS) and the SHCS drug resistance database are 
characterized by a high data quality and data density. These are great tools to study 
the emergence, mechanisms and transmission of HIV drug resistance and help to 
improve, respectively optimize, antiretroviral therapy. 
At a first glance, the six topics addressed may seem to be very diverse, but in fact 
they are all closely related and focus on important questions of today’s HIV drug 
resistance research. The development of resistance mutations against new 
antiretroviral drugs is an important aspect. These drugs are often the last option for 
patients to achieve viral suppression and should therefore be administered in an 
optimal way to avoid the emergence of drug resistance. Even more, because the 
drug pipeline for new antiretroviral drugs developed by the pharmaceutical industry 
seems to begin to decline. In chapter 1 and 2, we studied aspects of HIV drug 
resistance to two new antiretroviral drugs, etravirine and raltegravir. Further, we 
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aimed to contribute to the knowledge of optimizing salvage treatments and studied in 
chapter 3 the impact of partially active or inactive nucleoside reverse transcriptase 
inhibitors in salvage treatment with raltegravir. Today very little is known about how to 
optimally treat patients with multi-drug resistant viruses. A combination of too many 
drugs may expose the patients unnecessarily to toxic drugs, whereas too few drugs 
can lead to early emergence of drug resistance and loss of the very important 
salvage components. 
Another aspect of today’s HIV drug resistance research is to monitor and study 
trends in resource-limited settings. Although, the SHCS drug resistance database 
only includes data from Switzerland, it is an invaluable tool to answer questions 
raised in resource-limited settings, because data from these countries are often 
insufficient and no comparable database exists. In chapter 4 and 5, we addressed 
some of these questions. The increasing prevalence of multi-nucleoside resistance 
mutations in resource-limited settings motivated us to identify risk factors for its 
emergence. In chapter 6, we also studied a subject that is mainly relevant in 
resource-limited settings where non-B subtypes occur very often. We studied the 
efficacy of antiretroviral drugs among non-B subtypes and found promising results. 
The long-term viral suppression was comparable, or even better, among patient 
infected with non-B subtypes compared with subtype B. The unique aspect of our 
study was that we had enough data to control for the ethnic background, meaning we 
were able to study different subtypes within the same host ethnicity. Thus, we were 
able to exclude host genetic effects to a large extent, an issue that is often totally 
neglected in this type of research. 
To conclude, as long as HIV can not be cured, lifelong treatment with combination 
antiretroviral therapy will most likely be needed. Thus, HIV drug resistance will 
always emerge to a certain extent and potentially remain a severe obstacle to 
achieve longterm successful treatment results. The drug pipeline most likely will 
decline in the next few years and there will always be patients harboring multi-drug 
resistant viruses. Therefore, it is of high importance to focus in future research on 
optimization of salvage treatment strategies, thus the morbidity and mortality in these 
highly treatment-experienced patients can be reduced to a minimum. Further, it will 
be important to closely monitor drug resistance in resource-limited settings. 
Monitoring strategies in these countries should be improved to avoid the 
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accumulation of highly-drug resistant strains that can be transmitted. In these 
countries, high transmission rates of drug-resistant strains will have fatal 
consequences for newly infected patients, because the access to new drug classes is 
strongly limited due to lack of funds. Furthermore, it needs to be noted that ultimately 
emergence of drug resistance in resource-limited settings will also affect developed 
countries because of today’s high global migration.  
In conclusion, the field of HIV drug resistance is a dynamic topic and it is important to 
establish and maintain high-quality databases to monitor drug resistance and to be 
able to address new emerging research questions. 
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